Page 1 Page 3 IN THE COURT OF COMMON PLEAS 1 1 2 2 OF CUYAHOGA COUNTY, OHIO (Thereupon, Plaintiff's Deposition 3 3 Exhibits 1 through 4 were marked for purposes 4 WILLIAM J. GILL, III, 4 of identification.) 5 5 Executor of the Estate of 6 DANIEL P. GILL, deceased, 6 MARK J. BOTHAM, M.D., of lawful age, 7 7 Plaintiff, called for examination, as provided by the Ohio 8 Case No. 457634 8 Rules of Civil Procedure, being by me first duly vs. 9 ROGER A. MANSNERUS, M.D., 9 sworn, as hereinafter certified, deposed and 10 10 said as follows: et al., 11 11 EXAMINATION OF MARK J. BOTHAM, M.D. Defendants. 12 12 BY MR. MISHKIND: 13 DEPOSITION OF MARK J. BOTHAM, M.D. 13 Q. Could you state your name for the 14 TUESDAY, FEBRUARY 3, 2004 14 record? 15 15 Α. Mark Judson Botham. 16 Deposition of MARK J. BOTHAM, M.D., 16 Q. You are a physician; is that 17 a Witness herein, called by the Plaintiff for 17 correct? 18 examination under the statute, taken before me, 18 A. That is correct. Dr. Botham, you and I have never met 19 Cynthia A. Sullivan, a Registered Professional 19 Q. 20 Reporter and Notary Public in and for the State 20 before, have we? 21 of Ohio, pursuant to notice and stipulations of 21 A. No, we have not. 22 22 counsel, at the offices of Hillcrest Hospital, Q. My name is Howard Mishkind, and I 23 6780 Mayfield Road, Mayfield Heights, Ohio, on 23 represent the estate of Mr. Gill. I'm going to 24 the day and date set forth above, at 5:15 p.m. 24 be asking you some questions concerning the 25 opinions that you have expressed in your report 25 Page 2 Page 4 **APPEARANCES:** of November 29, 2002, that you sent to ļ 1 2 On behalf of the Plaintiff: 2 Mr. Warner and also some questions about your 3 Becker & Mishkind Co., LPA, by 3 background, and hopefully, we won't be terribly 4 HOWARD D. MISHKIND, ESQ. 4 long. Famous last words. 5 Skylight Office Tower 5 You have had your deposition taken 6 1660 West Second Street 6 before, I know, so you know the routine in terms 7 Suite 660 7 of waiting and making sure that you understand 8 Cleveland, Ohio 44113 8 my question before you answer it; right? 9 (216) 241-2600 9 A. Yes. 10 10 If you don't understand a question Q. 11 On behalf of the Defendant: 11 or if for some reason I ask a question that 12 Reminger & Reminger, by 12 somehow isn't intelligible, you'll tell me it 13 ROBERT D. WARNER, ESQ. 13 isn't, and I'll rephrase it; okay? 14 1400 Midland Building 14 A. That sounds fair. 15 101 West Prospect Avenue 15 Q. If you do answer the question, I 16 Cleveland, Ohio 44115 have every reason to accept that you understood 16 17 (216) 687-1311 17 the question; is that fair? 18 18 A. That is fair. 19 19 Q. Exhibit 1 is a copy of your report 20 20 that you wrote to Mr. Warner; is that correct? 21 21 A. That is correct. 22 22 Q. It appears that you were contacted 23 23 sometime in September of 2002 to review the 24 24 case. Exhibit 3 which I've just handed to you, 25 25 does that --

1 (Pages 1 to 4)

	I
Page 5	Page 7
1 A. It was either September or late	1 cardiothoracic surgeries that you do are
2 August, I believe, that I received a phone call	2 coronary artery bypass surgeries; is that
3 asking if I'd be willing to review that and then	3 correct?
4 subsequently received the materials stipulated	4 A. Well, things have changed in the
5 on Plaintiff's Exhibit 3.	5 last five years. I would suspect that probably
6 Q. Now, attached to Plaintiff's	6 60 to 70 percent of my present surgery involves
7 Exhibit 3 is it looks like a draft of your	7 cardiac surgery and 30 percent noncardiac
8 report?	8 thoracic surgery. Of the cardiac surgery that I
9 A. Yes. I believe so.	9 do, probably 70 to 80 percent of that is bypass,
10 Q. Did you review the draft of the	10 coronary bypass surgery.
11 report with Mr. Warner before you signed what is	11 Q. When did the percentages of your
12 Exhibit 1, the report on the Cleveland Clinic	12 surgical experience change?
13 stationery?	13 A. When the cardiologists became more
14 A. I don't know whether I actually	14 adept at doing balloon interventions,
15 would have spoken to him by phone regarding	15 percutaneous interventions, the number of
16 this. This is probably something that my	16 coronary bypass surgeries that we do as
17 secretary printed up for me to look at, and then	17 cardiothoracic surgeons decreased.
18 usually what I'll do is just check that I'm okay	18 Q. If a patient such as Mr. Gill came
19 with it, and they'll print that up on my	19 to you at a point in time where he was Stage I
20 letterhead. Sometimes the attorneys do wish to	20 nonsmall cell carcinoma and a patient that was
21 have me speak to them about the report prior to	21 an appropriate surgical candidate, would you be
22 actually sending it down; sometimes not. I	22 the type of surgeon that would perform surgery
23 don't recall whether I did or not.	23 on a Stage I nonsmall cell carcinoma lung
24 Q. Do you recall whether there were any	24 cancer?
25 changes made to the draft report which is	25 A. If it was a clinical Stage I
Page 6	Page 8
1 attached to Exhibit 3 and the report that you	1 carcinoma of the lung and we had done the
2 signed that is Exhibit 1 without going through	2 appropriate preoperative evaluation to ascertain
3 it line and verse?	3 that it was indeed a clinical Stage I disease
4 A. I don't believe so, no.	4 and that he was a candidate for surgical
5 Q. Exhibit 2 is a copy of your CV; is	5 resection based upon his medical condition and
6 that correct?	6 his pulmonary function test, yes, I would then
7 A. That is correct.	7 be the surgeon who would perform that surgery.
8 Q. If I could see Exhibit 3 for a	8 Q. What type of surgery would be
9 moment?	9 performed?
10 A. (Indicating.)	10 A. It can vary anywhere between a
11 Q. Your report, Exhibit 1, identifies	11 preoperative nodal sampling, be it a scalene
12 certain information that you apparently had at 13 the time that you reviewed the case and	12 node biopsy or a mediastinoscopy to ascertain
· · · · · · · · · · · · · · · · · · ·	13 the absence or presence of microscopic nodal
performent performent and the port of the performent of the performance of the performanc	14 disease that might preclude formal thoracotomy
15 correct? 16 A. That is correct.	15 and surgical resection of the primary tumor to
	16 actual resection of that primary tumor along
17 Q. Does that list of items that's 18 contained in Exhibit 1 constitute all of the	17 with the mediastinal lymph node dissection.
	18 The surgical resections that can be
19 information at that time that you had reviewed20 for purposes of your opinions?	19 encompassed in that type of resection can vary
	20 anywhere between a wedge resection, a lobectomy,
	21 or a pneumonectomy.
22 Q. You are a cardiothoracic surgeon; is 23 that correct?	22 Q. In terms of the initial
24 A. That's correct.	23 intervention, surgical intervention, that you
25 Q. The overwhelming percentage of your	 24 mentioned, if there has been expansion of the 25 tumor into the mediastinum, that would by
	25 tumor into the mediastinum, that would by

2 (Pages 5 to 8)

		1	
	Page 9		Page 11
1	definition no longer be a Stage I tumor;	1	histologic study and whether the tumor is well
2	correct?	2	differentiated or poorly differentiated and the
3	A. That is correct.	3	degree of anaplasia.
4	Q. If it had progressed into the	4	In general the survivability of the
11		1	- ,
5	mediastinum, would you abort the surgical	5	five-year survival will vary between 60 and 80
6	procedure at that point or not go on to do a	6	percent based upon those tumor subgroups, and
7	lobectomy or other further resective surgery?	7	then we take Stage I disease and classify it
8	A. That is correct. If they have	8	into Stage I-A and Stage I-B which is more
9	positive mediastinoscopic biopsies, in general	9	dependent upon tumor size. The smaller the
10	we do not recommend that they go on and have	10	tumor size, the better the prognosis.
11	resection of the primary tumor.	11	Q. I usually have a tendency of getting
12	There are rare instances where under	12	ahead of myself in a deposition just because I
13	protocol therapy we would identify positive	13	get all wound up and want to just jump right
14	nodal stations and then perhaps enter them in a	1	
11		14	into it. I'm now going to back up a bit, and
15	chemotherapy/radiation therapy protocol and	15	we'll move back into matters which are germane
16	subsequently re-mediastinoscope them. There are	16	to Mr. Gill.
17	some surgeons who are doing that. I am not one	17	Your report, does it contain all of
18	of those. There are very specific institutions	18	the opinions that you understand that you've
19	in the country that are carrying out those	19	been asked to provide and are prepared to
20	studies now to ascertain the benefit of that	20	provide at the time of the trial in this case?
21	type of therapy.	21	A. Yes, they do.
22	Q. In looking at your surgical	22	Q. Is there any information that you
23	practice, currently what percentage of your	23	have asked for of Mr. Warner that he has not
24	surgical cases involve resections of early lung	24	
25		1	provided to you that you feel somehow affects
	cancer patients as opposed to coronary artery or	25	your ability to evaluate this case?
	Page 10	E	B 10
	and the substantiant of the second		Page 12
1	cardiac patients? It may not be terribly	1	A. No, there is not.
2	artfully worded, but hopefully you understand.	2	A. No, there is not.Q. I see that you've reviewed expert
11	artfully worded, but hopefully you understand. A. I understand the question. I		A. No, there is not.
2 3 4	artfully worded, but hopefully you understand.	2	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan,
2 3	artfully worded, but hopefully you understand. A. I understand the question. I	2 3	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have
2 3 4	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be	2 3 4 5	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained
2 3 4 5	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those	2 3 4 5 6	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained from the plaintiff's side as well; correct?
2 3 4 5 6 7	 artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would 	2 3 4 5 6 7	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct.
2 3 4 5 6 7 8	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250	2 3 4 5 6 7 8	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you
2 3 4 5 6 7 8 9	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of	2 3 4 5 6 7 8 9	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report?
2 3 4 5 6 7 8 9	 artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that 	2 3 4 5 6 7 8 9 10	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so
2 3 4 5 6 7 8 9 10 11	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent	2 3 4 5 6 7 8 9 10	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus
2 3 4 5 6 7 8 9 10 11 12	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or	2 3 4 5 6 7 8 9 10 11 12	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to
2 3 4 5 6 7 8 9 10 11 12 13	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma.	2 3 4 5 6 7 8 9 10 11 12 13	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report.
2 3 4 5 6 7 8 9 10 11 12 13 14	 artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to 	2 3 4 5 6 7 8 9 10 11 12 13 14	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had
2 3 4 5 6 7 8 9 10 11 12 13 14 5	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic	2 3 4 5 6 7 8 9 10 11 12 13	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in
2 3 4 5 6 7 8 9 10 11 12 13 14	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic carcinoma nonsmall cell and a patient is	2 3 4 5 6 7 8 9 10 11 12 13 14	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in
2 3 4 5 6 7 8 9 10 11 12 13 14 5	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in any way altered, modified, changed, increased,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic carcinoma nonsmall cell and a patient is referred to you or someone that does this type	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in any way altered, modified, changed, increased, if you will, any one of those adjectives if
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic carcinoma nonsmall cell and a patient is referred to you or someone that does this type of surgery, what is your experience in terms of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in any way altered, modified, changed, increased, if you will, any one of those adjectives if that's an adjective, since reading the other
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic carcinoma nonsmall cell and a patient is referred to you or someone that does this type of surgery, what is your experience in terms of the prognosis for those patients without any	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in any way altered, modified, changed, increased, if you will, any one of those adjectives if that's an adjective, since reading the other expert reports or depositions?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 6 17 18 19 20	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic carcinoma nonsmall cell and a patient is referred to you or someone that does this type of surgery, what is your experience in terms of the prognosis for those patients without any other significant comorbidities?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 7 18 19 20	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in any way altered, modified, changed, increased, if you will, any one of those adjectives if that's an adjective, since reading the other expert reports or depositions? A. No, they have not.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 6 17 8 9 20 21	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic carcinoma nonsmall cell and a patient is referred to you or someone that does this type of surgery, what is your experience in terms of the prognosis for those patients without any other significant comorbidities? A. It depends a little bit upon the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in any way altered, modified, changed, increased, if you will, any one of those adjectives if that's an adjective, since reading the other expert reports or depositions? A. No, they have not. Q. Your report is silent with regard to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 6 17 18 19 20 21 22	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic carcinoma nonsmall cell and a patient is referred to you or someone that does this type of surgery, what is your experience in terms of the prognosis for those patients without any other significant comorbidities? A. It depends a little bit upon the pathologic stage. There are different aspects	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in any way altered, modified, changed, increased, if you will, any one of those adjectives if that's an adjective, since reading the other expert reports or depositions? A. No, they have not. Q. Your report is silent with regard to the topic of standard of care. May I assume
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 122 23	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic carcinoma nonsmall cell and a patient is referred to you or someone that does this type of surgery, what is your experience in terms of the prognosis for those patients without any other significant comorbidities? A. It depends a little bit upon the pathologic stage. There are different aspects of Stage I, pathologic Stage I bronchogenic	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in any way altered, modified, changed, increased, if you will, any one of those adjectives if that's an adjective, since reading the other expert reports or depositions? A. No, they have not. Q. Your report is silent with regard to the topic of standard of care. May I assume that you will not be providing testimony on
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 24	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic carcinoma nonsmall cell and a patient is referred to you or someone that does this type of surgery, what is your experience in terms of the prognosis for those patients without any other significant comorbidities? A. It depends a little bit upon the pathologic stage. There are different aspects of Stage I, pathologic Stage I bronchogenic carcinoma, and those include the absence or	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in any way altered, modified, changed, increased, if you will, any one of those adjectives if that's an adjective, since reading the other expert reports or depositions? A. No, they have not. Q. Your report is silent with regard to the topic of standard of care. May I assume that you will not be providing testimony on behalf of Dr. Mansnerus at the time of trial
2 3 4 5 6 7 8 9 10 11 12 3 14 5 6 7 8 9 10 11 12 3 14 15 16 17 18 19 20 1 22 23	artfully worded, but hopefully you understand. A. I understand the question. I probably do 500 operative procedures per year. Roughly 200 of those or 250 of those will be open heart surgery, so the remainder of those are general thoracic surgical cases. I would venture to say that of those 200 or 250 operative procedures, probably 60 percent of those relate to carcinoma of the lung. Of that number of procedures, probably 25 or 30 percent of those cases are patients with Stage I-A or Stage I-B bronchogenic carcinoma. Q. If you are fortunate enough to diagnose a patient in Stage I bronchogenic carcinoma nonsmall cell and a patient is referred to you or someone that does this type of surgery, what is your experience in terms of the prognosis for those patients without any other significant comorbidities? A. It depends a little bit upon the pathologic stage. There are different aspects of Stage I, pathologic Stage I bronchogenic	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A. No, there is not. Q. I see that you've reviewed expert reports of both sides, reports from Dr. Levitan, Dr. Rozman, as well as expert reports that have been retained by experts that have been retained by experts that have been retained from the plaintiff's side as well; correct? A. That is correct. Q. Did you review those before you prepared your report? A. No, I did not. I don't believe so with the exception perhaps of Dr. Mansnerus whose deposition I do believe I read prior to issuing this report. Q. Have the opinions that you had arrived at back in November, have they been in any way altered, modified, changed, increased, if you will, any one of those adjectives if that's an adjective, since reading the other expert reports or depositions? A. No, they have not. Q. Your report is silent with regard to the topic of standard of care. May I assume that you will not be providing testimony on

3 (Pages 9 to 12)

í 		Ē	<u> </u>
	Page 13		Page 15
1	below the standard of care for an internist or	1	Q. More likely than not, if he had been
2	family practice doctor in evaluating Mr. Gill in	2	operated on at a point in time where he was
3	December and early January of the years	3	Stage I-A or Stage I-B, would he have had more
4	involved?	4	likely than not a greater than 50 percent
5	A. That assumption would be correct.	5	probability of a good outcome?
6	Q. You will be providing testimony as	6	A. I think it's safe to say that he
7	it relates to that legal term called proximate	7	would have had a greater than 50 percent
8	cause; is that correct?	8	probability of surviving more than five years.
9	A. That is correct.	9	Q. That's sort of the magic period, is
10	Q. If Mr. Gill had been diagnosed	10	it not, that you use, a five-year survival, or
11	Stage I and knowing the histology that	11	do you go out further than that?
12	ultimately was appreciated in terms of the	12	A. Five-year survival is how we
13	poorly differentiated components, but if you	13	delineate percentages of survival. In
14	back up in time to a snippet in time, whenever	14	bronchogenic carcinoma, most patients who reach
15	that may have been, and he had been diagnosed	15	five years without evidence of a clinical
16	Stage I-A or Stage I-B and had come to someone	16	recurrence are more than likely going to stay
17	like you without any mediastinal involvement, he	17	that way throughout the duration as it pertains
18	would have been an appropriate candidate for	18	to bronchogenic carcinoma. So that's the reason
19	surgical treatment; correct?	19	why we use those numbers as a percentage of
20	A. In order to accurately answer that	20	survival.
21	question, I just want to make sure I understand	21	Q. They're sort of out of harm's way,
22	the question. Are we talking at any point in	22	if you will, if they make the five-year period
23	time prior to and/or including the presentation	23	of time without any recurrence or distal
24	on 12-9-99? Because it is my belief that on	24	metastasis?
25	12-9-99 he probably was not a Stage I-A or B.	25	A. The likelihood is extremely high
<u> </u>			A. The incliniood is extremely high
	Page 14		Page 16
1	So if you're asking the question could it	1	that they are out of harm's way from their
2	potentially be prior to that, if he had	2	original bronchogenic carcinoma. They still are
3	presented and at that time been clinically Stage	3	at risk, however, to develop a second primary
4	I-A or I-B, yes, I do believe that he might have	4	which is the reason we continue to follow them
5	been a candidate for surgical resection.	5	even after five years' time.
6	Q. I understand from reading your	6	Q. You mean they can't say good-bye to
7	report and we'll talk about certain snippets	7	the doctor after five years and a good report?
8	of it, but we're not going to go through the	8	A. No, they can't.
9	entire thing because they taught me how to read	9	Q. That's what you call job security;
10	in law school but my question is really,	10	right?
11	regardless of whether that point in time was	11	A. It's not so much job security but
12	December or whether it was months or years	12	just making sure that our patients continue to
11		13	do well.
113	before that, if we got to that snippet in time		
13	before that, if we got to that snippet in time and everyone agreed that he was a Stage I-A or	14	
14	and everyone agreed that he was a Stage I-A or	14 15	Q. I know. I say that obviously in
14	and everyone agreed that he was a Stage I-A or Stage I-B and he fell into your lap and you then	15	Q. I know. I say that obviously in Jest. Obviously, if you reach the five-year
14 15 16	and everyone agreed that he was a Stage I-A or Stage I-B and he fell into your lap and you then had the benefit of knowing, which this would	15 16	Q. I know. I say that obviously in jest. Obviously, if you reach the five-year time period after surgery in a patient without
14 15 16 17	and everyone agreed that he was a Stage I-A or Stage I-B and he fell into your lap and you then had the benefit of knowing, which this would never happen, but at Stage IV what the cancer	15 16 17	Q. I know. I say that obviously in jest. Obviously, if you reach the five-year time period after surgery in a patient without any significant comorbidities, the prognosis
14 15 16 17 18	and everyone agreed that he was a Stage I-A or Stage I-B and he fell into your lap and you then had the benefit of knowing, which this would never happen, but at Stage IV what the cancer looked like, but you were fortunate enough to be	15 16 17 18	Q. I know. I say that obviously in jest. Obviously, if you reach the five-year time period after surgery in a patient without any significant comorbidities, the prognosis would be favorable for long-term survival?
14 15 16 17 18 19	and everyone agreed that he was a Stage I-A or Stage I-B and he fell into your lap and you then had the benefit of knowing, which this would never happen, but at Stage IV what the cancer looked like, but you were fortunate enough to be able to turn the hands of the clock back and	15 16 17 18 19	 Q. I know. I say that obviously in jest. Obviously, if you reach the five-year time period after surgery in a patient without any significant comorbidities, the prognosis would be favorable for long-term survival? A. Ideally, yes.
14 15 16 17 18 19 20	and everyone agreed that he was a Stage I-A or Stage I-B and he fell into your lap and you then had the benefit of knowing, which this would never happen, but at Stage IV what the cancer looked like, but you were fortunate enough to be able to turn the hands of the clock back and treat him at Stage I-A or Stage I-B nonsmall	15 16 17 18 19 20	 Q. I know. I say that obviously in jest. Obviously, if you reach the five-year time period after surgery in a patient without any significant comorbidities, the prognosis would be favorable for long-term survival? A. Ideally, yes. Q. In a patient of Mr. Gill's age, his
14 15 16 17 18 19 20 21	and everyone agreed that he was a Stage I-A or Stage I-B and he fell into your Iap and you then had the benefit of knowing, which this would never happen, but at Stage IV what the cancer looked like, but you were fortunate enough to be able to turn the hands of the clock back and treat him at Stage I-A or Stage I-B nonsmall cell carcinoma, in a man of Mr. Gill's age and	15 16 17 18 19 20 21	 Q. I know. I say that obviously in jest. Obviously, if you reach the five-year time period after surgery in a patient without any significant comorbidities, the prognosis would be favorable for long-term survival? A. Ideally, yes. Q. In a patient of Mr. Gill's age, his comorbidity or lack thereof, and obviously he
14 15 16 17 18 19 20 21 22	and everyone agreed that he was a Stage I-A or Stage I-B and he fell into your Iap and you then had the benefit of knowing, which this would never happen, but at Stage IV what the cancer looked like, but you were fortunate enough to be able to turn the hands of the clock back and treat him at Stage I-A or Stage I-B nonsmall cell carcinoma, in a man of Mr. Gill's age and comorbidity factors, he would have been an	15 16 17 18 19 20 21 22	 Q. I know. I say that obviously in jest. Obviously, if you reach the five-year time period after surgery in a patient without any significant comorbidities, the prognosis would be favorable for long-term survival? A. Ideally, yes. Q. In a patient of Mr. Gill's age, his comorbidity or lack thereof, and obviously he was a smoker which in your opinion is the
14 15 16 17 18 19 20 21 22 23	and everyone agreed that he was a Stage I-A or Stage I-B and he fell into your lap and you then had the benefit of knowing, which this would never happen, but at Stage IV what the cancer looked like, but you were fortunate enough to be able to turn the hands of the clock back and treat him at Stage I-A or Stage I-B nonsmall cell carcinoma, in a man of Mr. Gill's age and comorbidity factors, he would have been an appropriate candidate for surgical	15 16 17 18 19 20 21 22 23	 Q. I know. I say that obviously in jest. Obviously, if you reach the five-year time period after surgery in a patient without any significant comorbidities, the prognosis would be favorable for long-term survival? A. Ideally, yes. Q. In a patient of Mr. Gill's age, his comorbidity or lack thereof, and obviously he was a smoker which in your opinion is the smoking a probable cause of the lung cancer?
14 15 16 17 18 19 20 21 22	and everyone agreed that he was a Stage I-A or Stage I-B and he fell into your Iap and you then had the benefit of knowing, which this would never happen, but at Stage IV what the cancer looked like, but you were fortunate enough to be able to turn the hands of the clock back and treat him at Stage I-A or Stage I-B nonsmall cell carcinoma, in a man of Mr. Gill's age and comorbidity factors, he would have been an	15 16 17 18 19 20 21 22	 Q. I know. I say that obviously in jest. Obviously, if you reach the five-year time period after surgery in a patient without any significant comorbidities, the prognosis would be favorable for long-term survival? A. Ideally, yes. Q. In a patient of Mr. Gill's age, his comorbidity or lack thereof, and obviously he was a smoker which in your opinion is the

4 (Pages 13 to 16)

Ir			
	Page 17		Page 19
1	lung cancer, there are literally thousands of	1	largest portion of the tennis ball. So it's
2	patients in which smoking causes lung cancer but	2	subject to error, and it's subject to
3	yet are fortunate enough to be diagnosed at a	3	interpretation. In general it does not change
4	Stage I-A or Stage I-B and have a good outcome;	4	the clinical presence of the tumor.
5	correct?	5	Q. Could I borrow that?
	A. That's correct.	6	A. (Indicating.)
6		7	
7	Q. So while it's not good to smoke	1 -	Q. I think you indicated that in your
8	because it creates the risk of cancer, if you're	8	opinion in this case had Mr. Gill's disease been
9	in the right place at the right time and a	9	diagnosed at the end of '99 or the early part of
10	doctor diagnoses it at an early stage, there can	10	2000 that the tumor would have been less bulky
	be a happy ending as long as the person doesn't	11	in size; correct? In that last paragraph about
12	continue to smoke after having the surgery; is	12	the fourth line down, do you see that?
13	that a fair statement?	13	A. Yes. I see that. The question is?
14	A. That's a fair statement.	14	I'm sorry.
15	Q. Again, with the assumption that	15	Q. That the tumor had it been diagnosed
16	Mr. Gill was diagnosed Stage I-A or Stage I-B,	16	at the end of December or January or that time
17	would he have required adjunctive therapy as	17	period, and I understand what your opinions are,
18	well to maximize his long-term survival?	18	but you do acknowledge that there is a
19	A. At the time of his diagnosis, no. I	19	probability that the tumor would have been less
20	think we are now revisiting that. More recently	20	bulky in size at that earlier period of time?
21	we've looked at patients who are Stage II and	21	A. I believe so, yes.
22	are recommending that they get adjunctive	22	Q. Just so I understand, because
23	chemotherapy and at times radiation therapy.	23	sometimes the term bulky may mean one thing to
24	There were some studies that now suggest a small	24	one person, if we use that 4.5 or 4 centimeter
25	but definitely significant benefit for those	t i	tumor and we reduce it in size to say 3.5, is
	, ,		· · ·
	Page 18		Page 20
1	patients.	1	the difference between 3.5 and 4 that 4 is
2	The overwhelming percentage of	2	bulkier than 3.5?
3	oncologists now I think probably still do not	3	A. By definition if it's larger in
4	recommend adjunctive therapy for Stage I	4	size, it truly is bulkier. In terms of the
5	disease.	5	histopathological classification and stages, it
		6	does not change the stage of the lesion at that
6	Q. Stage II-A would be what, T1-N1?	7	
7	A. T1 or T2 and N1 lesions.	-	time.
8	Q. There's some discrepancy, as I see	8	Q. Can you tell me, if you have an
9	it, in the records as to what the size of the	9	opinion, what size the tumor would have been in
10	tumor was when it was first diagnosed. At one	10	let's take from December of '99 into the turn of
	point I see 4 centimeters, and then at one	11	the year, into January and maybe the early part
12	point it's been a while since I've looked at		of February, if it was less bulky in size? I'll
13	this but at one point I think it was maybe	13	give you sort of a range. Tell me the smallest
14	4.5 centimeters. Is that significant, the	14	you believe it would have been and the largest
15	difference between 4 and 4.5 centimeters?	15	you believe it may have been as well those
II :			
16	A. No. I think that really depends on	16	months earlier.
II :	A. No. I think that really depends on when and how the CAT scans are done and the	17	MR. WARNER: Objection. Go ahead.
16	A. No. I think that really depends on when and how the CAT scans are done and the radiologist's interpretation. It's similar to	17 18	MR. WARNER: Objection. Go ahead. A. Again, it's pure supposition because
16 17	A. No. I think that really depends on when and how the CAT scans are done and the radiologist's interpretation. It's similar to taking a tennis ball and slicing it into	17	MR. WARNER: Objection. Go ahead. A. Again, it's pure supposition because I don't have the radiographs to look at and we
16 17 18 19 20	A. No. I think that really depends on when and how the CAT scans are done and the radiologist's interpretation. It's similar to	17 18	MR. WARNER: Objection. Go ahead. A. Again, it's pure supposition because
16 17 18 19 20 21	A. No. I think that really depends on when and how the CAT scans are done and the radiologist's interpretation. It's similar to taking a tennis ball and slicing it into	17 18 19	MR. WARNER: Objection. Go ahead. A. Again, it's pure supposition because I don't have the radiographs to look at and we
16 17 18 19 20	A. No. I think that really depends on when and how the CAT scans are done and the radiologist's interpretation. It's similar to taking a tennis ball and slicing it into multiple little pieces. It depends upon where	17 18 19 20	MR. WARNER: Objection. Go ahead. A. Again, it's pure supposition because I don't have the radiographs to look at and we don't have the benefit of retroactive staging
16 17 18 19 20 21	A. No. I think that really depends on when and how the CAT scans are done and the radiologist's interpretation. It's similar to taking a tennis ball and slicing it into multiple little pieces. It depends upon where in the ball you slice it, whether you slice it	17 18 19 20 21	MR. WARNER: Objection. Go ahead. A. Again, it's pure supposition because I don't have the radiographs to look at and we don't have the benefit of retroactive staging with any other study back in December, but if I
16 17 18 19 20 21 22	A. No. I think that really depends on when and how the CAT scans are done and the radiologist's interpretation. It's similar to taking a tennis ball and slicing it into multiple little pieces. It depends upon where in the ball you slice it, whether you slice it in the absolute maximum diameter or you miss	17 18 19 20 21 22	MR. WARNER: Objection. Go ahead. A. Again, it's pure supposition because I don't have the radiographs to look at and we don't have the benefit of retroactive staging with any other study back in December, but if I were to make that supposition, I would say the smallest the tumor size would have been would
16 17 18 19 20 21 22 23	A. No. I think that really depends on when and how the CAT scans are done and the radiologist's interpretation. It's similar to taking a tennis ball and slicing it into multiple little pieces. It depends upon where in the ball you slice it, whether you slice it in the absolute maximum diameter or you miss that by 2 or 3 or 4 millimeters.	17 18 19 20 21 22 23	MR. WARNER: Objection. Go ahead. A. Again, it's pure supposition because I don't have the radiographs to look at and we don't have the benefit of retroactive staging with any other study back in December, but if I were to make that supposition, I would say the

5 (Pages 17 to 20)

		T	
	Page 21		Page 23
1	have been similar to what it was when it was	1	Q. Just to give me an idea, in 2003
2	diagnosed eventually later that year, roughly 4	2	I won't ask you in 2004 because it's not old
3	to 4.5 centimeters.	3	enough in your surgical practice, how many
4	Q. If there were no other clinical,	4	situations were you called upon to perform
5	pathological, or histological findings other	5	resection on a lung cancer patient?
6	than a tumor of 3 centimeters, then that would	6	A. Without having the specific numbers,
7	by definition be a T1 nonsmall cell carcinoma?	7	I would guesstimate probably somewhere between
8	A. It would be a T2 lesion. Anything 3	8	100 and 150.
9	centimeters or larger is a T2 tumor.	9	Q. All of those patients were Stage I-A
10	Q. So once it hits 3, it kicks from T1	10	or Stage I-B?
11	to T2?	111	A. No. I suspect probably 20 or
12	A. That is correct.	12	
13	Q. Are there studies that indicate		30 percent of that group of patients were
11		13	Stage I.
14	anything above 3 centimeters is T2 and anything	14	Q. Until you went in and did the
15	3 centimeters and below is T1?	15	initial intervention, diagnostic intervention,
16	A. That's the standard classification	16	you didn't know whether or not they were
17	for bronchogenic carcinoma. A T1 tumor is less	17	Stage I-A or Stage I-B?
18	than 3 centimeters, and a T2 tumor is greater	18	A. That is correct.
19	than 3 centimeters. That's the specific size	19	Q. Have you reviewed any literature on
20	criteria that delineates a T1 and T2 tumor.	20	the topic of nonsmall cell lung cancer in terms
21	Q. Maybe I wasn't clear. If anything	21	of staging and prognosis that would be germane
22	greater than 3 centimeters is T2 and anything	22	and relevant to the topic in this case for
23	less than 3 centimeters is T1, what is a tumor	23	purposes of preparing your report?
24	that is 3 centimeters right on the button?	24	A. No, not specifically for purposes of
25	A. That would be by definition a T2	25	preparing the report.
	Page 22		Page 24
1	Page 22 tumor.	1	-
12	_	1	Q. Since you prepared your report, have
11	tumor.		Q. Since you prepared your report, have you reviewed any literature again on that same
2	tumor. Q. Have you seen any studies in this	2	Q. Since you prepared your report, have
2 3	tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters	2 3 4	Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case?
2 3 4	tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not	2 3	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no.
2 3 4 5	tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not.	2 3 4 5	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal
2 3 4 5 6	tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not.	2 3 4 5 6 7	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be
2 3 4 5 6 7	tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications?	2 3 4 5 6 7 8	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to
2 3 4 5 6 7 8	tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct.	2 3 4 5 6 7 8 9	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic
2 3 4 5 6 7 8 9 10	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? 	2 3 4 5 6 7 8 9 10	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in
2 3 4 5 6 7 8 9 10 11	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. 	2 3 4 5 6 7 8 9 10	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as
2 3 4 5 6 7 8 9 10 11 12	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications 	2 3 4 5 6 7 8 9 10 11 12	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients?
2 3 4 5 6 7 8 9 10 11 12 13	tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed?	2 3 4 5 6 7 8 9 10 11 12 13	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are
2 3 4 5 6 7 8 9 10 11 12 13 14	tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are.	2 3 4 5 6 7 8 9 10 11 12 13 14	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are. Q. Do any of them touch on the topic of 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and they're generated in an effort to educate their
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are. Q. Do any of them touch on the topic of the diagnosis and treatment of nonsmall cell 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and they're generated in an effort to educate their colleagues. The appropriate nature of education
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are. Q. Do any of them touch on the topic of the diagnosis and treatment of nonsmall cell lung tumors or lung cancer in general?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and they're generated in an effort to educate their colleagues. The appropriate nature of education for colleagues is to read those and to formulate
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are. Q. Do any of them touch on the topic of the diagnosis and treatment of nonsmall cell lung tumors or lung cancer in general? A. No, they do not. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and they're generated in an effort to educate their colleagues. The appropriate nature of education for colleagues is to read those and to formulate their own opinions based upon them.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 7 18 19	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are. Q. Do any of them touch on the topic of the diagnosis and treatment of nonsmall cell lung tumors or lung cancer in general? A. No, they do not. Q. Are all of the articles more in the 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and they're generated in an effort to educate their colleagues. The appropriate nature of education for colleagues is to read those and to formulate their own opinions based upon them. There are numerous historical
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 7 8 9 20	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are. Q. Do any of them touch on the topic of the diagnosis and treatment of nonsmall cell lung tumors or lung cancer in general? A. No, they do not. Q. Are all of the articles more in the area of the coronary artery and cardiac end of 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and they're generated in an effort to educate their colleagues. The appropriate nature of education for colleagues is to read those and to formulate their own opinions based upon them. There are numerous historical clinical as well as histopathological staging
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21	 Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are. Q. Do any of them touch on the topic of the diagnosis and treatment of nonsmall cell lung tumors or lung cancer in general? A. No, they do not. Q. Are all of the articles more in the area of the coronary artery and cardiac end of your surgical interests? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and they're generated in an effort to educate their colleagues. The appropriate nature of education for colleagues is to read those and to formulate their own opinions based upon them. There are numerous historical clinical as well as histopathological staging papers in terms of how they relate to prognosis
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21 22	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are. Q. Do any of them touch on the topic of the diagnosis and treatment of nonsmall cell lung tumors or lung cancer in general? A. No, they do not. Q. Are all of the articles more in the area of the coronary artery and cardiac end of your surgical interests? A. They are related to both cardiac as 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and they're generated in an effort to educate their colleagues. The appropriate nature of education for colleagues is to read those and to formulate their own opinions based upon them. There are numerous historical clinical as well as histopathological staging papers in terms of how they relate to prognosis in lung carcinoma which most cardiothoracic
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are. Q. Do any of them touch on the topic of the diagnosis and treatment of nonsmall cell lung tumors or lung cancer in general? A. No, they do not. Q. Are all of the articles more in the area of the coronary artery and cardiac end of your surgical interests? A. They are related to both cardiac as well as general thoracic topics. There is 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and they're generated in an effort to educate their colleagues. The appropriate nature of education for colleagues is to read those and to formulate their own opinions based upon them. There are numerous historical clinical as well as histopathological staging papers in terms of how they relate to prognosis in lung carcinoma which most cardiothoracic surgeons have read and hopefully encompassed
2 3 4 5 6 7 8 9 10 11 12 3 4 5 6 7 8 9 10 11 12 3 14 5 6 7 8 9 10 11 12 3 14 5 6 7 8 9 10 11 12 3 14 5 6 7 8 9 10 11 12 3 14 5 6 7 8 9 10 11 12 3 14 5 16 7 8 9 10 11 12 3 14 5 16 7 8 9 10 11 12 3 14 5 16 7 8 9 10 11 12 3 14 5 16 7 8 9 10 11 12 3 14 5 16 7 8 9 10 11 1 12 3 14 5 16 17 10 10 11 1 12 3 14 5 16 17 10 10 11 12 3 14 5 16 17 10 10 11 12 3 14 5 16 17 10 10 11 12 3 14 11 12 3 14 11 12 3 14 11 12 3 14 11 12 3 14 11 12 3 14 11 12 3 14 11 12 3 14 11 12 3 14 11 12 3 14 11 12 3 14 11 12 3 14 11 12 3 14 11 12 11 12 13 14 15 10 10 11 12 2 12 2 12 2 12 2 12 2 12	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are. Q. Do any of them touch on the topic of the diagnosis and treatment of nonsmall cell lung tumors or lung cancer in general? A. No, they do not. Q. Are all of the articles more in the area of the coronary artery and cardiac end of your surgical interests? A. They are related to both cardiac as well as general thoracic topics. There is nothing specifically there related to 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and they're generated in an effort to educate their colleagues. The appropriate nature of education for colleagues is to read those and to formulate their own opinions based upon them. There are numerous historical clinical as well as histopathological staging papers in terms of how they relate to prognosis in lung carcinoma which most cardiothoracic surgeons have read and hopefully encompassed into their practice in terms of how they present
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 tumor. Q. Have you seen any studies in this area that describe a 3 centimeter nodule, not more than 3 centimeters but just 3 centimeters exactly, as being T1 as opposed to T2? A. I have not. Q. In your CV, Doctor, you have nine publications? A. Correct. Q. Are there any in the works? A. Presently, no. Q. Are all of the nine publications peer reviewed? A. Yes, they are. Q. Do any of them touch on the topic of the diagnosis and treatment of nonsmall cell lung tumors or lung cancer in general? A. No, they do not. Q. Are all of the articles more in the area of the coronary artery and cardiac end of your surgical interests? A. They are related to both cardiac as well as general thoracic topics. There is 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. Since you prepared your report, have you reviewed any literature again on that same topic that you believe to be relevant or germane to the issues in this case? A. Not specifically, no. Q. Are there any articles, journal articles, or studies that you consider to be reasonably reliable or, as the lawyers like to say, authoritative on the topic of prognostic indicators for nonsmall cell lung cancer in terms of the diagnosis and treatment as well as the prognosis for those types of patients? A. I believe that all articles that are written are opinions of their authors, and they're generated in an effort to educate their colleagues. The appropriate nature of education for colleagues is to read those and to formulate their own opinions based upon them. There are numerous historical clinical as well as histopathological staging papers in terms of how they relate to prognosis in lung carcinoma which most cardiothoracic surgeons have read and hopefully encompassed

6 (Pages 21 to 24)

		T	
	Page 25		Page 27
1	Q. Are you able to cite me to any that	1	charged more than that unless I'm away for two
2	you, Dr. Botham, consider to be very reliable or	2	days' worth of work. If I have to fly somewhere
3	reasonably reliable on this very topic?	3	and stay for the night, then it may be two days'
4	A. Specifically, I don't think I could	4	worth of work.
5	give you the name of an article. Over the last	5	Q. After the diagnosis here I go
6	16 years I've read hundreds and hundreds of	6	again. I'm jumping off one topic and going on
7	articles that pertain to staging in lung	7	to another, but I'm going to come back to your
8	carcinoma and how it affects prognosis in an	8	medical-legal again, so you're not out of the
9	attempt to assimilate all those and generate my	9	woods yet.
10	opinions at to how we go about managing this	10	•
	type of problem.	1	After the diagnosis was made of the
12		11	cancer, it was a Grade IV at that time?
11	Q. Did you review the article that	12	A. At the time it was diagnosed, it was
13	Dr. Steele had referenced that was attached to	13	a Stage IV.
14	his deposition?	14	Q. Stage IV, I'm sorry. He was seen at
15	A. I don't believe that I did.	15	both the Cleveland Clinic and University
16	Q. The reason I ask you not about	16	Hospitals, but I think his treatment was pretty
17	Dr. Steele but about whether there are any	17	much confined to one institution. Do you
18	articles that you consider to be reliable is	18	remember which one that was?
19	that I want to find out whether or not you are	19	A. I believe it was at University
20	currently in a position to acknowledge a journal	20	Hospitals.
21	article or a section from a journal article on	21	Q. Do you know any of the doctors that
22	the topic of nonsmall cell lung cancer as being	22	were involved in Mr. Gill's care after the
23	reliable from the standpoint of having any	23	diagnosis of cancer was made?
24	evidentiary value in this case, and if I	24	A. The only one that I know by
25	understand what you're saying, it is that there	25	
-	· · · ·		•
	Page 26		Page 28
1	may be articles out there, but as you're sitting	1	patient interactions with him.
2	here right now there's nothing that you can cite	2	Q. Well, you're not an oncologist, so
3	me to?	3	you would not be treating from a nonsurgical
4	A. Correct.	4	standpoint a patient that is not a surgical
5	Q. To the extent that that position	5	candidate; correct?
6	changes and you are likely to take the stand and	6	A. That is correct.
7	acknowledge anything as being reasonably	0	A. HIALIS COITECL.
11 ×		7	\wedge Are your able to communit at all an
11		7	Q. Are you able to comment at all on whether or not the care that use provided hu
8	reliable or authoritative, just for the record I	8	whether or not the care that was provided by
8 9	reliable or authoritative, just for the record I would ask that I be notified before you take the	8 9	whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply
8 9 10	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect.	8 9 10	whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an
8 9 10 11	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy.	8 9 10 11	whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that?
8 9 10 11 12	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for	8 9 10 11 12	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion,
8 9 10 11 12 13	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions?	8 9 10 11 12 13	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I
8 9 10 11 12 13 14	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes.	8 9 10 11 12 13 14	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met
8 9 10 11 12 13 14 15	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes. Q. Trial testimony is \$4,000 to \$5,000	8 9 10 11 12 13 14 15	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met in their management of Mr. Gill.
8 9 10 11 12 13 14 15 16	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes. Q. Trial testimony is \$4,000 to \$5,000 for half a day?	8 9 10 11 12 13 14 15 16	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met in their management of Mr. Gill. Q. He received what type of therapy
8 9 10 11 12 13 14 15 16 17	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes. Q. Trial testimony is \$4,000 to \$5,000 for half a day? A. \$5,000 for a day.	8 9 10 11 12 13 14 15 16 17	whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met in their management of Mr. Gill. Q. He received what type of therapy when it was realized that it was too late to
8 9 10 11 12 13 14 15 16 17 18	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes. Q. Trial testimony is \$4,000 to \$5,000 for half a day? A. \$5,000 for a day. Q. So the \$4,000 is no longer current?	8 9 10 11 12 13 14 15 16 17 18	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met in their management of Mr. Gill. Q. He received what type of therapy
8 9 10 11 12 13 14 15 16 17 18 19	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes. Q. Trial testimony is \$4,000 to \$5,000 for half a day? A. \$5,000 for a day. Q. So the \$4,000 is no longer current? A. It has never been \$4,000. My fees	8 9 10 11 12 13 14 15 16 17	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met in their management of Mr. Gill. Q. He received what type of therapy when it was realized that it was too late to operate? A. I believe there were two separate
8 9 10 11 12 13 14 15 16 17 18 19 20	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes. Q. Trial testimony is \$4,000 to \$5,000 for half a day? A. \$5,000 for a day. Q. So the \$4,000 is no longer current? A. It has never been \$4,000. My fees haven't changed in 14 years.	8 9 10 11 12 13 14 15 16 17 18	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met in their management of Mr. Gill. Q. He received what type of therapy when it was realized that it was too late to operate? A. I believe there were two separate
8 9 10 11 12 13 14 15 16 17 18 19 20 21	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes. Q. Trial testimony is \$4,000 to \$5,000 for half a day? A. \$5,000 for a day. Q. So the \$4,000 is no longer current? A. It has never been \$4,000. My fees	8 9 10 11 12 13 14 15 16 17 18 19	whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met in their management of Mr. Gill. Q. He received what type of therapy when it was realized that it was too late to operate?
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes. Q. Trial testimony is \$4,000 to \$5,000 for half a day? A. \$5,000 for a day. Q. So the \$4,000 is no longer current? A. It has never been \$4,000. My fees haven't changed in 14 years.	8 9 10 11 12 13 14 15 16 17 18 19 20	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met in their management of Mr. Gill. Q. He received what type of therapy when it was realized that it was too late to operate? A. I believe there were two separate rounds of chemotherapy, as they like to say, I think. If you'll give me one second, I'll look
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes. Q. Trial testimony is \$4,000 to \$5,000 for half a day? A. \$5,000 for a day. Q. So the \$4,000 is no longer current? A. It has never been \$4,000. My fees haven't changed in 14 years. Q. In one deposition you may have 	8 9 10 11 12 13 14 15 16 17 18 19 20 21	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met in their management of Mr. Gill. Q. He received what type of therapy when it was realized that it was too late to operate? A. I believe there were two separate rounds of chemotherapy, as they like to say, I think. If you'll give me one second, I'll look through my notes here.
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes. Q. Trial testimony is \$4,000 to \$5,000 for half a day? A. \$5,000 for a day. Q. So the \$4,000 is no longer current? A. It has never been \$4,000. My fees haven't changed in 14 years. Q. In one deposition you may have slipped to say \$4,000 to \$5,000.	8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met in their management of Mr. Gill. Q. He received what type of therapy when it was realized that it was too late to operate? A. I believe there were two separate rounds of chemotherapy, as they like to say, I think. If you'll give me one second, I'll look through my notes here. Q. While you're doing that, you're
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	reliable or authoritative, just for the record I would ask that I be notified before you take the stand to that effect. A. I would be happy. Q. Do you still charge \$250 an hour for depositions? A. Yes. Q. Trial testimony is \$4,000 to \$5,000 for half a day? A. \$5,000 for a day. Q. So the \$4,000 is no longer current? A. It has never been \$4,000. My fees haven't changed in 14 years. Q. In one deposition you may have slipped to say \$4,000 to \$5,000. A. It has always been \$5,000.	8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 whether or not the care that was provided by Dr. Dowlati or any of his team seemed to comply with accepted standards, or do you not have an opinion one way or another on that? A. I would not testify to an opinion, but in my review of the medical records, I believe that accepted standard of care was met in their management of Mr. Gill. Q. He received what type of therapy when it was realized that it was too late to operate? A. I believe there were two separate rounds of chemotherapy, as they like to say, I think. If you'll give me one second, I'll look through my notes here.

7 (Pages 25 to 28)

	Page 29		Page 31
1	Exhibit 4. I take it this was sort of a work in	1	from August up until the time that he died?
2	progress. As you were reviewing the case, you	2	MR. WARNER: Note my objection.
3	made notes and continued to make notes as you	3	A. That's a little out of my realm, the
4	reviewed additional information?	4	realm of my involvement from a medical
11		1	
5	A. The exhibit that I'm reviewing is	5	standpoint. Unfortunately, I don't get involved
6	Plaintiff's Exhibit 4 which are the notes that I	6	in the chemotherapeutic or radiation therapy for
7	make as I review the case to originally generate	7	patients with either recurrent or Stage IV
8	my report, and it's a synopsis of what I feel	8	bronchogenic carcinoma, and I think it would be
9	are the important points of the medical record	9	difficult for me to fairly answer that question.
10	and allows me to review the case in a more	10	Q. We know that he had a bone scan that
11	succinct fashion so that I don't have to dig	11	showed that he had metastasis into the femur,
12	through a large chart at times when we're	12	but as it relates to the degree of pain that the
13	undergoing a deposition.	13	patient was experiencing because of the
14	Q. You at no time in your notes comment	14	metastatic disease, you would just defer on
15	at all on the level of care provided by	15	those issues?
16	Dr. Mansnerus; true?	16	A. Yes. I think that's probably the
17	A. No, I do not. This is specifically	17	fairest thing.
18	factual information that is generated from my	18	Q. Now, I'm going to take you back to
19	review of the medical record.	19	
20		E	your medical-legal and hopefully finish that and
11	Q. Did you ever make any notes when you	20	move on to the balance of your opinions. You
21	read the deposition transcripts and the expert	21	have been doing medical-legal work since about
22	reports that were sent to you at a later point	22	1988?
23	in time?	23	A. That is correct.
24	A. No, I did not.	24	Q. In terms of reviewing records, tell
25	Q. Please, continue.	25	me how many cases you review on average in a
		•	
	Page 30		Page 32
1	A. The initial chemotherapy that was	1	given year.
2	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin	2	given year. A. It varies between years. It can go
2 3	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he		given year. A. It varies between years. It can go anywhere between five to six to probably a high
2	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I	2	given year. A. It varies between years. It can go
2 3	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he	2 3	given year. A. It varies between years. It can go anywhere between five to six to probably a high
2 3 4	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I	2 3 4	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15
2 3 4 5	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not	2 3 4 5	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year?
2 3 4 5 6	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study.	2 3 4 5 6	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't
2 3 4 5 6 7	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and	2 3 4 5 6 7 8	 given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and
2 3 4 5 6 7 8	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year.	2 3 4 5 6 7 8 9	 given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the
2 3 4 5 6 7 8 9 10	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a	2 3 4 5 6 7 8 9 10	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may
2 3 4 5 6 7 8 9 10 11	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to	2 3 4 5 6 7 8 9 10	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a
2 3 4 5 6 7 8 9 10 11 11	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on	2 3 4 5 6 7 8 9 10 11 12	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me.
2 3 4 5 6 7 8 9 10 11 12 13	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to	2 3 4 5 6 7 8 9 10 11 12 13	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily
2 3 4 5 6 7 8 9 10 11 12 13 14	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive?	2 3 4 5 6 7 8 9 10 11 12 13 14	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive? A. I don't believe that this is an	2 3 4 5 6 7 8 9 10 11 12 13 14 15	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past? A. I may have. I don't recall.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive? A. I don't believe that this is an unusual sequence of events for somebody with	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past? A. I may have. I don't recall. Q. All the cases that you've been
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive? A. I don't believe that this is an unusual sequence of events for somebody with Stage IV bronchogenic carcinoma.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past? A. I may have. I don't recall. Q. All the cases that you've been Involved in, have they all been in state court?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive? A. I don't believe that this is an unusual sequence of events for somebody with Stage IV bronchogenic carcinoma. Q. Fortunately, never having had the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past? A. I may have. I don't recall. Q. All the cases that you've been Involved in, have they all been in state court? A. I have recently reviewed I believe a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive? A. I don't believe that this is an unusual sequence of events for somebody with Stage IV bronchogenic carcinoma. Q. Fortunately, never having had the experience of a family member going through this 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past? A. I may have. I don't recall. Q. All the cases that you've been Involved in, have they all been in state court? A. I have recently reviewed I believe a case for the State of Ohio which is not a civil
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive? A. I don't believe that this is an unusual sequence of events for somebody with Stage IV bronchogenic carcinoma. Q. Fortunately, never having had the experience of a family member going through this in a terminal phase, can you educate me just a 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past? A. I may have. I don't recall. Q. All the cases that you've been Involved in, have they all been in state court? A. I have recently reviewed I believe a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive? A. I don't believe that this is an unusual sequence of events for somebody with Stage IV bronchogenic carcinoma. Q. Fortunately, never having had the experience of a family member going through this in a terminal phase, can you educate me just a bit in terms of once you get past the 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past? A. I may have. I don't recall. Q. All the cases that you've been Involved in, have they all been in state court? A. I have recently reviewed I believe a case for the State of Ohio which is not a civil
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive? A. I don't believe that this is an unusual sequence of events for somebody with Stage IV bronchogenic carcinoma. Q. Fortunately, never having had the experience of a family member going through this in a terminal phase, can you educate me just a bit in terms of once you get past the realization that you have a terminal disease and 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past? A. I may have. I don't recall. Q. All the cases that you've been Involved in, have they all been in state court? A. I have recently reviewed I believe a case for the State of Ohio which is not a civil suit related to a physician. It's a case that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive? A. I don't believe that this is an unusual sequence of events for somebody with Stage IV bronchogenic carcinoma. Q. Fortunately, never having had the experience of a family member going through this in a terminal phase, can you educate me just a bit in terms of once you get past the realization that you have a terminal disease and 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past? A. I may have. I don't recall. Q. All the cases that you've been Involved in, have they all been in state court? A. I have recently reviewed I believe a case for the State of Ohio which is not a civil suit related to a physician. It's a case that is I think being defended by the State of Ohio. But other than that, they have all been cases
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive? A. I don't believe that this is an unusual sequence of events for somebody with Stage IV bronchogenic carcinoma. Q. Fortunately, never having had the experience of a family member going through this in a terminal phase, can you educate me just a bit in terms of once you get past the realization that you have a terminal disease and surgery is out of the question, how painful is 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past? A. I may have. I don't recall. Q. All the cases that you've been involved in, have they all been in state court? A. I have recently reviewed I believe a case for the State of Ohio which is not a civil suit related to a physician. It's a case that is I think being defended by the State of Ohio. But other than that, they have all been cases similar to what you mentioned.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A. The initial chemotherapy that was rendered by Dr. Dowlati consisted of carboplatin and taxol, and I believe at one point in time he was a candidate for robimycin therapy, and I think he started that therapy but did not respond well and was subsequently removed from that study. Q. His diagnosis was July-August and then he died in February of the following year. Is that a fairly common stretch of time in a Stage IV cancer of this type, for someone to live that length of time, or did he hold on longer than you would expect for a patient to survive? A. I don't believe that this is an unusual sequence of events for somebody with Stage IV bronchogenic carcinoma. Q. Fortunately, never having had the experience of a family member going through this in a terminal phase, can you educate me just a bit in terms of once you get past the realization that you have a terminal disease and 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	given year. A. It varies between years. It can go anywhere between five to six to probably a high of 13 or 14 per year. Q. Have you ever reviewed as many as 15 to 20 cases in a year? A. It's certainly possible. I don't keep track of the numbers of cases I do, and usually once they're done I get rid of the records. It's certainly possible that I may have done that many in one year. It would be a busy year for me. Q. That's not something you readily recall having done in the recent past? A. I may have. I don't recall. Q. All the cases that you've been involved in, have they all been in state court? A. I have recently reviewed I believe a case for the State of Ohio which is not a civil suit related to a physician. It's a case that is I think being defended by the State of Ohio. But other than that, they have all been cases similar to what you mentioned.

8 (Pages 29 to 32)

[
	Page 33		Page 35
1	you been an expert in a case that was venued in	1	last two to three years?
2	federal court?	2	A. I'm not sure I've been monopolized.
3	A. No, I have not.	3	I think it's been probably by my choice. There
4	Q. You have never been known to have	4	are two specific reasons. Since becoming a
5	prepared a Rule 26 disclosure of the cases and	5	Cleveland Clinic Foundation clinic, we're
6	the subject matter from which those cases	6	discouraged from reviewing cases for plaintiffs'
7	evolved for any court?	7	counsels, and I've had a couple of bad
8	A. No, I have not.	8	experiences in the past with plaintiffs'
9	Q. Or for any attorney for that matter?	9	counsels who decided they didn't want to pay for
10	A. No, I have not.	10	their services.
11	Q. Have you ever reviewed a case	11	Q. There are black sheep in every
12	similar to Mr. Gill where you were asked to	12	family.
13	provide an opinion on the issues of proximate	13	A. Yes. Lagree.
14	cause in a patient where an allegation was	14	Q. Since you haven't met me until now,
15	asserted that there was a delay in timely	15	we can honestly say that experience wasn't with
16	diagnosing lung cancer?	16	me.
17	A. Yes, I have.	17	A. That is correct.
18	Q. How many cases would fall in that	18	Q. I want to talk a moment about the
19	description?	19	topic of your own claim history. I think, at
20	A. Boy, I think probably only one that	20	least from some of my homework, that you've been
21	I can remember.	21	named is it five times as a defendant?
22	Q. Tell me, by that answer there might	22	A. I believe so.
23	be more but	23	Q. Are any of those cases currently
24	A. One that I remember for sure, and I		pending?
25	don't recall specifically other cases.	25	A. No. They are all resolved.
			~ ^^
1	Page 34 Q. Tell me about the one that you do	1	Page 36 Q. One got dismissed after voir dire?
2	remember.	2	A. That is correct.
3	A. It was a case I believe back in	3	Q. One was dismissed during the case,
4	1996. I was asked by Steve Charms to review a	4	perhaps opening statements, or dropped I should
5	case for a plaintiff in the same similar	5	say?
6	situation where there was a four- or six-month	6	A. I'm only aware of one case being
7	delay in making a diagnosis of bronchogenic	7	dismissed. Actually, I think it was after voir
8	carcinoma. At that time they did not feel that	8	dire. It was right at the time of opening
9	the delay was significant in terms of proximate	9	statements.
10	cause, and I don't believe that Mr. Charms	10	Q. Have any of the cases that you've
11	proceeded with the case, but that would be	11	been a defendant in involved issues arising out
12	something that you would have to ask him.	12	of cancer treatment?
13	Q. Have you ever testified as an expert	13	A. Yes, an esophageal carcinoma case.
14	in a case on either side in a case with similar	14 14	Q. Was that a Mt. Sinai case or a
15	issues to what we have in Mr. Gill's case?	15	Cleveland Clinic case?
16	A. No, I have not.	16	A. A University Hospital case.
17	Q. In the last two to three years in	17	Q. You were originally at Mt. Sinai;
18	terms of your review of cases in the medical	18	correct?
19	malpractice area, tell me what the breakdown has	19	A. That is correct.
20	been of plaintiff versus defendant where you've	20	Q. Then University, and your Cleveland
21	been asked.	21	Clinic affiliation has been for how long now?
22	A. In the last two to three years,	22	A. A little more than three years.
23	100 percent for the defense.	23	Q. So were you with Alan Markowitz back
24	Q. Do you know the reason why you have	24	at Mt. Sinai?
25	been monopolized by the defense bar over the	25	A. Yes.
	been monopolitied by the detende par over the	المد ساك	/ 1. ICJ.

9 (Pages 33 to 36)

r			
	Page 37		Page 39
1	Q. And Holland and all those guys?	1	Q. Dr. Rozman has referred his patients
2	A. Yes.	2	for surgical intervention, not just for cancer
3	Q. I'm starting to show my age. The	3	issues, but for other cardiothoracic issues to
4	esophageal cancer case, do you remember the name	4	you?
5	of the plaintiff in that matter?	5	A. I think they have all been for
6	A. Sidney Segal.	6	patients who have had cardiothoracic issues who
7	Q. Was the allegation against you	7	have been referred to a cardiologist who has
8	relative to surgical approach to the	8	called me regarding surgical interventions on
9	A. No. I believe it was management,	9	those patients. He himself specifically I don't
10	postoperative management.	10	believe has ever called me.
11	Q. Do you happen to remember who the	11	Q. There has been a middleman?
12	plaintiff's attorney was in that case?	12	A. Yes.
13	A. Peter Weinberger.	13	Q. Have you ever had any professional
11		14	
14	Q. How many times would you say in your		dealings with Dr. Rozman other than knowing that
15	best estimate that you have been deposed since	15	he was the attending for that patient that
16	1988 so now 16 years?	16	actually came to you?
17	A. Gee, it's got to be 60, 70, 80	17	A. No, I have not.
18	times.	18	Q. Dr. Levitan, you said that you've
19	Q. When was the last time you were	19	done some surgical work on some of his patients?
20	deposed in a medical malpractice case before	20	A. We have had patients where we have
21	today?	21	interacted together managing thoracic oncologic
22	A. Probably three months ago.	22	issues, be they lung carcinoma or esophageal
23	Q. Obviously, you were serving as an	23	carcinoma or other malignancies of the chest,
24	expert for the defense in that case.	24	, , ,
25	A. That is correct.	25	have either somehow developed a recurrent
		[
	Page 38		Page 40
1	Q. That was a Reminger & Reminger case?	1	disease or had significant enough disease that
2	A. I believe so.	2	they require oncologic consultation, and he has
3	Q. When are you scheduled next to give	3	been the oncologist of choice.
4	a deposition, assuming that we ever finish this	4	Q. Do you have an ongoing professional
5	one?	5	relationship?
6	A. I'm actually not, believe it or not.	6	A. Not really. He is a University
7	Q. This case is scheduled for trial in	7	Hospital physician, and I am now a Cleveland
8	April, I think. Rob and I were scratching our	8	Clinic physician. So we don't interact as we
9	heads before. Are you scheduled for any other	9	perhaps might have in the past. We do still
10	trials in the foreseeable future other than this	10	
11	matter?	11	he sees in follow-up that are patients of both
12	A. I don't believe so.	12	of us. But, obviously, that number becomes less
13	Q. I presume that Mr. Warner has asked	13	and less as I do more and more within the
14	you to testify in the trial of this case?	14	confines of the Cleveland Clinic Foundation, and
15		15	
H	A. Yes, he has.		his practice is within the confines of the
16	Q. What has your answer been?	16	University Hospitals Health System.
17	A. I'd be happy to, yes.	17	Q. Doctor, there's another expert
18	Q. Do you know Dr. Mansnerus?	18	pathologist whose name is escaping me.
19	A. I do not.	19	A. Dr. Casey. Yes, I do know her.
20	Q. Do you know any of the experts in	20	Q. You know Dr. Casey?
21	this case?	21	A. Yes.
22	A. I have operated upon a few patients	22	Q. How do you know Dr. Casey?
23	of Dr. Rozman's, and I have interacted with	23	A. She's a pathologist at Parma
24	patients with general thoracic malignancies with	24	Community General Hospital.
25	Dr. Levitan.	25	Q. Other than knowing she's a

10 (Pages 37 to 40)

	Page 41		Page 43
1	pathologist at Parma, what type of	1	at Reminger & Reminger?
	relationship	2	A. Yes, I have.
3	A. She has reviewed pathologic slides	3	Q. Besides Mr. Warner, are there any
18	of mine in cases that I've done in the past.	4	active files in your office that you are serving
5		5	
11	Q. Have you ever served as an expert to	-	as an expert on for other attorneys from
	your knowledge in a case where Dr. Rozman,	6	Reminger & Reminger currently?
	Dr. Levitan, or Dr. Casey were also serving as	7	A. I don't believe so for Reminger &
8	an expert?	8	Reminger. There are other firms, but I don't
9	A. I don't believe so. There may have	9	believe so for Reminger & Reminger.
10	been cases where Dr. Levitan was serving as an	10	Q. Those would be other defense firms?
	expert. Again, I can't tell you that with	11	A. Yes.
	certainty, but I know he does a fair amount of	12	
			Q. Other local Cleveland defense firms?
	medical malpractice work, and we may have	13	A. Yes.
	interacted in the past on a case. Again, I	14	Q. In terms of the attorneys that you
15	don't know a specific name clearly. I have not	15	have worked with in the past from Reminger ਲ
16	with Dr. Rozman or Dr. Casey.	16	Reminger, can you help me out with any of the
17	Q. Flipping tabs, Dr. Steele,	17	names?
18	Dr. Sutherland and Dr. Bass, do you know any one	18	A. I believe I have served as an expert
11	of them?	19	witness for Marc Groedel, Bill Meadows,
20	A. No, I do not.	20	P.J. Malnar, and I think that really probably is
21		1	
	Q. The young man seated to your left	21	about it.
	you're looking for a young man.	22	Q. You have also, have you not, served
23	MR. WARNER: You've got to look for	23	as an expert for Steve Walters?
24	a young man.	24	A. I may have.
25	Q. A number of years ago that would	25	Q. Jim Malone?
4	compliment. You have had occasion, have you not, to serve as an expert representing doctors that	3	Q. He is unless he has gotten kicked
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Mr. Warner has represented? A. Yes, I have. Q. On how many occasions have you been called on by Mr. Warner? A. A guesstimate, six or eight. Q. Have you testified at trial in any of those cases? A. Yes, I have. Q. How many? A. Three or four. Q. Was one of those in the fall of this last year? A. I believe so, yes. Q. Do you remember the name of the doctor or patient in that matter? 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	out recently. MR. WARNER: Yes, he is. Q. Steve Crandall when Steve Crandall was at Reminger? A. A long time ago, yes. MR. WARNER: He's now a plaintiff's counsel. A. Yes, he is. But at times in the past, yes. Q. But your testimony is that currently you don't have any open cases with Reminger & Reminger? A. I don't believe that I do. Q. Hopefully, I'm going to confine the remainder of my questions to your report. So if you want to get that, I'm not going to have you read over your notes, but I am going to want to
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Mr. Warner has represented? A. Yes, I have. Q. On how many occasions have you been called on by Mr. Warner? A. A guesstimate, six or eight. Q. Have you testified at trial in any of those cases? A. Yes, I have. Q. How many? A. Three or four. Q. Was one of those in the fall of this last year? A. I believe so, yes. Q. Do you remember the name of the doctor or patient in that matter? A. I think as I get older I remember 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	MR. WARNER: Yes, he is. Q. Steve Crandall when Steve Crandall was at Reminger? A. A long time ago, yes. MR. WARNER: He's now a plaintiff's counsel. A. Yes, he is. But at times in the past, yes. Q. But your testimony is that currently you don't have any open cases with Reminger & Reminger? A. I don't believe that I do. Q. Hopefully, I'm going to confine the remainder of my questions to your report. So if you want to get that, I'm not going to have you read over your notes, but I am going to want to get copies of that, if you would, just for
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 1	 Mr. Warner has represented? A. Yes, I have. Q. On how many occasions have you been called on by Mr. Warner? A. A guesstimate, six or eight. Q. Have you testified at trial in any of those cases? A. Yes, I have. Q. How many? A. Three or four. Q. Was one of those in the fall of this last year? A. I believe so, yes. Q. Do you remember the name of the doctor or patient in that matter? A. I think as I get older I remember less and less of the names. I can't, to be 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MR. WARNER: Yes, he is. Q. Steve Crandall when Steve Crandall was at Reminger? A. A long time ago, yes. MR. WARNER: He's now a plaintiff's counsel. A. Yes, he is. But at times in the past, yes. Q. But your testimony is that currently you don't have any open cases with Reminger & Reminger? A. I don't believe that I do. Q. Hopefully, I'm going to confine the remainder of my questions to your report. So if you want to get that, I'm not going to have you read over your notes, but I am going to want to get copies of that, if you would, just for purposes of housekeeping. If you could, just
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 1 22 1 23	 Mr. Warner has represented? A. Yes, I have. Q. On how many occasions have you been called on by Mr. Warner? A. A guesstimate, six or eight. Q. Have you testified at trial in any of those cases? A. Yes, I have. Q. How many? A. Three or four. Q. Was one of those in the fall of this last year? A. I believe so, yes. Q. Do you remember the name of the doctor or patient in that matter? A. I think as I get older I remember less and less of the names. I can't, to be honest with you. I can't remember specifically. 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	MR. WARNER: Yes, he is. Q. Steve Crandall when Steve Crandall was at Reminger? A. A long time ago, yes. MR. WARNER: He's now a plaintiff's counsel. A. Yes, he is. But at times in the past, yes. Q. But your testimony is that currently you don't have any open cases with Reminger & Reminger? A. I don't believe that I do. Q. Hopefully, I'm going to confine the remainder of my questions to your report. So if you want to get that, I'm not going to have you read over your notes, but I am going to want to get copies of that, if you would, just for purposes of housekeeping. If you could, just identify it. I think Exhibit 4 are your notes.
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 1 23 1 24	 Mr. Warner has represented? A. Yes, I have. Q. On how many occasions have you been called on by Mr. Warner? A. A guesstimate, six or eight. Q. Have you testified at trial in any of those cases? A. Yes, I have. Q. How many? A. Three or four. Q. Was one of those in the fall of this last year? A. I believe so, yes. Q. Do you remember the name of the doctor or patient in that matter? A. I think as I get older I remember less and less of the names. I can't, to be honest with you. I can't remember specifically. Q. What was I just asking you? You've 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	MR. WARNER: Yes, he is. Q. Steve Crandall when Steve Crandall was at Reminger? A. A long time ago, yes. MR. WARNER: He's now a plaintiff's counsel. A. Yes, he is. But at times in the past, yes. Q. But your testimony is that currently you don't have any open cases with Reminger & Reminger? A. I don't believe that I do. Q. Hopefully, I'm going to confine the remainder of my questions to your report. So if you want to get that, I'm not going to have you read over your notes, but I am going to want to get copies of that, if you would, just for purposes of housekeeping. If you could, just
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 1 22 1 23 1 24	 Mr. Warner has represented? A. Yes, I have. Q. On how many occasions have you been called on by Mr. Warner? A. A guesstimate, six or eight. Q. Have you testified at trial in any of those cases? A. Yes, I have. Q. How many? A. Three or four. Q. Was one of those in the fall of this last year? A. I believe so, yes. Q. Do you remember the name of the doctor or patient in that matter? A. I think as I get older I remember less and less of the names. I can't, to be honest with you. I can't remember specifically. 	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	MR. WARNER: Yes, he is. Q. Steve Crandall when Steve Crandall was at Reminger? A. A long time ago, yes. MR. WARNER: He's now a plaintiff's counsel. A. Yes, he is. But at times in the past, yes. Q. But your testimony is that currently you don't have any open cases with Reminger & Reminger? A. I don't believe that I do. Q. Hopefully, I'm going to confine the remainder of my questions to your report. So if you want to get that, I'm not going to have you read over your notes, but I am going to want to get copies of that, if you would, just for purposes of housekeeping. If you could, just identify it. I think Exhibit 4 are your notes.

11 (Pages 41 to 44)

		1	
	Page 45		Page 47
1	and I'm just going to trust you to or you'll	1	at in terms of determining how anaplastic a
2	work out arrangements with the court reporter	2	tumor is.
3	for copies.	3	Q. In the same last paragraph of your
4	A. There are a total of seven pages in	4	letter, the incurability of Mr. Gill's disease
5	Plaintiff's Exhibit 4.	5	was present at the time of his presentation in
6	Q. The last three words in your report	6	December 1999, et cetera, that is an opinion
7	are aggressive bronchogenic carcinoma?	7	that you hold in this case; correct?
8	A. Correct.	8	A. That is correct.
9	Q. Can you tell me when this	9	
10		1	Q. Can you tell me when, if you are
11	bronchogenic carcinoma became aggressive?	10	correct in regard to that opinion, when prior to
11	A. I think that term is used in	11	December of 1999 did his lung cancer become
12	relationship to bronchogenic carcinomas that are	12	incurable?
13	less aggressive, and it may end up with survival	13	A. I don't know that. I can't
14	at times measured in years from the time of	14	• •
15	diagnosis, whereas this one is measured in terms	15	supposition. The only information I have is the
16	of months. I think all bronchogenic carcinomas	16	time of his initial presentation in December of
17	are clearly aggressive because if untreated	17	1999. It is my opinion that at that point in
18	people die from them. His form I think was	18	time his cancer was incurable. I can't make a
19	reasonably virulent given the fact that his	19	projection back retrospectively from there
20	diagnosis was in August and his expiration was	20	because I have no information as to what the
21	in February.	21	clinical status was prior to that.
22	Q. Do you have an opinion as to when he	22	Q. Jump back to the first page of your
23	first developed the bronchogenic carcinoma?	23	report. On December 9 when Mr. Gill presented,
24	A. I would suspect years anteceding the	24	
25	actual diagnosis.	25	,
		25	symptoms that he presented to Dr. Mansnerus
		1	
11	Dogo 46		D
1	Page 46		Page 48
1	Q. Can you be more specific than years?	1	with, that being the left-sided chest pain and
2	Q. Can you be more specific than years?A. No, because I don't have factual	2	with, that being the left-sided chest pain and numbress or weakness of the left arm?
2 3	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling 	2 3	with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only
2 3 4	Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor	2 3 4	with, that being the left-sided chest pain and numbress or weakness of the left arm?A. These may not have been the only symptoms, but they were the ones that 1 felt
2 3 4 5	Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something	2 3 4 5	with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition.
2 3 4 5 6	Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to	2 3 4 5 6	with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as
2 3 4 5 6 7	Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan	2 3 4 5 6 7	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to
2 3 4 5 6 7 8	Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes	2 3 4 5 6	with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as
2 3 4 5 6 7 8 9	Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at	2 3 4 5 6 7 8 9	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review
2 3 4 5 6 7 8 9 10	Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters.	2 3 4 5 6 7 8	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit?
2 3 4 5 6 7 8 9 10 11	Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at	2 3 4 5 6 7 8 9	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review
2 3 4 5 6 7 8 9 10	Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters.	2 3 4 5 6 7 8 9 10	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate
2 3 4 5 6 7 8 9 10 11	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always 	2 3 4 5 6 7 8 9 10 11	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long
2 3 4 5 6 7 8 9 10 11 11 12	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they 	2 3 4 5 6 7 8 9 10 11 12	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred.
2 3 4 5 6 7 8 9 10 11 12 13	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? 	2 3 4 5 6 7 8 9 10 11 12 13 14	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel
2 3 4 5 6 7 8 9 10 11 12 13 14	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? A. I think the correct ideation here is 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel that the symptoms that Mr. Gill presented with
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? A. I think the correct ideation here is the more anaplastic the tumor is, the more 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel that the symptoms that Mr. Gill presented with on December 30, 1999, were consistent with the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? A. I think the correct ideation here is the more anaplastic the tumor is, the more likely it is to have rapid growth, the more 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel that the symptoms that Mr. Gill presented with on December 30, 1999, were consistent with the bronchogenic carcinoma?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? A. I think the correct ideation here is the more anaplastic the tumor is, the more likely it is to spread systemically rather than 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel that the symptoms that Mr. Gill presented with on December 30, 1999, were consistent with the bronchogenic carcinoma? A. I think that they were consistent
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 7 18 19	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? A. I think the correct ideation here is the more anaplastic the tumor is, the more likely it is to spread systemically rather than local regionally, and the greater the likelihood 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel that the symptoms that Mr. Gill presented with on December 30, 1999, were consistent with the bronchogenic carcinoma? A. I think that they were consistent
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? A. I think the correct ideation here is the more anaplastic the tumor is, the more likely it is to spread systemically rather than local regionally, and the greater the likelihood is that the outcome will be poor. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 7 18 19 20	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel that the symptoms that Mr. Gill presented with on December 30, 1999, were consistent with the bronchogenic carcinoma? A. I think that they were consistent with a probable postobstructive pneumonia. I think he probably did have a pneumonia at that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? A. I think the correct ideation here is the more anaplastic the tumor is, the more likely it is to spread systemically rather than local regionally, and the greater the likelihood is that the outcome will be poor. Q. Tell me what you mean by anaplastic. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel that the symptoms that Mr. Gill presented with on December 30, 1999, were consistent with the bronchogenic carcinoma? A. I think that they were consistent with a probable postobstructive pneumonia. I think he probably did have a pneumonia at that point in time. Perhaps, and again this is still
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? A. I think the correct ideation here is the more anaplastic the tumor is, the more likely it is to spread systemically rather than local regionally, and the greater the likelihood is that the outcome will be poor. Q. Tell me what you mean by anaplastic. A. The character of the tumor as you 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel that the symptoms that Mr. Gill presented with on December 30, 1999, were consistent with the bronchogenic carcinoma? A. I think that they were consistent with a probable postobstructive pneumonia. I think he probably did have a pneumonia at that point in time. Perhaps, and again this is still supposition, he had a bronchial mass that was
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? A. I think the correct ideation here is the more anaplastic the tumor is, the more likely it is to spread systemically rather than local regionally, and the greater the likelihood is that the outcome will be poor. Q. Tell me what you mean by anaplastic. A. The character of the tumor as you view it under the microscope, its histologic 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel that the symptoms that Mr. Gill presented with on December 30, 1999, were consistent with the bronchogenic carcinoma? A. I think that they were consistent with the probable postobstructive pneumonia. I think he probably did have a pneumonia at that point in time. Perhaps, and again this is still supposition, he had a bronchial mass that was obstructing the airway up to the left upper lobe
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? A. I think the correct ideation here is the more anaplastic the tumor is, the more likely it is to spread systemically rather than local regionally, and the greater the likelihood is that the outcome will be poor. Q. Tell me what you mean by anaplastic. A. The character of the tumor as you view it under the microscope, its histologic picture, how it invades things, the cytologic 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel that the symptoms that Mr. Gill presented with on December 30, 1999, were consistent with the bronchogenic carcinoma? A. I think that they were consistent with the probable postobstructive pneumonia. I think he probably did have a pneumonia at that point in time. Perhaps, and again this is still supposition, he had a bronchial mass that was obstructing the airway up to the left upper lobe that caused pneumonia to develop. Clearly, we
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. Can you be more specific than years? A. No, because I don't have factual evidence to stipulate what the tumor doubling time is. In general, what we know from tumor biology is that it takes years for something like this to develop from one or two cells to something that can be detectable by a CAT scan at 5 millimeters to something that then becomes detectable in a size similar to this at 4 centimeters. Q. Do bronchogenic carcinomas always follow a linear pattern in terms of growth, or are there certain cancers that the longer they go untreated the more aggressive they become? A. I think the correct ideation here is the more anaplastic the tumor is, the more likely it is to spread systemically rather than local regionally, and the greater the likelihood is that the outcome will be poor. Q. Tell me what you mean by anaplastic. A. The character of the tumor as you view it under the microscope, its histologic 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 with, that being the left-sided chest pain and numbness or weakness of the left arm? A. These may not have been the only symptoms, but they were the ones that I felt were pertinent to his clinical condition. Q. Do you know how long he had had as of December 9 the symptoms that he described to Dr. Mansnerus during that December 9 visit? A. I would have to review Dr. Mansnerus' office records. If you'd like, I can do that. It doesn't specifically stipulate in the transcribed letter of 12-9-99 how long those symptoms had occurred. Q. In retrospect, I believe you feel that the symptoms that Mr. Gill presented with on December 30, 1999, were consistent with the bronchogenic carcinoma? A. I think that they were consistent with the probable postobstructive pneumonia. I think he probably did have a pneumonia at that point in time. Perhaps, and again this is still supposition, he had a bronchial mass that was obstructing the airway up to the left upper lobe

12 (Pages 45 to 48)

1 bronchogenic malignancy, and that in concert 2 with his presentation puts together the picture 3 with these symptoms. 4 Q. With left-sided chest pain 5 associated with numbers and weakness of the 6 left arm in a patient who has obstructive 7 bronchogenic carcinoma? 10 bronchogenic carcinoma? 11 A. The left-sided chest pain clearly 14 oplinon that the numberss and weakness of the 15 left arm is a result of metastatic nodal disease 16 in the supraclavicular forss athat is either 17 ritrating or perhaps invading his brachial 18 plexus resulting in the numbness and weakness of the 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. 1 A. He may or may not have done the 2 examination. That's a question that you would 3 maybe nodal involvement? 24 MR. WARNER: Objection. 25 MR. WARNER: Objection. 2 A. He may or may not have done the 2 examination, and he did not note any palpable (mph)			T	·····
1 bronchogenic malignancy, and that in concert 2 with his presentation puts together the picture 3 with his presentation puts together the picture 4 Q. With left-sided chest pain 5 associated with numbers and weakness of the 6 left arm in a patient who has obstructive 7 bronchogenic carcinoma? 11 A. The left-sided chest pain clearly 12 would be a reflection of pleuritic irritation 13 from the obstructive pneumonia. It is my 14 oplino that the numberss and weakness of the 15 left arm is a result of metastatic nodal disease 16 in the supraclavicular forssa that is either 17 Q. Clinically, did Dr. Mansnerus from 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. 1 and 14 organot make as subjetion or the 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. 12 Q. Would you expect that palpable lymph 13 nodes would be detectable given what we know at 14 organtatic, yas a <td></td> <td>Page 49</td> <td></td> <td>Page 51</td>		Page 49		Page 51
2 with his presentation puts together the picture 3 with these symptoms. 4 Q. With left-sided chest pain 5 associated with numbness and weakness of the 6 left arm in a patient who has obstructive 7 pronchogenic carcinoma that first manifested 8 itself by a pneumonia, would those types of 9 symptoms be consistent with obstructive 10 Dorochogenic carcinoma? 11 A. The left-sided chest pain clearly 12 would be a reflection of pleuritic irritation 13 from the obstructive pneumonia. It is my 14 opinion that the numbness and weakness of the 16 in the supraclavicular fossa that is either 17 ritizing or perhaps invading his brachial 18 antibiotic therapy had been administered and thi 19 difficulties he was experiencing in his left 20 arm. 21 Q. Clinically, did Dr. Mansnerus from 22 MR. WARNER: Objection. Go ahead. 23 MR. WARNER: Objection. Go ahead. 24 A. He may or may not have too and have to aget this symptom complex without palpable lymph	1 1		1	
3substructive3supposition.4Q. With left-sided chest painIt would depend upon how his5associated with numbness and weakness of theistelf by a pneumonia, would those types ofpostobstructive pneumonia responded to the7bronchogenic carcinoma?It would be are nough to ascertain the10bronchogenic carcinoma?It would be a reflection of pleuritic irritation11A. The left-sided chest pain clearlyIt would be a reflection of pleuritic irritation12would be a reflection of pleuritic irritationIt is there13epriod, would that the numbness and weakness of theis the unusual or would that be14oplnion that the numbness and weakness of theis the upraclavicular fossa that is either13pretmodia would for the bostructive pneumonia. It is myin the supraclavicular fossa that is either14oplnion that the numbness and motorin the supraclavicular fossa that is either13g. Clinically, did Dr. Mansnerus from24discovered any nodal involvement?25MR. WARNER: Objection. Go ahead.14A. He may or may not have done the25mR. WARNER: Objection. That's a question that you would3have to ask. It's not stipulated specifically4in the medical record that he did the5nodes would be detectable given what we know at6MR. WARNER: Objection.7Q. Would you expect that palpable lymph8nodes would be detectable given what we know at9the end of the stor	1		1	-
4 Q. With left-sided chest pain 5 associated with numbness and weakness of the 6 left arm in a patient who has obstructive 7 bronchogenic carcinoma; 11 A. The left-sided chest pain clearly 2 would be a reflection of pleuritic irritation 12 would be a reflection of pleuritic irritation 13 From the obstructive pneumonia. It is my 14 opinion that the numbness and weakness of the 15 left arm is a result of metastatic nodal disease 16 in the supraclavicular fossa that is either 17 irritating or perhaps invading his brachial 18 pericod, would have been present. 21 Q. Clinically, did Dr. Mansnerus from 22 what you can see from his deposition or the 23 records do an exam where he palpated or 24 discovered ary nodal involvement? 25 MR. WARNER: Objection. Go ahead. 1 A. He may or may not have done the 2 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph nodes would be detectable giv	11		E	
5 associated with numbness and weakness of the 5 postobstructive pneumonia responded to the 6 left arm in a patient who has obstructive antibiotic therapy and whether or not the 7 bronchogenic carcinoma that first manifested antibiotic therapy and whether or not the 8 itself by a pneumonia, would those types of 9 9 symptoms be consistent with obstructive 7 10 bronchogenic carcinoma? 11 11 A. The left-sided chest pain clearly 0 If a film had been taken and it 12 would be a reflection of pleuritic irritation 15 in the supraclavicular fossa that is either 15 left arm is a result of metastatic nodal disease 16 not supraclavicular fossa that is either 16 of clincally, did Dr. Mansnerus from 18 antibiotic therapy and what not resolved. Potentially, both 18 patient what is a former smoker 21 Q. Clinically, did Dr. Mansnerus from 24 discovered any nodal involvement? 22 In a patient what is a former smoker 25 MR. WARNER: Objection. Go ahead. 1 Index of substatial years, if a 25 MR. WARNER: Objection. Go ahead. 1 <td< td=""><td>H</td><td></td><td>1</td><td></td></td<>	H		1	
6 left arm in a patient who has obstructive 6 antibiotic therapy and whether or not the 7 bronchogenic carcinoma that first mailfested absence or presence of a lung mass, and I can't 9 symptoms be consistent with obstructive absence or presence of a lung mass, and I can't 10 bronchogenic carcinoma? 10 Q. If a film had been taken and it 11 A. The left-sided chest pain clearly 11 showed continued infiltrates at a six-week time 12 would be a reflection of pleuritic irritation 13 from the obstructive pneumonia. It is my 14 opinion that the numbness and weakness of the 15 left arm is a result of metastatic nodal disease 16 in the supractavicular fosts that is either 17 oftaren arcitecy pneumonia? 17 Q. Clinically, did Dr. Mansnerus from 18 oft those issues could have been present. 21 Q. Clinically, did Dr. Mansnerus from 23 chest X-ray had been done, a follow-up chest 24 discovered any notal involvement? 23 oft those issues could have been present. 25 MR. WARNER: Objection. Go ahead. 7 MR. WARNER: Objection. 7 Q. Would you expect that palpable lymph nodes. <td< td=""><td>11</td><td></td><td></td><td></td></td<>	11			
7bronchogenic carcinoma that first manifested8itself by a pneumonia, would those types of9symptoms be consistent with obstructive10bronchogenic carcinoma?11A. The left-sided chest pain clearly12would be a reflection of pleuritic irritation13rom the obstructive pneumonia. It is my14opinion that the numbness and weakness of the15left arm is a result of metastatic nodal disease16in the supraclavicular fossa that is either17irritating or perhaps invading his brachial18plexus resulting in the numbness and motor19difficulties he was experiencing in his left20arm.21Q. Clinically, did Dr. Mansnerus from22MR. WARNER: Objection. Go ahead.23MR. WARNER: Objection. Go ahead.24discovered any nodal involvement?25MR. WARNER: Objection. Go ahead.26I27Q. Would you expect that palpable (hymph3nodes would be detectable given what we know at4modes would be detectable given what we know at5nodes. You can get this symptom complex without palpable (hymph11A. They may or may not have. You can12Q. Would you expect that palpable (hymph3modes would be detectable given what we know at4the end of the story, if you will?10A. They may or may not have. You can11get this symptom complex without palpable (hymph12nodes. You can	11		1	
8 itself by a pneumonia, would those types of 9 9 symptoms be consistent with obstructive 0 10 bronchogenic carcinoma? 11 11 A. The left-sided chest pain clearly 10 12 would be a reflection of pleuritic irritation 11 13 from the obstructive pneumonia. It is my 13 14 oplinion that the numbness and weakness of the 15 15 left arm is a result of metastatic nodal disease 16 16 in the supraclavicular fossa that is either 17 17 irritating or perhaps invading his brachial 18 18 plexus resulting in the numbness and motor 18 18 plexus resulting in the numbness and motor 18 20 A. I think both. I think it would be 21 Q. Clinically, did Dr. Mansnerus from 28 22 MR. WARNER: Objection. Go ahead. 21 23 MR. WARNER: Objection. Go ahead. 21 24 discovered any nodal involvement? 22 24 discovered any nodal involvement? 22 24 discovered any nodal inot note any palpable	8		1	
 9 symptoms be consistent with obstructive 9 bronchogenic carcinoma? 11 A. The left-sided chest pain clearly 12 would be a reflection of pleuritic irritation 13 from the obstructive pneumonia. It is my 14 opinion that the numbness and weakness of the 15 left arm is a result of metastatic nodal disease 16 in the supraclavicular fossa that is either 17 irritating or perhaps invading his brachlal 19 glexus resulting in the numbness and motor 19 difficulties he was experiencing in his left 20 arm. 21 Q. Clinically, did Dr. Mansnerus from 22 what you can see from his deposition or the 23 records do an exam where he palpated or 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. 10 A. He may or may not have done the examination. That's a question that you would 3 have to ask. It's not stipulated specifically 4 in the medical record that he did the examination, and he did not note any palpable f ymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 4 the end of the story, if you will? 10 A. The may or may not have. You can 11 get this symptom complex withou 12 should keep in the back of his mind that that is a possibility, yes. 13 should keep in the back of his mind that that is a possibility, yes. 14 available to that astute clinician to rule out 15 hroolybement as well. It's not always a 16 strouts? 	1			
10 bronchogenic carcinoma? 11 A. The left-sided chest pain clearly 12 would be a reflection of pleuritic irritation 13 from the obstructive pneumonia. It is my 14 opinion that the numbness and weakness of the 15 left arm is a result of metastatic nodal disease 16 in the supraclavicular fossa that is either 17 irritating or perhaps invading his brachial 18 plexus resulting in the numbness and motor 19 difficulties he was experiencing in his left 20 artibiotic therapy had been administered and the 21 Q. Clinically, did Dr. Mansnerus from 22 what you can see from his deposition or the 23 records do an exam where he palpated or 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. Page 50 1 A. He may or may not have done the 2 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph 10 A. They may or may not have. You can 11 get this symptom complex wi	11		4	
11 A. The left-sided chest pain clearly 11 showed continued infiltrates at a sk-week time 12 would be a reflection of pleuritic irritation 12 period, would that be unusual or would that be 13 from the obstructive pneumonia. It is my 14 showed continued infiltrates at a sk-week time 14 opinion that the numbness and weakness of the 15 a concerning at all in a patient with a diagnosis 15 left arm is a result of metastatic nodal disease of garden variety pneumonia? 15 16 in the supraclavicular fossa that is either 15 A. I think both. I think it would be 16 order arm, and pain bis brachial antibiotic therapy had been administered and the 17 artibiotic data escentially, did Dr. Mansnerus from 21 Q. Clinically, did Dr. Mansnerus from 21 Q. Clinically, did Dr. Mansnerus from 21 Q. In a patient that is a former smoker 22 what you can see from his deposition or the 22 but yet a smoker of substantial years, if a 23 chest X-ray had been done, a follow-up chest X-ray, and it showed continued infiltrates, does 24 discovered any nodal involvement? 3 MR. WARNER: Objection. 3 have t	9			do that without having the film to look at.
12 would be a reflection of pleuritic irritation 13 from the obstructive pneumonia. It is my 14 opinion that the numbness and weakness of the 15 left arm is a result of metastatic nodal disease 16 in the supraclavicular fossa that is either 17 irritating or perhaps invading his brachial 18 plexus resulting in the numbness and motor 17 Q. Clinically, did Dr. Mansnerus from 20 arm. 21 Q. Clinically, did Dr. Mansnerus from 22 what you can see from his deposition or the 23 records do an exam where he palpated or 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. Page 50 1 A. He may or may not have done the 2 examination, and he did not note any palpable 1/mph nodes. fymph nodes. 7 Q. Would you expect that palpable lymph 11 get this symptom complex without palpable lymph 12 nodes would be detectable given what we know at 13 small lung tumor in the apex of the left chest 14 available to that astu	10	bronchogenic carcinoma?	10	Q. If a film had been taken and it
 13 from the obstructive pneumonia. It is my 14 opinion that the numbness and weakness of the 15 left arm is a result of metastatic nodal disease 16 in the supraclavicular fossa that is either 17 irritating or perhaps invading his brachial 18 plexus resulting in the numbness and motor 19 difficulties he was experiencing in his left 20 arm. 21 Q. Clinically, did Dr. Mansnerus from 22 what you can see from his deposition or the 23 records do an exam where he palpated or 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. 26 mR. WARNER: Objection. Go ahead. 27 A. He may or may not have done the 28 examination, That's a question that you would 29 have to ask. It's not stipulated specifically 4 in the medical record that he did the 5 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex without any discernible nodal station 13 involvement as well. It's not always a 14 of garden variety pneumonia? 13 sould keep in the back of his mind that that is 14 of garden variety pneumonia? 14 of garden variety pneumonia? 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 	11	A. The left-sided chest pain clearly	11	showed continued infiltrates at a six-week time
13 from the obstructive pneumonia. It is my 14 opinion that the numbness and weakness of the 15 left arm is a result of metastatic nodal disease 16 in the supraclavicular foss athat is either 17 irritating or perhaps invading his brachial 18 plexus resulting in the numbness and motor 19 difficulties he was experiencing in his left 20 arm. 21 Q. Clinically, did Dr. Mansnerus from 22 what you can see from his deposition or the 23 records do an exam where he palpated or 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. Page 50 1 A. He may or may not have done the 2 examination. That's a question that you would 3 have to ask. It's not stipulated specifically 4 in the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 Q. Would you expect that palpable lymph 13 nodes. You can get this symptom complex without palpable lymph 14	12		12	
14opinion that the numbness and weakness of the15left arm is a result of metastatic nodal disease16in the supraclavicular fossa that is either17irritating or perhaps invading his brachial18plexus resulting in the numbness and motor19difficulties he was experiencing in his left20arm.21Q. Clinically, did Dr. Mansnerus from22what you can see from his deposition or the23records do an exam where he palpated or24discovered any nodal involvement?25MR. WARNER: Objection. Go ahead.7Q. Waat You can see from his deposition or the26mR. warNER: Objection. Go ahead.7Q. Would you expect that palpable8nodes would be detectable given what we know at9he end of the story, if you will?10A. They may or may not have. You can11get this symptom complex without palpable lymph12A. They may or may not have. You can11get this symptom complex without palpable lymph13small lung tumor in the apex of the left chest14of garden variety pneumonia?15involvement a well. It's not always a16involvement a well. It's not always a16involvement a well. It's not always a16situation where you have to feel the lymph nodes	13		•	
15left arm is a result of metastatic nodal disease16in the supraclavicular fossa that is either17irritating or perhaps invading his brachial18plexus resulting in the numbness and motor19difficulties he was experiencing in his left20arm.21Q. Clinically, did Dr. Mansnerus from22what you can see from his deposition or the23records do an exam where he palpated or24discovered any nodal involvement?25MR. WARNER: Objection. Go ahead.7Q. Mart was to situated specifically4in the medical record that he did the5examination, and he did not note any palpable6MR. WARNER: Objection.7Q. Would you expect that palpable lymph8nodes would be detectable given what we know at9the end of the story, if you will?10A. They may or may not have. You can11sond settis symptom complex without palpable lymph12nodes. You can get this symptom complex with a13small lung tumor in the apex of the left chest14without any discernible nodal station15involvement a well. It's not always a16situation where you have to feel the lymph nodes	11		1	
16in the supraclavicular fossa that is either17irritating or perhaps invading his brachial18plexus resulting in the numbness and motor19difficulties he was experiencing in his left20arm.21Q. Clinically, did Dr. Mansnerus from22what you can see from his deposition or the23records do an exam where he palpated or24discovered any nodal involvement?25MR. WARNER: Objection. Go ahead.21A. He may or may not have done the2examination. That's a question that you would3have to ask. It's not stipulated specifically4in the medical record that he did the5examination, and he did not note any palpable6lymph nodes.7Q. Would you expect that palpable lymph8nodes would be detectable given what we know at10A. They may or may not have. You can11get this symptom complex without palpable lymph12nodes. You can get this symptom complex without palpable lymph13small lung turnor in the apex of the left chest14without any discernible nodal station15involvement as well. It's not always a16situation where you have to feel the lymph nodes17G. What types of diagnostic tools are18available to that astute clinician to rule out19involvement as well. It's not always a10situation where you have to feel the lymph nodes	13		1	
 17 irritating or perhaps invading his brachial 18 plexus resulting in the numbness and motor 19 difficulties he was experiencing in his left 20 arm. 21 Q. Clinically, did Dr. Mansnerus from 22 what you can see from his deposition or the 23 records do an exam where he palpated or 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. 21 A. He may or may not have done the 2 examination. That's a question that you would 3 have to ask. It's not stipulated specifically 4 in the medical record that he did the 2 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex without any discernible nodal station 13 small lung turnor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 16 situation where you have to feel the lymph nodes 17 other reason for the pneumonia of if the wrong antibility is not always a 16 situation where you have to feel the lymph nodes 			1	
 18 plexus resulting in the numbness and motor 19 difficulties he was experiencing in his left 20 arm. 21 Q. Clinically, did Dr. Mansnerus from 22 what you can see from his deposition or the 23 records do an exam where he palpated or 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. 26 J. A. He may or may not have done the 27 examination. That's a question that you would 3 have to ask. It's not stipulated specifically 4 in the medical record that he did the 5 examination, and he did not note any palpable 6 Jymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex without palpable lymph 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 	11	•	1	
 19 difficulties he was experiencing in his left 20 arm. 21 Q. Clinically, did Dr. Mansnerus from 22 what you can see from his deposition or the 23 records do an exam where he palpated or 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. 26 MR. WARNER: Objection. Go ahead. 27 Page 50 1 A. He may or may not have done the 28 examination. That's a question that you would 3 have to ask. It's not stipulated specifically 4 in the medical record that he did the 5 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 	11			
 20 arm. 21 Q. Clinically, did Dr. Mansnerus from 22 what you can see from his deposition or the 23 records do an exam where he palpated or 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. 20 of those issues could have been present. 21 Q. In a patient that is a former smoker 22 but yet a smoker of substantial years, if a 23 chest X-ray had been done, a follow-up chest 24 X-ray, and it showed continued infiltrates, does 25 MR. WARNER: Objection. Go ahead. 26 Page 50 27 Page 50 28 Page 50 29 Page 50 20 Page 50 21 A. He may or may not have done the 22 examination. That's a question that you would 3 have to ask. It's not stipulated specifically 4 in the medical record that he did the 5 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex withat 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 	EE		1	
21Q. Clinically, did Dr. Mansnerus from22what you can see from his deposition or the23records do an exam where he palpated or24discovered any nodal involvement?25MR. WARNER: Objection. Go ahead.26MR. WARNER: Objection. Go ahead.27Page 501A. He may or may not have done the2examination. That's a question that you would3have to ask. It's not stipulated specifically4in the medical record that he did the5examination, and he did not note any palpable6lymph nodes.7Q. Would you expect that palpable lymph8nodes would be detectable given what we know at9the end of the story, if you will?10A. They may or may not have. You can11get this symptom complex without palpable lymph12apossibility, yes.13small lung tumor in the apex of the left chest14without any discernible nodal station15involvement as well. It's not always a16situation where you have to feel the lymph nodes			1	
 22 what you can see from his deposition or the 23 records do an exam where he palpated or 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. 26 Page 50 1 A. He may or may not have done the 2 examination. That's a question that you would 3 have to ask. It's not stipulated specifically 4 in the medical record that he did the 5 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex without palpable lymph 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 	11		1	•
 23 records do an exam where he palpated or 24 discovered any nodal involvement? 25 MR. WARNER: Objection. Go ahead. 23 chest X-ray had been done, a follow-up chest 24 X-ray, and it showed continued infiltrates, does 25 one normally have to at least have within their 26 examination. That's a question that you would 3 have to ask. It's not stipulated specifically 4 in the medical record that he did the 5 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex without palpable lymph 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 	11		1	
24discovered any nodal involvement?24X-ray, and it showed continued infiltrates, does25MR. WARNER: Objection. Go ahead.24X-ray, and it showed continued infiltrates, does2699ge 5099ge 501A. He may or may not have done the1index of suspicion the possibility that there2examination. That's a question that you would3have to ask. It's not stipulated specifically4in the medical record that he did the3MR. WARNER: Objection.5examination, and he did not note any palpable4Q. That there may be a potential cancer6lymph nodes.7Q. Would you expect that palpable lymph8nodes would be detectable given what we know at9the end of the story, if you will?10A. They may or may not have. You can11sersistent infiltrates that11get this symptom complex without palpable lymph12nodes. You can get this symptom complex with a13small lung tumor in the apex of the left chest13without any discernible nodal station15involvement as well. It's not always a13G. What types of diagnostic tools are16situation where you have to feel the lymph nodes15or confirm the presence of something more16situation where you have to feel the lymph nodes16serious?	1		1	
25MR. WARNER: Objection. Go ahead.25one normally have to at least have within theirPage 50Page 501A. He may or may not have done theindex of suspicion the possibility that there2examination. That's a question that you wouldindex of suspicion the possibility that there3have to ask. It's not stipulated specificallyin the medical record that he did the4in the medical record that he did theMR. WARNER: Objection.5examination, and he did not note any palpableMR. WARNER: Objection.6lymph nodes.MR. WARNER: Objection.7Q. Would you expect that palpable lymphMR. WARNER: Objection.8nodes would be detectable given what we know atMR. WARNER: Objection.9the end of the story, if you will?MR. WARNER: Objection.10A. They may or may not have. You canMR. weeks subsequent to an initial X-ray,11get this symptom complex without palpable lymphIthere still is persistent infiltrates that12nodes. You can get this symptom complex with aSmall lung tumor in the apex of the left chest14without any discernible nodal stationQ. What types of diagnostic tools are15involvement as well. It's not always aSor confirm the presence of something more16situation where you have to feel the lymph nodesSor confirm the presence of something more	21		i i	
Page 50Page 501A. He may or may not have done theindex of suspicion the possibility that there2examination. That's a question that you wouldin the medical record that he did themay be nodal involvement?3have to ask. It's not stipulated specificallyMR. WARNER: Objection.4in the medical record that he did theMR. WARNER: Objection.5examination, and he did not note any palpableMR. WARNER: Objection.6lymph nodes.MR. WARNER: Objection.7Q. Would you expect that palpable lymphMR. WARNER: Objection.8nodes would be detectable given what we know atMR. WARNER: Objection.9the end of the story, if you will?A. They may or may not have. You can10A. They may or may not have. You canIn the back of his mind that that is11get this symptom complex without palpable lymphIn should keep in the back of his mind that that is12nodes. You can get this symptom complex with aIn should keep in the back of his mind that that is13small lung tumor in the apex of the left chestIn without any discernible nodal station15involvement as well. It's not always aIn or confirm the presence of something more16situation where you have to feel the lymph nodesIn or confirm the presence of something more	17			
 A. He may or may not have done the examination. That's a question that you would have to ask. It's not stipulated specifically in the medical record that he did the examination, and he did not note any palpable lymph nodes. Q. Would you expect that palpable lymph nodes would be detectable given what we know at the end of the story, if you will? A. They may or may not have. You can get this symptom complex without palpable lymph nodes. You can get this symptom complex without palpable lymph small lung tumor in the apex of the left chest without any discernible nodal station involvement as well. It's not always a situation where you have to feel the lymph nodes 	25	MR. WARNER: Objection. Go ahead.	25	one normally have to at least have within their
1A. He may or may not have done the2examination. That's a question that you would3have to ask. It's not stipulated specifically4in the medical record that he did the5examination, and he did not note any palpable6lymph nodes.7Q. Would you expect that palpable lymph8nodes would be detectable given what we know at9the end of the story, if you will?10A. They may or may not have. You can11get this symptom complex without palpable lymph12nodes. You can get this symptom complex with a13small lung tumor in the apex of the left chest14without any discernible nodal station15involvement as well. It's not always a16situation where you have to feel the lymph nodes			ļ	
 A. He may or may not have done the examination. That's a question that you would have to ask. It's not stipulated specifically in the medical record that he did the examination, and he did not note any palpable lymph nodes. Q. Would you expect that palpable lymph nodes would be detectable given what we know at the end of the story, if you will? A. They may or may not have. You can get this symptom complex without palpable lymph nodes. You can get this symptom complex with at is small lung tumor in the apex of the left chest small lung tumor in the apex of the left chest situation where you have to feel the lymph nodes 		Page 50		Page 52
 2 examination. That's a question that you would 3 have to ask. It's not stipulated specifically 4 in the medical record that he did the 5 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex without palpable lymph 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 2 may be nodal involvement? 3 MR. WARNER: Objection. 4 Q. That there may be a potential cancer 5 in the lungs? 6 MR. WARNER: Objection. 7 A. I think an astute clinician at six 8 to eight weeks subsequent to an initial X-ray, 9 if there still is persistent infiltrates that 10 has not completely resolved, an astute clinician 11 should keep in the back of his mind that that is 12 a possibility, yes. 13 Q. What types of diagnostic tools are 14 available to that astute clinician to rule out 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 	1		1	
 3 have to ask. It's not stipulated specifically 4 in the medical record that he did the 5 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex with at 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 3 MR. WARNER: Objection. 4 Q. That there may be a potential cancer 5 in the lungs? 6 MR. WARNER: Objection. 7 A. I think an astute clinician at six 8 to eight weeks subsequent to an initial X-ray, 9 if there still is persistent infiltrates that 10 has not completely resolved, an astute clinician 11 should keep in the back of his mind that that is 12 a possibility, yes. 13 Q. What types of diagnostic tools are 14 available to that astute clinician to rule out 15 or confirm the presence of something more 16 serious? 	2		2	
 4 in the medical record that he did the 5 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex with at 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 	3	· · ·	1	
 5 examination, and he did not note any palpable 6 lymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex with a 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 	4		1	· · · · · · · · · · · · · · · · · · ·
 6 lymph nodes. 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex with a 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 6 MR. WARNER: Objection. 7 A. I think an astute clinician at six 8 to eight weeks subsequent to an initial X-ray, 9 if there still is persistent infiltrates that 10 has not completely resolved, an astute clinician 11 should keep in the back of his mind that that is 12 a possibility, yes. 13 Q. What types of diagnostic tools are 14 available to that astute clinician to rule out 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 	5		È	
 7 Q. Would you expect that palpable lymph 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex with a 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 7 A. I think an astute clinician at six 8 to eight weeks subsequent to an initial X-ray, 9 if there still is persistent infiltrates that 10 has not completely resolved, an astute clinician 11 should keep in the back of his mind that that is 12 a possibility, yes. 13 Q. What types of diagnostic tools are 14 available to that astute clinician to rule out 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 	F		1	
 8 nodes would be detectable given what we know at 9 the end of the story, if you will? 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex with at 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 8 to eight weeks subsequent to an initial X-ray, 9 if there still is persistent infiltrates that 10 has not completely resolved, an astute clinician 11 should keep in the back of his mind that that is 12 a possibility, yes. 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 				
 9 the end of the story, if you will? 9 if there still is persistent infiltrates that 10 A. They may or may not have. You can 11 get this symptom complex without palpable lymph 12 nodes. You can get this symptom complex with a 13 small lung tumor in the apex of the left chest 14 without any discernible nodal station 15 involvement as well. It's not always a 16 situation where you have to feel the lymph nodes 9 if there still is persistent infiltrates that 10 has not completely resolved, an astute clinician 11 should keep in the back of his mind that that is 12 a possibility, yes. 13 Q. What types of diagnostic tools are 14 available to that astute clinician to rule out 15 or confirm the presence of something more 16 situation where you have to feel the lymph nodes 				
10A. They may or may not have. You can10has not completely resolved, an astute clinician11get this symptom complex without palpable lymph11should keep in the back of his mind that that is12nodes. You can get this symptom complex with a12a possibility, yes.13small lung tumor in the apex of the left chest13Q. What types of diagnostic tools are14without any discernible nodal station14available to that astute clinician to rule out15involvement as well. It's not always a15or confirm the presence of something more16situation where you have to feel the lymph nodes16serious?		the end of the story if you will?		
11get this symptom complex without palpable lymph11should keep in the back of his mind that that is12nodes. You can get this symptom complex with a11should keep in the back of his mind that that is13small lung tumor in the apex of the left chest13Q.What types of diagnostic tools are14without any discernible nodal station14available to that astute clinician to rule out1515involvement as well. It's not always a15or confirm the presence of something more16situation where you have to feel the lymph nodes16	1			
12nodes. You can get this symptom complex with a12a possibility, yes.13small lung tumor in the apex of the left chest13Q.What types of diagnostic tools are14without any discernible nodal station14available to that astute clinician to rule out15involvement as well. It's not always a15or confirm the presence of something more16situation where you have to feel the lymph nodes16serious?	1			
13 small lung tumor in the apex of the left chest13Q. What types of diagnostic tools are14 without any discernible nodal station14available to that astute clinician to rule out15 involvement as well. It's not always a15or confirm the presence of something more16 situation where you have to feel the lymph nodes16			1	
14 without any discernible nodal station14 available to that astute clinician to rule out15 involvement as well. It's not always a15 or confirm the presence of something more16 situation where you have to feel the lymph nodes16 serious?	1			
15 involvement as well. It's not always a15 or confirm the presence of something more16 situation where you have to feel the lymph nodes16 serious?				
16 situation where you have to feel the lymph nodes 16 serious?	1			
	1			
117 or paya painable lymph podes to have this type 117 A 15	E .			
	17	or have palpable lymph nodes to have this type	17	A. I believe there are probably two
18 of disease. 18 things that you would do at that point in time.	3			
19 Q. If Mr. Gill had a repeat chest X-ray 19 MR. WARNER: Note my objection. I	1	Q. If Mr. Gill had a repeat chest X-ray		
20 at the end of January or early part of February 20 think you're getting into standard of care, and		at the end of January or early part of February		
21 and knowing what we know in July or August, do 21 we've already indicated he is not an internist				
22 you have an opinion as to what that repeat chest 22 or family doctor.			22	
23 X-ray more likely than not would have shown? 23 A. One might then obtain a chest CAT			23	A. One might then obtain a chest CAT
A MR. WARNER: Objection. Go ahead. 24 scan and potentially refer the patient to a		MR. WARNER: Objection. Go ahead.	24	
25 A. I don't know that I can answer that 25 pulmonologist for further evaluation.	25			

13 (Pages 49 to 52)

February 3, 2004

·			
	Page 53		Page 55
1	Q. is the CAT scan more the gold	1	December 9th to base our clinical judgment and
2	standard in terms of the initial diagnostic	2	clinical suspicion on.
3	workup for a patient that you have a suspicion	3	Q. Can you say to a probability that it
4	that there might be a carcinoma?	4	wasn't the month before?
5	A. I think the gold standard still is a	5	A. I don't know that I could give you
11			
6	screen chest radiograph. If there are	6	any specific time before that.
7	abnormalities there that lead you to believe	7	Q. The July 2000 exam was remarkable
8	there is a potential for there to be a	8	for a 3 centimeter smooth firm tender mass at
9	pathologic process going on in the lung, most	9	the anterior angle of the left clavicle. Of
10	clinicians at this point in time would then	10	what significance is a 3 centimeter mass at this
11	obtain a CAT scan.	11	stage of the process? What does that tell you?
12	Q. You typically don't diagnose lung	12	A. It's a reflection of an N3 nodal
13	cancer on a plain X-ray, though, do you?	13	station that is involved with metastatic
14	A. Frequently you do, yes.	14	carcinoma.
15	Q. Really. But a CT scan is more	15	MR. MISHKIND: Off the record.
16	sensitive; is it not?	16	(Brief recess.)
17	A. It provides you with more	17	Q. Can we agree that generally speaking
18	information.	18	the earlier you diagnose lung cancer the better?
8			
19	Q. Is the fact that Mr. Gill is still	19	A. That's a fair statement.
20	able to exercise vigorously even as late as June	20	Q. Sort of the corollary of that, it's
21	of 2000 and able to exercise earlier than that,	21	always best to diagnose lung cancer as early as
22	to start and to compete in or to attempt to	22	possible?
	compete in a marathon, is that at all clinically	23	A. That's a fair statement as well.
	significant to you in terms of trying to	24	Q. Can we agree the patient has the
25	evaluate what was going on with this cancer that	25	best chance of a good outcome the earlier the
	Page 54		Page 56
	we know he had?		lung cancer is diagnosed?
2	A. No. It's of no import. We've got a	2	MR. WARNER: Objection. Go ahead.
3	gentleman who had widely metastatic testicular	3	A. Yes.
4	cancer who won the Tour de France with it.	4	Q. Mr. Gill had nonsmall cell lung
5	People can be very functional and healthy and	5	cancer; correct?
6	athletic with widely metastatic cancer.	6	A. Correct.
7	Q. In terms of when he became	7	Q. Is the prognosis for a patient that
8	metastatic, are you able to state to a	8	has nonsmall cell lung cancer that's diagnosed
9	probability a particular month or months in the	9	at Stage I-A or Stage I-B better than a patient
10	continuum of time where you are comfortable	10	that has the other type of small cell carcinoma?
11	saying Dan Gill developed or advanced into	11	A. Generally, yes.
12	metastatic cancer at X month of X year?	12	Q. We can agree that Mr. Gill was not
13	A. It's my strong opinion that at the	13	diagnosed until he was clinically and
14	time of his initial presentation on December 9th	14	diagnostically a Stage IV?
15	with the complaints that he had and the eventual	15	A. Correct.
16	clinical course, at that time on December 9th,	16	Q. By that time the probability of
17	1999, when he presented he had metastatic	17	Mr. Gill beating the cancer with optimal care
	disease at that time, almost assuredly	1	
1 1 0	טוסכמסכ מר נוומנ נווווכי מוווטצר מצעו לנווא	18	and blessing from above was what, what percent chance?
18			CDATEET
19	Stage III-B disease.	19	
19 20	Stage III-B disease. Q. Are you intending to provide an	20	A. Extremely small.
19 20 21	Stage III-B disease. Q. Are you intending to provide an opinion as to how much earlier than December 9	20 21	A. Extremely small. Q. Are we talking 10, 15?
19 20 21 22	Stage III-B disease. Q. Are you intending to provide an opinion as to how much earlier than December 9 he acquired, if you will, the metastatic	20 21 22	A. Extremely small.Q. Are we talking 10, 15?A. Less.
19 20 21 22 23	Stage III-B disease. Q. Are you intending to provide an opinion as to how much earlier than December 9 he acquired, if you will, the metastatic component to the disease?	20 21 22 23	A. Extremely small.Q. Are we talking 10, 15?A. Less.Q. Are you able to tell me in January
19 20 21 22 23 24	 Stage III-B disease. Q. Are you intending to provide an opinion as to how much earlier than December 9 he acquired, if you will, the metastatic component to the disease? A. There's no way to know because we 	20 21 22 23 24	 A. Extremely small. Q. Are we talking 10, 15? A. Less. Q. Are you able to tell me in January and February how large the tumor was in the lung
19 20 21 22 23	Stage III-B disease. Q. Are you intending to provide an opinion as to how much earlier than December 9 he acquired, if you will, the metastatic component to the disease?	20 21 22 23	A. Extremely small.Q. Are we talking 10, 15?A. Less.Q. Are you able to tell me in January

14 (Pages 53 to 56)

MARK J. BOTHAM, M.D.

Page 57 Page 59 MR. WARNER: Objection. of cancer cells in bronchogenic carcinoma it 1 1 2 No, I'm not. 2 takes to establish a clinically significant Α. 3 Do you know how large the tumor was 3 metastasis? Q. – in the lung in April of 2000? THE WITNESS: Could you repeat that 4 4 5 A. I couldn't tell you that, either. 5 question one more time? 6 In May of 2000? 6 (Record read.) Q. 7 7 Again, I couldn't tell you that. One cell. Α. Α. 8 In June of 2000? 8 Just one cell? Q. **O**. 9 I could not tell you that. 9 That's correct. Α. A. 10 10 In July it's anywhere between 4 and Don't tumors shed millions of cells? Q. O. They may. 11 5 centimeters depending upon which view we're 11 Α. looking at; right? 12 Doesn't it normally take the 12 Q. shedding of millions of cells before one 13 Correct. 13 A. 14 Q. Do you see any evidence on exam or 14 actually gets set up and succeeds in forming a 15 anything that Dr. Mansnerus described in terms 15 metastasis? 16 of nodal involvement in January of 2000? 16 A. That depends upon the host's 17 No, I do not. 17 response to a shower of tumor emboli. A. 18 Do you have any evidence that there 18 Q. The host being the patient? Q. 19 was nodal involvement in March of 2000? That would be correct. 19 Α. 20 A. The clinical evidence that we have 20 Q. I'm sorry. I may have cut you off. You started to say some --21 is the symptom complex that he presented with in 21 22 December of 1999, that being the numbness and 22 A. That would be correct. Some host's 23 loss of motor function in the left arm. That's 23 response to a tumor embolus can be that of cell 24 consistent with nodal disease involving a 24 death. It can either kill the tumor cell, or it 25 supraclavicular scalene node station. 25 can allow it to replicate. So one can develop Page 58 Page 60 clinically significant metastasis from as little There's no reference to those 1 1 Ο. 2 as one cell or develop no metastasis from one 2 symptoms when he's seen in January in 3 Dr. Mansnerus' records; are there? cell. Be it as it may, it still is important if 3 you have a cell embolus that results in the 4 Α. There is not. 4 5 Are you able to explain why there is 5 active development of the potential clinical Q. no reference to them? 6 6 metastasis that it be identified. 7 No, I am not. 7 Q. Do you know with this host what the Α. 8 In June when Dr. Mansnerus saw him, 8 likely scenario was in terms of how many cells Q. 9 from what you can tell from looking at the 9 needed to be shed, if you will, before he was 10 records or the deposition, did he perform an 10 able to set up and succeed in forming a exam of the lymph nodes? 11 clinically significant metastasis? 11 12 MR. WARNER: You're in June now? 12 A. I don't know that you would know 13 MR. MISHKIND: June, yes. 13 that, nor would you ever be able to estimate 14 A. There is nothing specific in the 14 that. 15 record that stipulates a nodal examination. 15 О. Have you ever seen any studies that 16 However, on physical examination he described a 16 have talked about the shedding of cancer cells 17 tender left sternomastoid which is in the region 17 and the fact that you and I may have cells that 18 of the supraclavicular lymph node change. 18 potentially could be metastatic in nature going 19 Q. Can a patient have micrometastasis 19 through our body, but they aren't necessarily 20 of cancer cells and not necessarily develop a 20 clinically significant? 21 clinically significant metastasis? 21 A. I'm not aware of studies that have 22 Α. With bronchogenic carcinoma? 22 been written. I'm sure, though, there are 23 Q. Yes. 23 theories about that. In terms of an actually scientific factual basis for that, I'm not aware 24 Α. It is very unlikely. 24 25 Q. Can you tell me how many metastases 25 of it.

15 (Pages 57 to 60)

Γ		1	
	Page 61		Page 63
1	Q. Did Mr. Gill have metastasis to the	1	that question to an oncologist?
2	hilar nodes as of May in your opinion?	2	A. Yes, I would.
3	A. In May of that year?	3	Q. In light of what you just said about
4	Q. Yes.	4	deferring to an oncologist, do you have an
5	A. Prior to the CAT scan that was done?	5	opinion as to what Mr. Gill's life expectancy
6	MR. WARNER: In May of '99 or May of	6	would have been had his diagnosis been made in
7	2000?	7	your opinion consistent with your opinion in
8	MR. MISHKIND: May of 2000.	8	January or February as opposed to July and
9	A. I would believe so knowing his	9	August?
10	clinical presentation. We don't have scan	10	We know he died in February of the
11	evidence that stipulates to that.		
		11	next year, but had he been diagnosed with the
12	Q. But that would be your opinion, that	12	type of cancer that you believe he had in
13	he had metastasis to the hilar?	13	January or February, what would his life
14	A. Yes.	14	expectancy have been?
15	Q. Do you have any basis to say that he	15	A. I think his life expectancy would
16	had metastasis to any other nodes other than the	16	have been identical to what it was when he was
17	hilar nodes as of May?	17	diagnosed in July or August. I don't think it
18	A. There's no way to actually tell you	18	would have changed at all.
19	that with 100 percent certainty, but in general	19	Q. You believe he still would have more
20	they are spread along a specific nodal chain	20	likely than not died in February of the
21	beginning with the intrapulmonary and then the	21	following year?
22	hilar and then the mediastinal and then last the	22	A. I think there's no question he would
23	scalene supraclavicular node.	23	have.
24	Q. Would you agree that the less nodal	24	
25	involvement that there is, the better the	25	· · · · · · · · · · · · · · · · · · ·
25	involvement that there is, the better the	25	what basis do you say that there's no question?
	Page 62		D 04
1	prognosis?	1	Page 64
2		1	A. Because I feel very strongly that at
3	A. It depends upon where the nodal stations are that are involved. I think once	2	the time of his initial presentation in December
4		3	he had Stage III-B disease at the least,
11	you had mediastinal nodal disease, be it	4	potentially Stage IV disease knowing the
5	microscopic or bulky nodal disease, your	5	eventual involvement in his femur and the
6	prognosis is quite dismal.	6	micrometastasis or small metastasis in his left
7	Q. If Mr. Gill had been diagnosed with	7	lung tissue itself.
8	lung cancer in January or early February, I take	8	The III-B disease would have been
9	it your opinion is that he would not have been a	9	treated identical to Stage IV disease, that
10	surgical candidate for the reasons we've	10	being chemotherapy, potentially chemotherapy
11	discussed and are set forth in your report?	11	with radiation therapy. Surgical therapy would
12	A. I believe so, yes.	12	not have been an option for him. As that is the
13	Q. Do you have an opinion as to what	13	case, the prognostic limb of his therapy would
14	treatment modalities would have been appropriate	14	not have changed given the fact that he would
15	for the patient in January or February as	15	not have been a candidate for surgical
16	compared to the treatment modalities that were	16	intervention.
17	implemented as of July and August?	17	
18	A. I believe they would have been the		Q. Mr. Gill was seen in December by
19	same.	18	Dr. Mansnerus twice, on December 9 and
20		19	December 30?
11	Q. Any differences at all?	20	A. That is correct.
21	A. Again, I'm not an oncologist, so	21	Q. And then seen again I think
22	it's difficult for me to answer that question,	22	January 6th of 2000; correct?
23	but I believe the same type of systemic	23	A. That is correct.
1		0.4	
24	chemotherapy would have been given to him.	24	Q. At no time during any of those three
1	Chemotherapy would have been given to him. Q. Would you defer on the specifics of		Q. At no time during any of those three visits is there any reference to or suggestion

16 (Pages 61 to 64)

r		1	
	Page 65		Page 67
1	of his clinical course being consistent with or	1	likelihood of survival?
2	potentially consistent with cancer; correct?	2	A. I don't believe that's remotely the
3	A. I believe his clinical course is	3	case. I think any appropriate cardiothoracic
4	consistent with what we know retrospectively.	4	surgeon would have done a mediastinoscopy on him
5	There was no mention made in the record about it	5	at the least to ascertain the absence or
6	potentially being consistent with that. We have	6	presence of mediastinal nodal involvement. Even
7	the benefit of retrospectively looking back and	7	if he presented and was diagnosed as early as
8	seeing what initially he presented with and what	8	December of 1999, it's my strong belief that
9	his eventual demise was from.	9	those nodal stations along with potentially even
10	Q. Right. I understand that. I'm just	10	the scalene node would have been positive if not
11	asking just as a matter of fact, the symptoms in	11	clear microscopically, and that would have
12	December, two visits, and the symptoms in	12	precluded him from being an operative candidate
13	January were not, right, wrong, or otherwise,	13	in any way, shape, or form.
14	were not correlated by Dr. Mansnerus to be	14	Q. Did Dr. Mansnerus, from what you can
15	potentially consistent with what ultimately was	15	see in the record, refer Mr. Gill to a surgeon
16	diagnosed?	16	for any type of evaluation in January or
17	MR. WARNER: Objection.	17	February?
18	A. I can't answer that question.	18	A. I don't believe so.
19	That's a question that only he can answer	19	Q. I don't want to cut you off, but
20	because I can't get into his head and know what	20	have we covered the opinions on the issue of
21	he was thinking at the time.	21	proximate cause in terms of treatment
22	Q. You don't see any evidence from the	22	modalities, likelihood of survival, and the
23	deposition or from the records that he was	23	impact of this cancer that you believe you have
24	thinking or considering lung cancer as an	24	as it relates to this case?
25	explanation?	25	A. Yes.
			7 . 7 . 7
	Page 66		
1	A. I do not see that in the medical	1	Page 68
2	record.	1	Q. Are there any other areas that you
3	Q. What I want to do is tie loose ends	2	believe that because I haven't taken a thorough
4		3	enough deposition you hold opinions on that you
5	together, and we will be done.	4	anticipate providing testimony at the time of
11	I think in essence your opinions on	5	trial on that we have not covered?
6	proximate cause, without restating them again,	6	A. I don't believe so.
7	are that by the early part of 2000 unfortunately	7	Q. To the extent that you do arrive at
8	in your professional opinion Mr. Gill was not a	8	any additional opinions, would you please let
9	surgical candidate and that an earlier	9	Mr. Warner know and within two to three weeks
10	diagnosis, even if a jury is to conclude that an		he'll probably let me know?
11	earlier diagnosis should have been made and that	11	A. Yes, I will.
	the standard of care was violated, your opinion	12	MR. MISHKIND: Doctor, thank you for
	would be that it wouldn't have made any	13	your time. It's nice to meet you.
	difference anyway?	14	THE WITNESS: I would like to read
15	A. Correct. He would not have been a	15	lt.
	surgical candidate even in December of 1999; and	16	~ ~ ~ ~ ~
17	therefore, his treatment limb would not have	17	(Deposition concluded at 7:00 p.m.)
	changed.	18	(Signature not waived.)
19	Q. Are you in a position to comment at	19	,
20	all on the opinions that were expressed by	20	
	Dr. Steele or Dr. Bass or Dr. Sutherland with	21	
	regard to the prognosis of Mr. Gill? You recall	22	
F	that they indicated that they felt that had a	23	
	diagnosis been made in January or February be	74	
24	diagnosis been made in January or February, he would have had a greater than 50 percent	24 25	

17 (Pages 65 to 68)

February 3, 2004

Page 69 1 AFFIDAVIT 2 I have read the foregoing transcript from 3 page 1 through 68 and note the following 4 corrections: 5 PAGE 6 7 7 8 9 10 11 12 13 14 15 16 16 17 9 Subscribed and sworn to before me this 20 Subscribed and sworn to before me this 21	Page 71 1 INDEX 2 DEPOSITION OF MARK J. BOTHAM, M.D. 3 4 BY MR. MISHKIND:
Page 70 CERTIFICATE State of Ohio,) Gunty of Cuyahoga.) I, Cynthia A. Sullivan, a Notary Public within and for the State of Ohio, duly Commissioned and qualified, do hereby certify that the within named MARK J. BOTHAM, M.D. was Hoy me first duly sworn to testify to the truth, the whole truth and nothing but the truth in the cause aforesaid; that the testimony as above set forth was by me reduced to stenotypy, afterwards transcribed, and that the foregoing is a true and correct transcription of the testimony. I do further certify that this deposition was taken at the time and place specified and was completed without adjournment; that I am not a relative or attorney for either party or otherwise interested in the event of this raction. I am not, nor is the court reporting firm with which I am affiliated, under a contract as defined in Civil Rule 28(D). N WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, Ohio, on this 9th day of February 2004. Cynthia A. Sullivan, Notary Public Within and for the State of Ohio S My commission expires October 6, 2006.	

18 (Pages 69 to 71)

				Page
A	41:14 47:14 48:21	apparently 6:12	attorneys 5:20	belief 13:24 67:8
ability 11:25	51:2 57:7 62:21	appearance 46:25	42:25 43:5,14	believe 5:2,9 6:4,21
able 14:19 25:1	64:21 66:6	APPEARANCES	August 5:2 31:1	12:10,12 14:4,25
28:7 53:20,21	against 37:7	2:1	45:20 50:21 62:17	19:21 20:14,15
54:8 56:23 58:5	age 3:6 14:21 16:20	appears 4:22	63:9,17	24:3,13 25:15
	37:3	applicable 42:1	authoritative 24:9	27:19 28:14,19
60:10,13 abnormalities 53:7	aggressive 45:7,10	appreciated 13:12	26:8	30:3,15 32:18
abort 9:5	45:13,17 46:14	approach 37:8	authors 24:14	34:3,10 35:22
about 4:2 5:21 14:7	ago 37:22 41:25	appropriate 7:21	available 52:14	37:9 38:2,6,12
19:11 25:10,16,17	44:8	8:2 13:18 14:23	Avenue 2:15	39:10 41:9 42:18
	agree 35:13 55:17	24:16 62:14 67:3	average 31:25	43:7,9,18 44:16
31:21 34:1 35:18	55:24 56:12 61:24	April 38:8 57:4	aware 36:6 60:21	48:14 52:17 53:7
43:21 60:16,23	agreed 14:14	area 22:3,20 34:19	60:24	61:9 62:12,18,23
63:3 65:5	ahead 11:12 20:17	areas 68:1	away 27:1	63:12,19 65:3
above 1:24 21:14	49:25 50:24 56:2	arising 36:11		67:2,18,23 68:2,6
56:18 70:12	airway 48:23	arm 48:2 49:6,15	B	below 13:1 21:15
absence 8:13 10:24	al 1:10	49:20 57:23	B 13:25	benefit 9:20 14:16
51:8 67:5	Alan 36:23	around 20:24	back 11:14.15	17:25 20:20 65:7
absolute 18:22	allegation 33:14	arrangements 45:2	12:15 13:14 14:19	Besides 43:3
accept 4:16	37:7	arrive 68:7	20:21 27:7 31:18	best 37:15 55:21,25
accepted 28:10,14	allow 59:25	arrived 12:15	34:3 36:23 47:19	best 57.15 55.21,25 better 11:10 55:18
accurately 13:20	allows 29:10	artery 7:2 9:25	47:22 52:11 65:7	56:9 61:25
acknowledge 19:18	almost 16:24 54:18	22:20	background 4:3	between 8:10,20
25:20 26:7		artfully 10:2	bad 35:7	11:5 18:15 20:1
acquired 54:22	along 8:16 61:20			23:7 32:2,3 57:10
action 70:17	67:9	article 25:5,12,21 25:21	balance 31:20	Bill 43:19
active 43:4 60:5	already 52:21	articles 22:19 24:6	ball 18:19,21 19:1	
actual 8:16 45:25	altered 12:16		balloon 7:14 bar 34:25	biology 46:5
actuality 18:25	always 26:23 46:11	24:7,13 25:7,18		biopsies 9:9
actually 5:14,22	50:15 55:21	26:1	base 55:1	biopsy 8:12
18:25 32:25 36:7	amount 41:12	ascertain 8:2,12	based 8:5 11:6	bit 10:21 11:14
38:6 39:16 59:14	anaplasia 11:3	9:20 51:7 67:5	24:18	30:21
60:23 61:18	anaplastic 46:16,21	asked 11:19,23	basis 60:24 61:15	black 35:11
additional 29:4	47:1	33:12 34:4,21	63:25	blessing 56:18
68:8	and/or 13:23	38:13	Bass 41:18 66:21	body 60:19
adept 7:14	angiolymphatic	asking 3:24 5:3	beating 56:17	bone 31:10
adjective 12:18	10:25	14:1 42:24 65:11	became 7:13 45:10	borrow 19:5
adjectives 12:17	angle 55:9	aspects 10:22	54:7	both 12:3 22:22
adjournment 70:15	another 27:7 28:11	asserted 33:15	Becker 2:3	27:15 40:11 51:15
adjunctive 17:17	40:17	assimilate 25:9	become 46:14	51:19
17:22 18:4	answer 4:8,15	associated 49:5	47:11	Botham 1:13,16 3:6
administered 51:18	13:20 31:9 33:22	assume 12:22	becomes 40:12 46:8	3:11,15,19 25:2
advanced 54:11	38:16 50:25 62:22	assuming 38:4	becoming 35:4	69:18 70:10 71:2
affects 11:24 25:8	65:18,19	assumption 13:5	before 1:18 3:20	Boy 33:20
AFFIDAVIT 69:1	anteceding 45:24	17:15	4:6,8 5:11 12:8	brachial 49:17
affiliated 70:17	anterior 55:9	assuredly 16:24	14:13 26:9 37:20	breakdown 34:19
affiliation 36:21	antibiotic 51:6,18	54:18	38:9 55:4,6 59:13	Brief 55:16
affixed 70:19	anticipate 68:4	astute 52:7,10,14	60:9 69:20	bronchial 48:22
aforesaid 70:12	anything 21:8,14	athletic 54:6	beginning 61:21	bronchogenic
after 16:5,7,16	21:14,21,22 26:7	attached 5:6 6:1	behalf 2:2,11 12:24	10:13,15,23 15:14
17:12 27:5,10,22	57:15	25:13	being 3:8 22:5	15:18 16:2 21:17
36:1,7	anyway 66:14	attempt 25:9 53:22	25:22 26:7 30:25	22:25 30:17 31:8
afterwards 70:12	anywhere 8:10,20	attending 39:15	32:21 36:6 48:1	34:7 45:7,10,12
again 17:15 20:18	32:3 57:10	attorney 33:9 37:12	57:22 59:18 64:10	45.16,23 46:11
24:2 27:6,8 41:11	apex 50:13	70:16	65:1,6 67:12	48:17 49:1,7,10
27.227.0,0 71 .11	-		· · · · · ·	

58:22 59:1

Page 2

	38:22 39:1	C
	Building 2:14	
	bulkier 20:2,4	
	bulky 19:10,20,23	
	20:12 62:5	l c
	1	1
	busy 32:12	c
	button 21:24	
	bypass 7:2,9,10,16	
	С	
	call 5:2 16:9	
	called 1:17 3:7 13:7	
	23:4 39:8,10 42:9	
	came 7:18 39:16	1
	cancer 7:24 9:25	
	14:17 16:23 17:1	1
	17:2,8 22:17 23:5	
	23:20 24:10 25:22	
	IE	c
	27:11,23 30:11	1
	33:16 36:12 37:4	
	39:2 47:11,18	
	52:4 53:13,25	
	54:4,6,12 55:18	
	55:21 56:1,5,8,17	1
	58:20 59:1 60:16	
	62:8 63:12 65:2	0
	65:24 67:23	
	cancers 46:13	ŀ
	candidate 7:21 8:4	c c
	13:18 14:5,23	
		[
	28:5 30:4 62:10	ŀ
	64:15 66:9,16	C C
	67:12	c
	carboplatin 30:2	c
	carcinoma 7:20,23	
	8:1 10:10,13,16	
	10:24 14:21 15:14	
	10:24 14:21 15:14	
	15:18 16:2 21:7	
	21:17 22:25 24:22	c
	25:8 30:17 31:8	
	34:8 36:13 39:22	
	39:23 45:7,10,23	e
	48:17 49:7,10	
	53:4 55:14 56:10	
		c
	58:22 59:1	
	carcinomas 45:12	
	45:16 46:11	
	cardiac 7:7,8 10:1	
	22:20,22	
	cardiologist 39:7	
		C
ļ	cardiologists 7:13	
	cardiothoracic 6:22	c
l	7:1,17 24:22 39:3	c
	39:6 67:3	
	,	

	care 12:22 13:1	CERTIFICATE	57:20 60:5 61:10	49:9 57:24 63:7
	27:22 28:8,14	70:1	65:1,3	65:1,2,4,6,15
	29:15 52:20 56:17	certified 3:9	clinically 14:3	constitute 6:18
	66:12	certify 70:10,14	49:21 53:23 56:13	consultation 40:2
	2	1 .	58:21 59:2 60:1	contacted 4:22
	carrying 9:19	cetera 47:6 chain 61:20		
	case 1:8 4:24 6:13		60:11,20	contain 11:17
~	11:20,25 19:8	chance 55:25 56:19	clinician 52:7,10,14	contained 6:18
5	23:22 24:4 25:24	change 7:12 19:3	clinicians 53:10	continue 16:4,12
	29:2,7,10 32:19	20:6 58:18 69:5	clock 14:19	17:12 29:25
	32:20 33:1,11	changed 7:4 12:16	Co 2:3	continued 29:3
	34:3,5,11,14,14	26:20 63:18 64:14	colleagues 24:16,17	51:11,24
:7	34:15 36:3,6,13	66:18	come 13:16 27:7	continuum 54:10
:9	36:14,15,16 37:4	changes 5:25 26:6	comfortable 54:10	contract 70:18
	37:12,20,24 38:1	character 46:22	comment 28:7	copies 44:21 45:3
	38:7,14,21 41:6	charge 26:12	29:14 66:19	copy 4:19 6:5
1	41:14 47:7 64:13	charged 27:1	commission 69:25	corollary 55:20
:5	67:3,24	Charms 34:4,10	70:25	coronary 7:2,10,16
22	cases 9:24 10:7,12	chart 29:12	commissioned	9:25 22:20
	31:25 32:6,8,16	check 5:18	70:10	correct 3:17,18
4	32:22 33:5,6,18	chemotherapeutic	common 1:1 30:10	4:20,21 6:6,7,15
	33:25 34:18 35:6	31:6	Community 40:24	6:16,23,24 7:3
	35:23 36:10 41:4	chemotherapy	comorbidities	9:2,3,8 12:6,7
	41:10 42:12 44:14	17:23 28:20 30:1	10:20 16:17	13:5,8,9,19 17:5,6
7	Casey 40:19,20,22	62:24 64:10,10	comorbidity 14:22	19:11 21:12 22:9
6	41:7,16	chemotherapy/ra	16:21	23:18 26:4 28:5,6
	CAT 18:17 46:7	9:15	compared 62:16	31:23 35:17 36:2
	52:23 53:1,11	chest 39:23 48:1	compete 53:22,23	36:18,19 37:25
	61:5	49:4,11 50:13,19	complaints 54:15	44:24 45:8 46:15
4	cause 13:8 16:23	50:22 51:23,23	completed 70:15	47:7,8,10 56:5,6
	33:14 34:10 66:6	52:23 53:6	completely 52:10	56:15 57:13 59:9
	67:21 70:12	choice 35:3 40:3	complex 50:11,12	59:19,22 64:20,22
	caused 16:25 48:24	cite 25:1 26:2	57:21	64:23 65:2 66:15
	causes 17:2	civil 3:8 32:19	compliment 42:3	70:13
	cell 7:20,23 10:16	70:18	comply 28:9	corrections 69:4
3	14:21 21:7 22:16	claim 35:19	component 54:23	correlated 65:14
	23:20 24:10 25:22	classification 20:5	components 13:13	counsel 1:22 44:10
14	56:4,8,10 59:7,8	21:16	concerning 3:24	counsels 35:7,9
	59:23,24 60:2,3,4	classify 11:7	51:13,16	count 44:25
22	cells 46:6 58:20	clavicle 55:9	concert 49:1	country 9:19
	59:1,10,13 60:8	clear 21:21 51:7	conclude 66:10	County 1:2 70:5
2	60:16,17	67:11	concluded 68:17	couple 35:7
3	centimeter 19:24	clearly 41:15 45:17	condition 8:5 48:5	course 54:16 65:1,3
	22:3 55:8,10	48:24 49:11	confine 44:17	court 1:1 32:17
)	centimeters 18:11	Cleveland 2:8,16	confined 27:17	33:2,7 45:2 70:17
	18:14,15 20:24	5:12 27:15 35:5	confines 40:14,15	covered 67:20 68:5
	21:3,6,9,14,15,18	36:15,20 40:7,14	confirm 52:15	Crandall 44:6,6
	21:19,22,23,24	43:12 70:19	consider 24:7 25:2	creates 17:8
	22:4,4 46:10	clinic 5:12 27:15	25:18	criteria 21:20
	57:11	35:5,5 36:15,21	consideration	CT 53:15
l	certain 6:12 14:7	40:8,14	14:24	current 26:18
ĺ	46:13	clinical 7:25 8:3	considered 6:14	currently 9:23
22	certainly 32:7,10	15:15 19:4 21:4	considering 65:24	25:20 35:23 43:6
3	certainty 41:12	24:20 47:21 48:5	consisted 30:2	44:13
	61:19	54:16,25 55:1,2	consistent 48:16,18	cut 59:20 67:19
1			1	

				Page
Cuyahoga 1:2 70:5	deposition 1:13,16	dig 29:11	53:21 54:21 55:18	60:13,15
CV 6:5 22:7	3:2 4:5 11:12	dire 36:1,8	55:25 66:9,11	every 4:16 35:11
Cynthia 1:19 70:9	12:12 25:14 26:21	discernible 50:14	early 9:24 13:3	everyone 14:14
70:23	29:13,21 38:4	disclosure 33:5	17:10 19:9 20:11	evidence 15:15 46:3
cytologic 46:24	49:22 58:10 65:23	discouraged 35:6	50:20 55:21 62:8	57:14,18,20 61:11
	68:3,17 70:14	discovered 49:24	66:7 67:7	65:22
D	71:2,6	discrepancy 18:8	educate 24:15	evidentiary 25:24
D 2:4,13	depositions 12:19	discussed 62:11	30:20	evolved 33:7
Dan 54:11	26:13	disease 8:3,14 11:7	education 24:16	exactly 22:5
DANIEL 1:6	describe 22:3	18:5 19:8 30:22	effect 26:10	exam 49:23 55:7
date 1:24	described 48:7	31:14 40:1,1 47:4	effort 24:15	57:14 58:11
day 1:24 26:16,17	57:15 58:16	49:15 50:18 54:18	eight 42:10 52:8	examination 1:18
26:24,25 69:21	description 33:19	54:19,23 57:24	either 5:1 31:7	3:7,11 50:2,5
70:20	detectable 46:7.9	62:4,5 64:3,4,8,9	34:14 39:25 49:16	58:15,16
days 27:2,3	50:8	dismal 62:6	57:5 59:24 70:16	exception 12:11
de 54:4	determining 47:1	dismissed 36:1,3,7	emboli 59:17	Executor 1:5
dealings 39:14	develop 16:3 46:6	dissection 8:17	embolus 59:23 60:4	exercise 53:20,21
death 59:24	48:24 58:20 59:25	distal 15:23	encompassed 8:19	exhibit 4:19,24 5:5
deceased 1:6	60:2	doctor 13:2 16:7	24:23	5:7,12 6:1,2,5,8
December 13:3	developed 39:25	17:10 22:7 40:17	end 19:9,16 22:20	6:11,18 29:1,5,6
14:12 19:16 20:10	45:23 54:11	42:20 52:22 68:12	45:13 50:9,20	44:23 45:5
20:21 47:6,11,16	development 60:5	doctors 27:21 42:5	ending 17:11	Exhibits 3:3 71:7
47:23 48:7,8,16	diagnose 10:15	doing 7:14 9:17	ending 17.11 ends 66:3	expansion 8:24
54:14,16,21 55:1	53:12 55:18,21	28:23 31:21		
57:22 64:2,17,18	diagnosed 13:10,15	done 8:1 18:17 32:9	enough 10:14 14:18	expect 30:13 50:7
64:19 65:12 66:16	17:3,16 18:10		17:3 23:3 40:1 51:7 68:3	expectancy 63:5,14
67:8	19:9,15 21:2	32:11,14 39:19		63:15
decided 35:9	27:12 56:1,8,13	41:4 50:1 51:23 61:5 66:4 67:4	enter 9:14	experience 7:12
decreased 7:17	62:7 63:11,17	1	entire 14:9	10:18 30:19 35:15
defendant 2:11	65:16 67:7	doubling 46:3	error 19:2	experiences 35:8
		Dowlati 27:25 28:9	escaping 40:18	experiencing 31:13
34:20 35:21 36:11	diagnoses 17:10	30:2	esophageal 36:13	49:19
Defendants 1:11	diagnosing 33:16	down 5:22 19:12	37:4 39:22	expert 12:2,4,19
defended 32:21	diagnosis 17:19	Dr 3:19 12:3,4,11	ESQ 2:4,13	29:21 33:1 34:13
defense 34:23,25	22:16 24:11 27:5	12:24 25:2,13,17	essence 66:5	37:24 40:17 41:5
37:24 43:10,12	27:10,23 30:8	27:25 28:9 29:16	establish 59:2	41:8,11 42:5 43:5
defer 31:14 62:25	34:7 45:15,20,25	30:2 38:18,23,25	estate 1:5 3:23	43:18,23
deferring 63:4	51:13 63:6 66:10	39:1,14,18 40:19	estimate 37:15	experts 12:5 38:20
defined 70:18	66:11,24	40:20,22 41:6,7,7	60:13	expiration 45:20
definitely 17:25	diagnostic 23:15	41:10,16,16,17,18	et 1:10 47:6	expires 69:25 70:25
definition 9:1 20:3	52:13 53:2	41:18 47:25 48:8	evaluate 11:25	explain 58:5
21:7,25	diagnostically	48:10 49:21 57:15	53:25	explanation 65:25
degree 11:3 31:12	56:14	58:3,8 64:18	evaluating 13:2	expressed 3:25
delay 33:15 34:7,9	diameter 18:22	65:14 66:21,21,21	evaluation 8:2	66:20
delineate 15:13	die 45:18	67:14	52:25 67:16	extent 26:5 68:7
delineates 21:20	died 30:9 31:1	draft 5:7,10,25	even 16:5,25 53:20	extremely 15:25
demise 65:9	63:10,20	dropped 36:4	66:10,16 67:6,9	56:20
depend 51:4	difference 18:15	duly 3:8 70:9,11	event 70:16	
dependent 11:9	20:1 66:14	duration 15:17	events 30:16	F
depending 57:11	differences 62:20	during 36:3 48:8	eventual 54:15 64:5	fact 12:25 45:19
depends 10:21	different 10:22	64:24	65:9	53:19 60:17 64:14
18:16,20 59:16	differentiated 11:2	dying 30:24	eventually 21:2	65:11
62:2	11:2 13:13	···	ever 29:20 32:5	factors 14:22
deposed 3:9 37:15	difficult 31:9 62:22	Е	33:11 34:13 38:4	factual 29:18 46:2
37:20	difficulties 49:19	earlier 19:20 20:16	39:10,13 41:5	60:24

			·	Page
fair 4:14,17,18	60:10	53:19 54:11 56:4	Health 40:16	identify 9:13 44:23
17:13,14 41:12	formulate 24:17	56:12,17 61:1	healthy 54:5	II 17:21
55:19,23	forth 1:24 62:11	62:7 64:17 66:8	heart 10:6	III 1:4
fairest 31:17	70:12	66:22 67:15	Heights 1:23	III-B 54:19 64:3,8
fairly 30:10 31:9	fortunate 10:14	Gill's 14:21 16:20	help 43:16	II-A 18:6
fall 33:18 42:16	14:18 17:3	19:8 27:22 34:15	her 40:19	impact 67:23
family 13:2 30:19	Fortunately 30:18	47:4 63:5	hereinafter 3:9	implemented 62:17
35:12 52:22	fossa 49:16	give 20:13 23:1	hereunto 70:19	import 54:2
Famous 4:4	found 56:25	25:5 28:21 38:3	he'll 68:10	important 29:9
fashion 29:11	Foundation 35:5	55:5	high 15:25 32:3	60:3
favorable 16:18	40:14	given 30:25 32:1	hilar 61:2,13,17,22	include 10:24
February 1:14	four 34:6 42:15	45:19 50:8 62:24	Hillcrest 1:22	including 13:23
20:12 30:9 45:21	fourth 19:12	64:14	him 5:15 14:20 28:1	increased 12:16
50:20 56:24 62:8	France 54:4	go 9:6,10 14:8	34:12 58:8 62:24	incurability 47:4
62:15 63:8,10,13	Frequently 53:14	15:11 20:17 25:10	64:12 67:4,12	incurable 47:12,18
63:20 66:24 67:17	from 12:3,6 14:6	27:5 32:2 46:14	himself 39:9	indeed 8:3
70:20	16:1 20:10 21:10	49:25 50:24 56:2	histologic 11:1	index 52:1 71:1
federal 33:2	25:21,23 28:3	going 3:23 6:2	46:23	indicate 21:13
feel 11:24 29:8 34:8	29:18 30:6 31:1,4	11:14 14:8 15:16	histological 21:5	indicated 19:7
48:14 50:16 64:1	33:6 35:6,20 43:5	27:6,7 30:19	histology 13:11	52:21 66:23
fees 26:19	43:15 45:14,18	31:18 44:17,19,20	histopathological	Indicating 6:10
fell 12:25 14:15	46:4,6 47:19	45:1 53:9,25	20:5 24:20	19:6
felt 48:4 66:23	49:13,21,22 56:18	60:18	historical 24:19	indicators 24:10
femur 31:11 64:5	58:9,9 60:1,2	gold 53:1,5	history 35:19	infiltrates 51:11,24
few 38:22	65:9,22,23 67:12	good 15:5 16:7 17:4	hit 18:25	52:9
files 43:4	67:14 69:2	17:7 55:25	hits 21:10	information 6:12
film 51:9,10	function 8:6 57:23	good-bye 16:6	hold 30:12 47:7	6:19 11:22 24:25
find 25:19	functional 54:5	gotten 44:3	68:3	
findings 21:5	further 9:7 15:11	Grade 27:11	Holland 37:1	29:4,18 47:15,20 53:18
finish 31:19 38:4	52:25 70:14	greater 15:4,7	homework 35:20	initial 8:22 23:15
firm 55:8 70:17	future 38:10	21:18,22 46:19	honest 42:23	30:1 47:16 52:8
firms 43:8,10,12	Juture 56.10	66:25	honestly 35:15	F
first 3:8 18:10	G	Groedel 43:19	hopefully 4:3 10:2	53:2 54:14 64:2
45:23 47:22 49:7	garden 51:14			initially 65:8
70:11	Gee 37:17	group 23:12	24:23 31:19 44:17	instances 9:12
five 7:5 15:8,15	general 9:9 10:7	growth 46:12,17	Hospital 1:22 36:16	institution 27:17
16:5,7 32:3 35:21	11:4 19:3 22:17	guess 42:2	40:7,24	institutions 9:18
five-year 11:5	1	guesstimate 23:7	Hospitals 27:16,20	intelligible 4:12
15:10,12,22 16:15	22:23 38:24 40:24 46:4 61:19	42:10	40:16	intending 54:20
Flipping 41:17		guys 37:1	host 59:18 60:7	interact 40:8
fipping 41.77 fly 27:2	generally 55:17	Н	host's 59:16,22	interacted 38:23
follow 16:4 46:12	56:11		hour 26:12	39:21 41:14
following 30:9	generate 25:9 29:7	half 26:16	housekeeping	interactions 28:1
63:21 69:3	generated 24:15	hand 70:19	44:22	interested 70:16
	29:18	handed 4:24	Howard 2:4 3:22	interests 22:21
follows 3:10 follow-up 40:10,11	gentleman 54:3	hands 14:19	hundreds 25:6,6	internist 13:1 52:21
51:23	germane 11:15	happen 14:17 37:11	······¥	interpretation
foregoing 69:2	23:21 24:3	happy 17:11 26:11	I :	18:18 19:3
70:13	gets 59:14	38:17	idea 23:1	intervention 8:23
	getting 11:11 32:25	harm's 15:21 16:1	Ideally 16:19	8:23 23:15,15
foreseeable 38:10	52:20	having 17:12 23:6	ideation 46:15	39:2 64:16
form 45:18 67:13	Gill 1:4,6 3:23 7:18	25:23 30:18 32:14	identical 63:16 64:9	interventions 7:14
formal 8:14 former 51:21	11:16 13:2,10	51:9	identification 3:4	7:15 39:8
00'8488'31'/1 \$	17:16 28:15 33:12	head 65:20	identified 60:6	intrapulmonary
forming 59:14	47:23 48:15 50:19	heads 38:9	identifies 6:11	61:21

Page 5

[r				1 aye
invades 46:24	jump 11:13 47:22	64:3 67:5	46:25 51:9	65:14 67:14
invading 49:17	jumping 27:6	left 41:21 48:2,23	looked 14:18 17:21	many 23:3 31:25
invasion 10:25	June 53:20 57:8	49:6,15,19 50:13	18:12	32:5,11 33:18
involve 9:24	58:8,12,13	55:9 57:23 58:17	looking 9:22 28:24	37:14 42:8,14
involved 13:4 27:22	jury 66:10	64:6	41:22 57:12 58:9	58:25 60:8
31:5 32:17 36:11	just 4:24 5:18 11:12	left-sided 48:1 49:4	65:7	1
11		49:11		marathon 53:23
55:13 62:3	11:13 13:21 16:12		looks 5:7	Marc 43:19
involvement 13:17	19:22 22:4 23:1	legal 13:7 28:24	loose 66:3	March 57:19
31:4 49:24 50:15	26:8 30:20 31:14	length 30:12	loss 57:23	Mark 1:13,16 3:6
52:2 57:16,19	39:2 42:2,24	lesion 20:6 21:8	LPA 2:3	3:11,15 69:18
61:25 64:5 67:6	44:21,22,25 45:1	lesions 18:7	lung 7:23 8:1 9:24	70:10 71:2
involves 7:6	59:8 63:3 65:10	less 19:10,19 20:12	10:10 16:23 17:1	marked 3:3 28:25
involving 57:24	65:11	21:17,23 40:12,13	17:2 22:17,17	71:7
irritating 49:17	T/	42:22,22 45:13	23:5,20 24:10,22	Markowitz 36:23
irritation 49:12	K	56:22 61:24	25:7,22 33:16	mass 48:22 51:8
issue 67:20	keep 32:8 52:11	let 68:8,10	39:22 47:11 50:13	55:8,10
issues 24:4 31:15	kicked 44:3	letter 47:4 48:12	51:8 53:9,12	materials 5:4
33:13 34:15 36:11	kicks 21:10	letterhead 5:20	55:18,21 56:1,4,8	matter 33:6,9 37:5
39:3,3,6,22 51:20	kill 59:24	let's 20:10	56:24 57:4 62:8	38:11 42:20 65:11
issuing 12:13	know 4:6,6 5:14	level 29:15	64:7 65:24	matters 11:15
items 6:17	16:14 23:16 27:21	Levitan 12:3 38:25	lungs 52:5	maximize 17:18
IV 14:17 27:11,13	27:24 31:10 34:24	39:18 41:7,10	lymph 8:17 50:6,7	maximum 18:22
27:14 30:11,17	38:18,20 40:19,20	life 63:5,13,15	50:11,16,17 58:11	may 10:1 12:22
31:7 56:14 64:4,9	40:22 41:12,15,18	light 63:3	58:18	13:15 18:24 19:23
I-A 10:12 11:8	46:4 47:13 48:6	like 5:7 13:17 14:18		20:15 26:1,21
13:16,25 14:4,14	48:25 50:8,21,25	24:8 28:20 46:6	M	27:3 32:10,15
14:20 15:3 17:4	54:1,24 55:5 57:3	48:10 68:14	made 5:25 27:10,23	41:9,13 43:24
17:16 23:9,17	60:7,12,12 63:10	likelihood 15:25	29:3 63:6 65:5	45:13 48:3 50:1,1
56:9	65:4,20 68:9,10	46:19 67:1,22	66:11,13,24	50:10,10 52:2,4
I-B 10:13 11:8	knowing 13:11	likely 15:1,4,16	magic 15:9	57:6 59:11,20
13:16 14:4,15,20	14:16 39:14 40:25	26:6 46:17,18	make 13:21 15:22	60:3,17 61:2,3,6,6
15:3 17:4,16	50:21 61:9 64:4	50:23 60:8 63:20	20:22 29:3,7,20	61:8,17
23:10,17 56:9	knowledge 41:6	limb 64:13 66:17	47:18	maybe 18:13 20:11
	known 33:4	line 6:3 19:12 69:5	making 4:7 16:12	21:21
J		linear 46:12	34:7	Mayfield 1:23,23
J 1:4,13,16 3:6,11	L	list 6:17	malignancies 38:24	Meadows 43:19
69:18 70:10 71:2	lack 16:21	literally 17:1	39:23	mean 16:6 19:23
January 13:3 19:16	lap 14:15	literature 23:19	malignancy 49:1	46:21
20:11 50:20 56:23	large 29:12 56:24	24:2	Malnar 43:20	measured 45:14,15
57:16 58:2 62:8	57:3	little 10:21 18:20	Malone 43:25 44:1	mediastinal 8:17
62:15 63:8,13	larger 20:3 21:9	31:3 36:22 60:1	malpractice 34:19	13:17 61:22 62:4
64:22 65:13 66:24	largest 19:1 20:14	live 30:12	37:20 41:13	67:6
67:16	20:25	lobe 48:23	man 14:21 41:21,22	mediastinoscopic
jest 16:15	last 4:4 7:5 19:11	lobectomy 8:20 9:7	41:24	9:9
Jim 43:25 44:1	25:5 34:17,22	local 43:12 46:19	management 28:15	mediastinoscopy
job 16:9,11	35:1 37:19 42:17	long 4:4 17:11	37:9,10	8:12 67:4
journal 24:6 25:20	45:6 47:3 61:22	36:21 44:8 48:6	managing 25:10	mediastinum 8:25
25:21	late 5:1 28:17 53:20	48:12	39:21	9:5
judgment 55:1	later 21:2 29:22	longer 9:1 26:18	manifested 49:7	medical 8:5 28:13
Judson 3:15	law 14:10	30:13 46:13	Mansnerus 1:9	
July 50:21 55:7	lawful 3:6	long-term 16:18	12:11,24 29:16	29:9,19 31:4
57:10 62:17 63:8	lawyers 24:8	17:18		34:18 37:20 41:13
63:17	lead 53:7	look 5:17 18:24	38:18 47:25 48:8 48:10 49:21 57:15	50:4 66:1
July-August 30:8	least 35:20 51:25	20:19 28:21 41:23	48.10 49.21 57.15 58:3,8 64:18	medical-legal 27:8
saij migust 50.0	1043t 55.20 51.25	20.17 20.21 41.23	50.5,0 04:18	31:19,21
	1			

				Page
meet 68:13	59:5 63:19	52:19 69:3	18:10,11,13,24	27:8 30:23 31:3
member 30:19	most 15:14 24:22	notes 28:22,25 29:3	19:23,24 26:21	36:11 43:16 44:4
mention 65:5	53:9	29:3,6,14,20	27:6,17,18,24	45:2 52:14
mentioned 8:24	motor 49:18 57:23	44:20,23	28.11,21 30.3	outcome 15:5 17:4
32:23	move 11:15 31:20	nothing 22:24 26:2	32:11 33:20,24	46:20 55:25
met 3:19 12:25	Mt 36:14,17,24	58:14 70:11	34:1 36:1,3,6	over 25:5 34:25
28:14 35:14	much 16:11 27:17	notice 1:21	38:5 41:18 42:16	44:20
metastases 58:25	54:21	notified 26:9	45:15 46:6 51:25	overwhelming 6:2:
metastasis 15:24	multiple 18:20	November 4:1	52:23 59:5,7,8,13	18:2
31:11 58:21 59:3	myself 11:12	12:15	59:25 60:2,2	own 24:18 35:19
59:15 60:1,2,6,11	M.D 1:9,13,16 3:6	number 7:15 10:11	ones 48:4	
61:1,13,16 64:6	3:11 69:18 70:10	28:24 40:12 41:25	ongoing 40:4	P
metastatic 31:14	71:2	numbers 15:19	only 27:24 33:20	P 1:6
49:15 54:3,6,8,12		23:6 32:8	36:6 47:15,24	pad 28:24
54:17,22 55:13	<u>N</u>	numbness 48:2	48:3 65:19	page 47:22 69:3,5
60:18	name 3:13,22 25:5	49:5,14,18 57:22	open 10:6 44:14	pages 28:25 44:25
micrometastasis	37:4 40:18 41:15	numerous 24:19	opening 36:4,8	45:4
58:19 64:6	42:19	N1 18:7	operate 28:18	pain 31:12 48:1
microscope 46:23	named 35:21 70:10	N3 55:12	operated 15:2	49:4,11
microscopic 8:13	names 42:22 43:17		38:22 39:24	painful 30:23,24
62:5	nature 24:16 60:18	0	operative 10:4,9	palpable 50:5,7,11
microscopically	necessarily 58:20	objection 20:17	67:12	50:17
67:11	60:19	31:2 49:25 50:24	opinion 16:22 19:8	palpated 49:23
middleman 39:11	needed 60:9	52:3,6,19 56:2	20:9 28:11,12	papers 24:21
Midland 2:14	never 3:19 14:17	57:1 65:17	33:13 45:22 47:6	paragraph 19:11
might 8:14 14:4	26:19,25 30:18	obstructing 48:23	47:10,17 49:14	47:3
33:22 40:9 52:23	33:4	obstructive 49:6,9	50:22 54:13,21	Parma 40:23 41:1
53:4	next 38:3 63:11	49:13	61:2,12 62:9,13	part 19:9 20:11
millimeters 18:23	nice 68:13	obtain 52:23 53:11	63:5,7,7 66:8,12	32:25 50:20 66:7
46:8	night 27:3	obviously 16:14,15	opinions 3:25 6:20	particular 54:9
millions 59:10,13	nine 22:7,12	16:21 37:23 40:12	11:18 12:14 19:17	party 70:16
mind 52:11	nodal 8:11,13 9:14	occasion 42:4,25	24:14,18 25:10	past 30:21 32:14
mine 41:4	49:15,24 50:14	occasions 42:8	31:20 66:5,20	35:8 40:9 41:4,14
Mishkind 2:3,4	52:2 55:12 57:16	occurred 48:13	67:20 68:3,8	43:15 44:12
3:12,22 55:15	57:19,24 58:15	October 70:25	opposed 9:25 22:5	pathologic 10:22,2
58:13 61:8 68:12	61:20,24 62:2,4,5	off 27:6 55:15 59:20	63:8	41:3 53:9
71:4	67:6,9	67:19	optimal 56:17	pathological 21:5
miss 18:22	node 8:12,17 57:25	office 2:5 43:4	option 64:12	pathologist 40:18
modalities 62:14,16	58:18 61:23 67:10	48:10 70:19	order 13:20	40:23 41:1
67:22	nodes 50:6,8,12,16	offices 1:22	original 16:2	patient 7:18,20
modified 12:16	50:17 58:11 61:2	Ohio 1:2,21,23 2:8	originally 29:7	10:15,16 16:16,20
moment 6:9 35:18	61:16,17	2:16 3:7 32:19,21	36:17	23:5 28:1,4 30:13
monopolized 34:25	nodule 22:3	70:3,9,20,24	other 9:7 10:20	30:25 31:13 33:1
35:2	noncardiac 7:7	okay 4:13 5:18	12:18 20:21 21:4	
month 54:9,12 55:4	nonsmall 7:20,23	old 23:2	21:5 32:22 33:25	39:15 42:20 49:6
months 14:12 20:16	10:16 14:20 21:7	older 42:2,21		51:13,21 52:24
37:22 45:16 54:9	22:16 23:20 24:10	once 21:10 30:21	38:9,10 39:3,14 39:23 40:25 42:25	53:3 55:24 56:7,9
more 7:13 11:8	25:22 56:4,8	t		58:19 59:18 62:1:
15:1,3,8,16 17:20		32:9 62:3	43:5,8,10,12	patients 9:25 10:1
22:4,19 27:1	nonsurgical 28:3	oncologic 39:21 40:2	51:17 56:10 61:16	10:12,19 15:14
29:10 33:23 36:22	normally 51:25		61:16 68:1	16:12 17:2,21
	59:12 Notory 1:20 (0:24	oncologist 28:2	otherwise 65:13	18:1 23:9,12
40:13,13 46:1,14	Notary 1:20 69:24	40:3 62:21 63:1,4	70:16	24:12,25 31:7
46:16,16,17 50:23 52:15 53:1,15,17	70:9,23 note 31:2 50:5	oncologists 18:3 one 9:17 12:17	out 9:19 15:11,21 16:1 25:19 26:1	38:22,24 39:1,6,9
1/ 11/ 11/ 11/	1 HOLE VEL 2015 1	CARE YET / TPT /	L 361.75114.261	39:19,20 40:10,1

Page 7

pattern 46:12 point 7:19 9:6 prine 5:21 1:21 purpose 3:3 6:14 recently 17:20 perd 22:13 18:11,21:3 29:22 13:23 14:247:10 4:22 purpose 3:3 6:14 fecently 17:20 perd 22:13 18:11,21:3 29:22 13:23 14:247:10 4:22 pursuant 1:21 precently 6:15:15 purpose 3:3 6:14 recently 17:20 32:18 4:44 perde 4:51:84 55:15 point 29:9 pip 19:94:95:55 pursuant 1:21 precent 7:67.9 poor 4:20 poor 4:20 purpose 3:3 6:14 recommend 9:10 percent 7:67.9 poor 4:20 poort 11:21:31:3 probable 16:23 qualified 70:10 qualified 7		2010/0010333433847733777722777423477424474747474747474			
pay 35:9 13:22 14:11 15:2 prior 5:21 12:12 6:22 23:2.4 7:22 13:23 4:42 47:10 pending 35:24 30:3 47:17 48:21 32:32 4:42 47:10 puts 49:2 probability 15:5.8 puts 49:2 recommend 9:10 per 10:4 32:4 points 29:9 poor 46:20 56:16 puts 49:2 recommend 9:10 per 10:4 32:7 23:12 34:23 32:24 points 29:9 probably 5:16 7:5.9 puts 49:2 recommend 9:10 percent rec 6:25 portion 19:1 probably 5:16 7:5.9 quatified 70:10 29:9,19 50:4 percent rec 6:25 portion 25:20 26:5 10:4,9,11 13:25 quatified 70:10 55:15 8:15 50:6 percent rec 7:1 postibut 92:1,13 13:33 11:6 13:2,12 14:1,10:3 55:15 8:15 50:6 perform 7:22 8:7 postibu 52:7,10 #2:20 32:17 68:10 6:32 56:51.8,19 question 32:24 4:2 perform 8:9 potsbatractive procedure 38:9:6 question 32:24 4:2 recurrent 51:16 periati 35:7 67:9 10:10 16:17 32:21 radiograph 51:7 refere 52:24 67:15 periati 15:7 progeorative 39:24 4:20 precoerat 28:4 5:16	pattern 46:12	point 7:19 9:6	printed 5:17	purposes 3:3 6:14	recent 32:14
per proding 35:24 18:11,12,13 29:22 13:23 (4:2 4:7:10) 44:22 13:43 4:44 pending 35:24 30:3 47:17 48:21 47:21 54:25 61:5 pursunt 1:21 recess 55:16 per(14) 4 32:4 points 29:9 19:19 54:95:53 P.J 43:20 recemend 9:10 per(14) 4 32:4 poorty 11:2 13:13 frobable 16:23 P.J 43:20 recommend 9:10 15:7 23:12 42:23 32:24 position 25:20 26:5 10:4,9,11 13:25 quatified 70:10 quatified 70:10 greatmaneous 7:15 positive 9:9,13 23:7,11 31:16 13:21,22 44:1,10 55:15 58:15 59:6 perform 7:22 8:7 posibile 32:7,10 probable 70:10 62:2 65:11,22,24 99:23 51:99:5 pertaps 9:14 12:11 A8:19 9 procedure 38:9:6 questions 3:24 4:2 recurrence 15:16 person 17:11 12:24 potential 12:4 53:3 procedure 38:9:9 refere 52:24 67:15 refere 22:24 67:15 periaps 9:14 12:11 8:14 9:19 5:5 procedure 38:9:6 refere 22:45:16 refere 22:45:16 perform 7:22 8:7 postbirtuctive proble 15:11 proceded 3:11 refere 22:45:16			1 1		E Contraction of the second se
pendig 35:24 people 45:18 54:5 people 45:18 54:5 percent 7:67.9 10:9;111:16 15:4 percent 7:67.9 percent 7:11 percent 7:12 percent 7:12 p					
people 35:18 32:4 per 10:4 32:4 per 10:4 32:4 10:9,11 11:6 15:4 poor 46:20 percent 7:6,7,9 percent 7:10 percent 7:11 percent 7:12 percent 7:11 percent 7:12 percent 7:11 percent 7:12 percent 7:11 percent 7:12 percent 7:12 percen				1	1
per 10:4 32:4 per cent 7:67,9 por 46:20 por					1
percent 7:6,7,9 poor 46:20 fs:12 section probable 16:23 probable 13:21,22 procent 21:13 probable 13:21,22 probable 13:21,22 procent 23:13 procent 23:14 procent 23:13 procent					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	1 -		1		1
15:7 23:12 24:23 32:24 48:19				p.m 1.24 00.17	1
56:18 61:19 66:25 portion 19:1 probably start record 31:4 26:8 percentage 62:5 position 25:0 10:4,9,11 13:25 qualified 70:10 35:15 55:15 55:15 55:15 55:15 55:15 55:15 55:15 55:12 7ecord 18:3 23:3 13:16 13:13 65:16 65:26 65:26 71:15 95:15 90:55:11 55:22 7ecord 13:12 42:10 48:19 43:12 43:13 14:12:14 49:12 43:12 14:12:14 49:12 49:17 55:12 probem 10:11 procedure 38:9:6 44:18 question 32:24 42:12 15:12 7ecurrence 15:16 15:23 redure 19:25 redure 19:25 redure 19:25 redure 19:25 redure 10:17:23 redure 70:12 redure 19:25 redure 10:17 79:15 39:13:40:66:11 reference 25:13 <			-	0	
percentage 6:25 position 25:20 26:5 10:4.9(11 13:25 question 4:8(10,11) 29:9.19 50.4 9:23 15:19 18:2 66:19 23:7,11 31:16 13:21,22 14:1,10 56:5 66:2 67:15 percentages 7:11 positive 9:9,13 23:7,11 31:16 13:21,22 14:1,10 56:5 66:2 67:15 perform 7:22 8:7 posible 32:7,10 48:20 52:17 68:10 62:22 63:1,22,24 49:23 58:3,10 gerformed 8:9 postobstructive prodeure 3:89 (24:13) 64:18 7ecurrence 15:16 perform 7:22 8:7 postobstructive procedures 10:4,9 question 3:24 4:2 65:23 performed 8:9 postobstructive proceedure 3:89 quite 62:6 7ecurrence 15:16 perform 15:9,22 potential 52:4 53:8 process 30:24 53:9 7ecurrence 15:16 7ecure 62:17 51:12 potential 52:4 50:8 spita 40:4 66:8 radiographs 20:19 reference 58:1,6 pertain 15:17 practice 9:23 13:2 24:12,21 25:8 radiographs 20:19 reference 25:13 pertain 25:7 67:9 frepered 62:12 fradiographs 20:19 reference 25:14 pertains 15:17					1
9:23 15:19 18:2 66:19 18:3 20:24,25 415,17 10:3 55:15 88:15 59:6 percentages 7:11 posibile 9:9,13 23:7,11 31:16 13:21,22 14:1,10 65:5 66:2 67:15 percontages 7:11 possibility 52:1,12 35:3 37:22 43:20 90:2 51:1 59:5 31:24 32:10 48:14 perform 7:22 8:7 possibile 32:7,10 48:20 52:17 68:10 62:22 63:1,22,24 49:23 58:3,10 perform 8:9 postobstructive problem 25:11 pos:25 61:8,19 percurrent 51:6 perform 9:22 postobstructive postobstructive procedure 38:9:6 questions 3:24:22 44:18 9:17 37:10 postobstructive postobstructive proceedure 31:41 quite 62:6 72:24 9:17 37:10 postobstructive proceedure 31:41 quite 62:6 72:24 72:5 pertain 51:7 potential 52:4 53:8 processional 1:19 31:6 64:11 referce 25:13 referece 25:13 pertain 51:1 practide 67:12 67:9 11:10 16:17 23:21 radiograph 51:7 regard 12:21,25 referece 01:13 71:7 referce 01:17 39:1 3					
percentages 7:11 positive 9:9,13 23:7,11 31:16 13:21,22 14:1,10 65:5 66:2 67:15 15:13 67:10 32:3,24 33:20 19:13 30:23 31:9 records 18:9 28:13 perform 7:22 8:7 posibility 52:1,12 35:3 37:22 43:20 50:2 51:1 59:5 19:13 30:23 31:9 perform 7:22 8:7 posibostructive prodeure 38:90 10:11 48:20 52:17 68:10 63:25 65:18,19 65:23 perform 48:9 postobstructive procedure 38:90 questions 3:24 42:10 55:23 recurrence 15:16 perform 512:0 postoperative 10:11 questions 3:24 42:10 55:23 reduce 70:12 perform 512:0 potential 52:4 53:8 process 30:24 53:9 R 39:25 reduce 70:12 reduce 70:12 reduce 70:12 reduce 70:12 referece 22:13: person 17:11 19:24 64:4,10 65:2,6,15 prognosis 10:19 31:6 64:11 reference 22:13 pertine 14:5: 23:3 24:24 40:15 56:7 62:16 66:22 radiologist's 18:18 reference 22:13 pertine 21:15:17 preclude 8:14 prognoss2:25 read 12:12 14:9 regard 12:2		*			
15:13 67:10 32:3,24,33:20 19:13,30:23,31:9 records 18:9,28:13 perform 7:22,8:7 possibil 32:7,10 48:20,52:17,68:10 62:25,63:1,22,24 31:24,32:10,48:10 perform 68:9 postobstructive procedure 38:96 questions 3:24,42: recurrence 15:16 period 15:9,22 postoperative 10:11 questions 3:24,42: recurrence 15:16 period 15:9,22 postoperative 30:13,40:43:66:8 reduce 19:25 reduce 19:25 16:16 19:17,20 60:5 55:11 processional 11:9 31:64:11 reference 52:46:71.5 pertains 15:17 practice 9:23,13:2 24:12,21 25:8 radiographs 20:19 reference 52:46:71.5 reference 25:13 pertains 15:17 practice 9:23,13:2 24:12,21 25:8 radiologist's 18:18 reference 25:13 pertains 15:17 preclude 67:12 progensis 29:2 radiologist's 18:18 reference 02:13 pibine 52:15 precelude 8:14 prognosis 29:2 radiologist's 18:18 reference 02:13 pertains 15:17 preclude 67:12 prostoce 21:5 regard 10:21:2,5 regard 10:21:2,5 pibine 17:970:15 preclude 67:12 prognosis 29:2 <td></td> <td></td> <td></td> <td></td> <td></td>					
percutaneous 7:15 perform 7:22 8:7 possibility 52:1,12 possible 32:7,10 35:3 37:22 43:20 48:20 52:17 68:10 50:22 51:1 59:5 62:22 63:1,8,19 31:24 32:10 48:10 perform 7:22 8:7 possible 32:7,10 48:20 52:17 68:10 55:22 formal 8:10 formal 8:11 formal 8:11 <tdf< td=""><td></td><td></td><td></td><td></td><td>1</td></tdf<>					1
perform 7:22 8:7 possible 32:7,10 48:20 52:17 68:10 62:22 63:1,22,24 49:23 58:3,10 23:4 58:10 55:22 problem 25:11 63:26 55:18,19 65:23 performed 8:9 postobstructive procedure 3:8 9:6 quiet 62:6 recurrence 15:16 perhaps 9:14 12:11 48:19 51:5 procedure 3:8 9:6 quiet 62:6 recurrence 15:16 period 15:9,22 potential 52:4 53:8 process 30:24 53:9 R reduced 70:12 period 15:9,22 potential 14:2 professional 1:19 31:6 64:11 refers 52:24 67:15 persistent 52:9 51:19 52:24 60:18 39:13 40:4 66:8 radiograph 51:7 referece 25:13 pertain 25:7 67:9 11:10 16:17 23:21 radiologist's 18:18 refereced 25:13 pertain 51:17 preclude 8:14 progresse 9:2 ratiologist's 18:18 39:7 preter 37:13 preclude 67:12 64:13 rare 9:12 75:10 66:22 physicial 31:16 p:29:24:13:5 projection 47:19 read 15:14 16:15 47:10 66:22 physicial 31:16 prepared 11:19 progresse 9:2 <			t '	F	
23:4 58:10 55:22 problem 25:11 63:25 65:18,19 65:23 performed 8:9 postobstructive procedure 3:8 9:6 questions 3:24 4:2 recurrence 15:16 36:4 40:9 48:21 postoperative 10:11 quite 62:6 recurrent 31:7 49:17 37:10 proceeds 30:24 53:9 R reduce 19:25 16:16 19:17,20 60:5 55:11 radiation 17:23 reduce 19:25 51:12 potential 52:4 53:8 professional 1:19 31:6 64:11 reference 58:1,6 persistent 52:9 51:19 52:24 60:18 sp1:3 40:4 66:8 radiograph 51:7 reference 25:13 pertain 25:7 67:9 11:10 16:17 23:21 radiograph 51:7 reference 25:13 pertain 25:7 67:9 11:10 16:17 23:21 radiograph 51:7 reference 45:13 pertain 25:7 67:9 reclude 8:14 prognostic 24:9 rapid 46:17 reference 45:13 paks 30:20 preclude 8:14 progress 29:2 rather 46:18 regard 12:21,25 39:8 physician 3:16 12:9 24:1 33:5 projectin 47:19 read 15:14				ſ	
performed 8:9 pertaps 9:14 12:11 49:17 postobstructive 48:19 51:5 postoperative 10:11 procedure 3:8 9:6 procedures 10:4.9 questions 3:24 4:2 44:18 recurrence 15:16 15:23 49:17 7:10 postoperative 10:11 proceeded 34:11 process 30:24 53:9 quite 62:6 39:25 16:16 19:17,20 60:5 55:11 proceeded 34:11 professional 1:19 R reduce 19:25 16:16 19:17,20 60:5 55:11 professional 1:19 31:6 64:11 refere 52:24 67:15 person 17:11 19:24 64:4,10 65:2,6,15 prognosis 10:19 53:6 reduce 19:25 pertains 15:17 practice 9:23 13:2 24:12,21 25:8 radiographs 20:19 reference 25:13 pertains 15:17 pracelude 8:14 prognosis 10:19 rade radiographs 20:19 reference 10:17 39:1 pertains 15:17 preclude 67:12 64:13 rare 9:12 regard 12:21,25 regard 12:21,25 physical 38:16 prepared 11:19 progress 29:2 rather 46:18 regard 12:21,25 physical 38:16 prepared 11:19 protocol 9:13,15 29:21 44:20 59:6 regit 33:13 piteture 46:24 49:2					
perhaps 9:14 12:11 48:19 51:5 procedures 10:11 quite 62:6 49:17 37:10 postoperative 10:11 proceeded 34:11 guite 62:6 39:25 16:16 19:17,20 60:5 55:11 radiation 17:23 reduced 70:12 persistent 52:9 potentially 14:2 professional 11:9 31:6 64:11 reduced 70:12 persistent 52:9 potentially 14:22 professional 11:9 31:6 64:11 refer 52:24 67:15 pertain 51:17 practice<9:23			, x		
36:4 40:9 48:21 49:17 postoperative 37:10 10:11 process 30:24 53:9 quite 62:6 recurrent 31:7 39:25 period 15:9,22 16:16 19:17,20 60:5 potential 52:4 53:8 process 30:24 53:9 radiation 17:23 reduce 19:25 persistent 52:9 51:19 52:24 60:18 39:13 40:4 66:8 radiograph 51:7 refer 52:24 67:15 pertain 25:7 67:9 11:10 16:17 23:21 radiograph 51:7 reference 58:1,6 pertains 15:17 practice 9:23 13:2 24:12,21 25:8 radiograph 50:9 reference 10:17 39:1 phone 5:2,15 preclude 67:12 66:13 rare 9:12 rsite regard 12:21,25 phone 5:2,15 preparing 23:23,25 projection 47:19 read 12:12 14:9 regarding 5:15 picture 46:24 49:2 present 7:6 24:24 provide 11:19,20 68:14 69:2 regardles 14:11 plain 53:13 present 13:3 54:20 10:25 19:4 51:8 provide 13:7 11:24 readi 22:12 14:20 readi 22:12 14:9 reading 12:18 14:6 region 48:17 plain 53:13 present 7:6 24:24 provide 13:15 provide 3:7 11:24 read 12:21 2:5 readi 12:12 14:9 regard					
49:17 37:10 proceeded 34:11					
period 15:9,22 potential 52:4 53:8 process 30:24 53:9 R reduce 19:25 16:16 19:17,20 60:5 55:11 radiation 17:23 reduced 70:12 persistent 52:9 51:19 52:24 60:18 39:13 40:4 66:8 radiograph 51:7 reference 58:1,6 persistent 52:9 67:9 11:10 16:17 23:21 radiograph 51:7 reference 25:13 pertain 55:7 67:9 11:10 16:17 23:21 radiograph 51:7 referenced 10:17 39:1 pertain 48:5 23:3 24:24 40:15 56:7 62:16, 66:22 rage 20:13 39:7 Peter 37:13 preclude 67:12 64:13 rare 9:12 55:12 phone 5:2,15 preoperative 8:2,11 progress 29:2 rather 46:18 regard 12:21,25 physicia 3:16 12:9 24:1 33:5 projection 47:19 reach 15:14 16:15 47:10 66:22 pisteur 46:24 49:2 presence 8:13 protocol 91:15 29:21 44:20 59:6 gegandig 5:15 jate 17:9 70:15 52:15 67:6 33:13 54:20 reading 12:18 14:6 Registered 1:19 plaintiff 3:7:17 present3:25:5,6 54:14,25 61:10 13:6 68:4				quite 02:0	1
16:16 19:17,20 60:5 55:11 radiation 17:23 reduced 70:12 51:12 potentially 14:2 professional 1:19 31:6 64:11 refuced 70:12 person 17:11 19:24 64:4.10 65:2,6.15 prognosis 10:19 53:6 64:25 pertain 25:7 67:9 11:10 16:17 23:21 radiograph 51:7 reference 25:13 pertains 15:17 practice 9:23 13:2 24:12,21 25:8 radiograph 520:19 referenced 10:17 39:1 pertains 35:17 preclude 8:14 prognosis 10:19 radiograph 520:19 referenced 10:17 39:1 phase 30:20 preclude 67:12 64:3 rare 9:12 55:12 physical 58:16 prepared 11:19 progress 29:2 rather 46:18 regarding 5:15 32:20 40:7,8 preparing 23:23,25 prospect 2:15 24:17,23 25:6 39:8 picture 46:24 49:2 present 7:6 24:24 provide 3:7 11:24 reading 12:18 14:6 regarding 5:15 glaintiff 17:17 2:2 47:5 51:20 provide 3:7 11:24 realized 28:17 related 12:22 2,24 plaintiff 3:56,8 47:5,16 49:2 provide 3:517 realized 28:17 relate 13:7 realing 12:18 14:6 <t< td=""><td></td><td>+</td><td></td><td>p</td><td>1</td></t<>		+		p	1
51:12 potentially 14:2 professional 1:19 31:6 64:11 refer 52:24 67:15 person 17:11 19:24 51:19 52:24 60:18 39:13 40:4 66:8 radiograph 51:7 reference 58:1,6 pertain 25:7 67:9 11:10 16:17 23:21 radiograph 20:19 reference 12:13 pertain 25:7 practice 9:23 13:2 24:12,21 25:8 radiograph 20:19 reference 12:17 pertain 25:7 preclude 8:14 prognosis 20:2 rage 20:13 reference 10:17 39:1 phase 30:20 preclude 67:12 prognosis 29:2 rather 46:18 regard 12:21,25 phone 5:2,15 prepared 11:19 progress 29:2 rather 46:18 regard 12:21,25 picture 46:24 49:2 preparing 23:23,25 prospect 2:15 projection 47:19 reach 15:14 16:15 47:10 66:22 plaint 11':7, 70:15 52:15 67:6 33:13 54:20 regardless 14:11 region 58:17 plaint 11':7, 71 7:2 47:5 51:20 provide 11:19,20 68:14 69:2 region 58:17 plaint 11'':7, 72:2 present 7:6 24:24 provide 37:11:24 realing 12:18 14:6 72:20 plaint 11':7, 72:	-				1
persistent 52:9 pertain 25:7 51:19 52:24 60:18 64:4,10 65:2,6,15 67:9 39:13 40:4 66:8 prognosis 10:19 radiograph 51:7 53:6 reference 58:1,6 64:25 pertain 25:7 67:9 11:10 16:17 23:21 radiograph 51:7 referenced 25:13 pertain 15:17 practice 9:23 13:2 23:12,21 25:8 radiograph 51:7 referenced 25:13 pertains 15:17 preclude 8:14 prognostic 24:9 rage 20:13 spertains 18:17 phase 30:20 preclude 67:12 progness 29:2 rather 46:18 regard 12:21,25 physical 58:16 prepared 11:19 progress 29:2 rather 46:18 regard 12:21,25 pisticur 46:24 49:2 present 7:6 24:24 prospect 2:15 29:21 44:20 59:6 39:8 plaintiff 1:7,17 2:2 35:15 67:6 33:13 54:20 reading 12:18 14:6 regionally 46:19 plaintiff 3:5:6,8 47:5,16 49:2 provide 53:17 realized 28:17 relate 10:10 24:21 plaintiff 3:5:5,6 54:14,25 61:10 13:6 68:4 40:64:32:05:15 32:20 plaintiff 1:7,17 2:2 54:16 54:17,57:21 65:8 67:21 realized 28:17 realized 28:17					6
person 17:11 19:24 pertain 25:7 64:4,10 65:2,6,15 67:9 prognosis 10:19 11:10 16:17 23:21 53:6 64:25 pertain 25:7 67:9 11:10 16:17 23:21 radiographs 20:19 radiologist's 18:18 referenced 25:13 pertain 48:5 23:3 24:24 40:15 56:7 62:1,6 66:22 range 20:13 39:7 phase 30:20 preclude 67:12 prognosic 24:9 raid 00gist's 18:18 referred 10:17 39:1 physical 58:16 prepared 11:19 progress 29:2 rath 46:18 regard 12:21,25 gistign 3:16 12:9 24:1 33:5 prognosic 24:9 read 12:12 14:9 regard 15:15 32:20 40:7,8 preparing 23:23,25 prospect 2:15 24:17,23 25:6 39:8 picture 46:24 49:2 presence 8:13 provide 11:19,20 readily 32:13 regardless 14:11 place 17:9 70:15 52:15 67:6 33:13 54:20 regio 58:17 regardless 14:11 plaintiff's 3:5:6,6 54:14,25 61:10 13:6 68:4 realization 30:22 realized 28:17 plaintiff's 3:5:5,6 54:14,25 61:10 13:6 68:4 40:6 43:20 53:15 relatet 31:7 31:12 plaintiff's 3:5:5,6				1	
pertain 25:7 67:9 11:10 16:17 23:21 radiographs 20:19 referenced 25:13 pertains 15:17 practice 9:23 13:2 24:12,21 25:8 radiologist's 18:18 referred 10:17 39:1 pertains 15:17 practice 9:23 13:2 24:12,21 25:8 range 20:13 39:7 Peter 37:13 preclude 67:12 66:13 range 20:13 39:7 phase 30:20 preclude 67:12 prognostic 24:9 rather 46:18 regard 12:21,25 phone 5:2,15 preoperative 8:2,11 progress 29:2 rather 46:18 regard 12:21,25 physician 3:16 12:9 24:1 33:5 projection 47:19 read 12:12 14:9 regarding 5:15 32:20 40:7,8 presparing 23:23,25 prospect 21:5 29:21 44:20 59:6 regardless 14:11 picer 17:9 70:15 ps2:15 67:6 33:13 54:20 realing 12:18 14:6 region 58:17 plaintiff 17:17 2:2 37:5 provide 11:19,20 68:14 69:2 relate 10:10 24:21 plaintiff 35:6,8 present 7:6 24:24 provide 3:7 11:24 realized 28:17 relate 10:10 24:21 plaintiff 3: 3:2 5:5,6 54:14,25 61:10	1 -				
pertains 15:17 practice 9:23 13:2 24:12,21 25:8 radiologist's 18:18 referred 10:17 39:1 pertinent 48:5 23:3 24:24 40:15 56:7 62:1,6 66:22 range 20:13 39:7 Peter 37:13 preclude 8:14 prognostic 24:9 rapid 46:17 reflection 49:12 phase 30:20 preclude 67:12 progress 29:2 rather 46:18 regard 12:21,25 physician 3:16 12:9 24:1 33:5 progress 29:2 reach 15:14 16:15 47:10 66:22 picture 46:24 49:2 presence 8:13 protocol 9:13,15 29:21 44:20 59:6 39:8 plate 17:9 70:15 52:15 67:6 33:13 54:20 reading 12:18 14:6 region 58:17 plaintiff 15:7,17 2:2 47:5 51:20 provide 13:19,20 68:14 69:2 relaization 30:22 plaintiff 35:6,8 47:5,16 49:2 provides 53:17 realization 30:22 relate 01:0 24:21 plaintiff 35:6,8 54:14,25 61:10 13:6 68:4 40:6 43:20 53:15 relate 37: 71:12 plaintiff 35:6,8 54:17 57:21 65:8 67:21 realing 42:10 18:16 22:20 presented 14:3 provides 12:23 <td< td=""><td></td><td></td><td></td><td></td><td></td></td<>					
pertinent 48:5 23:3 24:24 40:15 56:7 62:1,6 66:22 range 20:13 39:7 Peter 37:13 preclude 8:14 prognostic 24:9 rapid 46:17 reflection 49:12 phase 30:20 preclude 67:12 64:13 rare 9:12 rspid 46:17 reflection 49:12 physical 58:16 prepared 11:19 progress 29:2 rather 46:18 regard 12:21,25 physical 38:16 prepared 11:19 progress 29:2 rather 46:18 regard 12:21,25 physical 38:16 prepared 18:19 projection 47:19 reach 15:14 16:15 47:10 66:22 physical 38:20 10:25 19:4 51:8 protocol 9:13,15 29:21 44:20 59:6 regard 18:14 plaint 17 1:7,17 2:2 present 7:6 24:24 provide 11:19,20 68:14 69:2 reading 12:18 14:6 plaintiff 1:7,17 2:2 47:5 51:20 28:8 29:15 realization 30:22 relate 10:10 24:21 glaintiff 1:7,17 2:2 present 7:6 24:24 provide 3:7 11:24 realized 28:17 relate 10:10 24:21 glaintiff 1:7,17 2:2 d4:5 51:20 28:8 29:15 realized 28:17 relate 10:10 24:21 glaintiff 1:7,17					
Peter 37:13 preclude 8:14 prognostic 24:9 rapid 46:17 reflection 49:12 phase 30:20 preclude 67:12 64:13 rare 9:12 rspid 46:17 reflection 49:12 physical 58:16 prepared 11:19 progress 29:2 rather 46:18 regard 12:21,25 physical 31:6 12:9 24:1 33:5 progress 29:2 rather 46:18 regard 12:21,25 pivsical 31:6 12:9 24:1 33:5 prospect 21:5 24:17,23 25:6 39:8 picture 46:24 49:2 presence 8:13 protocol 9:13,15 29:21 44:20 59:6 regardless 14:11 plaint 53:13 present 7:6 24:24 provide 3:7 11:24 reading 32:13 region 58:17 plaint fff 17, 17 2:2 34:5,20 37:5 present 3:6 49:2 provide 3:7 11:24 realization 30:22 relate 10:10 24:21 plaint fff 15 3:2.5 6 54:14,25 61:10 13:6 68:4 40:6 43:20 53:15 relate 10:10 24:21 plaint fff 15 3:2.5 6 54:14,25 61:10 13:6 68:4 40:6 43:20 53:15 relate 13:7 31:12 presented 14:3 proximate 13:7 realm 31:3,4 67:24 67:24 ptaint f		-			
phase 30:20 precluded 67:12 64:13 rare 9:12 55:12 phone 5:2,15 preoperative 8:2,11 progress 29:2 rather 46:18 regard 12:21,25 physical 58:16 prepared 11:19 progress 29:2 rather 46:18 regard 12:21,25 32:20 40:7,8 preparing 23:23,25 prospect 2:15 24:17,23 25:6 39:8 picture 46:24 49:2 presence 8:13 protocol 9:13,15 29:21 44:20 59:6 regardless 14:11 pieser 17:9 70:15 52:15 67:6 33:13 54:20 readily 32:13 region 58:17 plain 53:13 present 7:6 24:24 provide 11:19,20 28:8 29:15 realization 30:22 relate 10:10 24:21 st5,20 37:5 present 7:6 16:49:2 provides 53:17 realized 28:17 relate 10:10 24:21 plainiffs 3:6,8 47:5,16 49:2 providing 12:23 realm 31:3,4 67:24 plainiffs 3:2 5:5,6 54:14,25 61:10 13:6 68:4 40:6 43:20 53:15 relates 13:7 31:12 plainiffs 3:2 5:5,6 54:17 57:21 65:8 Public 1:20 69:24 34:24 51:17 relates 13:7 31:12 plaxe 29:25 68:8 54:17					
phone 5:2,15 preoperative 8:2,11 progress 29:2 rather 46:18 regard 12:21,25 physical 58:16 prepared 11:19 progressed 9:4 pred 12:12 14:9 regarding 5:15 32:20 40:7,8 preparing 23:23,25 prospect 2:15 24:17,23 25:6 39:8 picture 46:24 49:2 presence 8:13 protocol 9:13,15 29:21 44:20 59:6 regardless 14:11 picces 18:20 10:25 19:4 51:8 provide 11:19,20 68:14 69:2 region 58:17 place 17:9 70:15 52:15 67:6 33:13 54:20 reading 12:18 14:6 region 58:17 plaintiff 1:7,17 2:2 47:5 51:20 28:8 29:15 realized 28:17 related 02:22,24 plaintiff s 35:6,8 47:5,16 49:2 provides 53:17 realized 28:17 relate 10:10 24:21 plaintiff s 3:2 57.6 54:14,25 61:10 13:6 68:4 40:6 43:20 53:15 relates 13:7 31:12 12:6 29:6 37:12 64:2 proximate 13:7 realm 31:3,4 67:24 plaintiff s 3:2 57.6 54:17 57:21 65:8 Public 1:20 69:24 34:24 51:17 relates 13:7 31:12 plaintiff s 3:2 57.6 54:17 57:21 65:8 </td <td></td> <td></td> <td></td> <td></td> <td>1</td>					1
physical 58:16 physician 3:16prepared 11:19 12:9 24:1 33:5progressed 9:4 projection 47:19reach 15:14 16:15 read 12:12 14:947:10 66:22 regarding 5:1532:20 40:7,8 picture 46:24 49:2preparing 23:23,25prospect 2:15 prospect 2:1524:17,23 25:6 29:21 44:20 59:639:8picture 46:24 49:2 picture 46:24 49:2presence 8:13 present 7:6 24:24protocol 9:13,15 provide 11:19,2029:21 44:20 59:6 68:14 69:2regardless 14:11 region 58:17plati 53:13 plain 53:13present 7:6 24:24 47:5 51:20provide 3:7 11:24 28:8 29:15reading 12:18 14:6 realization 30:22region 28:17 relate 10:10 24:21 relate 10:10 24:21plaintiffs 35:6,8 plaintiff's 3:2 5:5,654:14,25 61:10 54:14,25 61:1013:6 68:4 67:2140:6 43:20 53:15 realm 31:3,4 relate 13:7relates 13:7 31:12 relates 13:7 31:12flamitiff's 3:2 5:5,6 plaintiff's 3:2 5:5,654:17 57:21 65:8 54:14,25 61:1067:21 70:9,23reason 4:11,16 relations 22:8relationship 40:5 relate 12:12 24:3plaintiff's 9:18 presenty 12 presum 38:13 plexus 49:18 presum 38:13 presum 48:19 48:20,24 49:8,13Presenty 22:11 primary 8:15,16 9:11 16:3pulmonary 8:6 52:25recall 5:23,24 32:14 recall 5:23,24 32:14reliable 24:8 25:2,3 remainder 10:6at:21 pneumonia 48:19 48:20,24 49:8,13primary 8:15,16 9:11 16:3pulmonologist 52:2532:15 33:25 66:22 received 5:2,444:18 remainder 10:6				1	
physician 3:16 12:9 24:1 33:5 projection 47:19 read 12:12 14:9 regarding 5:15 32:20 40:7,8 preparing 23:23,25 prospect 2:15 24:17,23 25:6 39:8 picture 46:24 49:2 presence 8:13 protocol 9:13,15 29:21 44:20 59:6 regarding 5:15 place 17:9 70:15 52:15 67:6 33:13 54:20 region 58:17 region 12:18 14:6 plain 53:13 present 7:6 24:24 provided 3:7 11:24 realization 30:22 relate 10:10 24:21 34:5,20 37:5 presentation 13:23 provides 53:17 realization 30:22 relate 10:10 24:21 plaintiffs 3:6,8 47:5,16 49:2 providing 12:23 really 14:10 18:16 32:20 plaintiff's 3:2 5:5,6 54:14,25 61:10 13:6 68:4 40:6 43:20 53:15 relates 13:7 31:12 12:6 29:6 37:12 64:2 proximate 13:7 realm 31:3,4 67:24 plane 12:12 67:2 problic 1:20 69:24 15:18 16:4 25:16 41:2 45:12 plawe 49:18 presented 14:3 33:13 34:9 66:6 reason 4:11,16 relation s1:37 31:12 plaintiff's 49:12 67:7 79:9				3	
32:20 40:7,8 preparing 23:23,25 Prospect 2:15 24:17,23 25:6 39:8 picture 46:24 49:2 presence 8:13 protocol 9:13,15 29:21 44:20 59:6 regardless 14:11 pieces 18:20 10:25 19:4 51:8 provide 11:19,20 68:14 69:2 region 58:17 place 17:9 70:15 52:15 67:6 33:13 54:20 reading 12:18 14:6 region 58:17 plain 53:13 present 7:6 24:24 provided 3:7 11:24 realization 30:22 relate 10:10 24:21 34:5,20 37:5 presentation 13:23 provides 53:17 realized 28:17 related 22:22,24 plaintiff's 3:2 5:5,6 54:14,25 61:10 13:6 68:4 40:6 43:20 53:15 relates 13:7 31:12 12:6 29:6 37:12 64:2 proximate 13:7 realm 31:3,4 67:24 44:9 45:5 71:6 presented 14:3 33:13 34:9 66:6 reason 4:11,16 relationship 40:5 plexes 12:1 presently 22:16 public 1:20 69:24 34:24 51:17 relationship 40:5 plexes 49:18 presently 22:11 public 1:20 69:24 34:24 51:17 relative 37:8 70:16 pleuritic 49:12 67:7					
picture 46:24 49:2 pieces 18:20 place 17:9 70:15 plain 53:13presence 8:13 10:25 19:4 51:8 52:15 67:6 47:5 51:20protocol 9:13,15 provide 11:19,20 33:13 54:20 provided 3:7 11:24 28:8 29:1529:21 44:20 59:6 (8:14 69:2)regardless 14:11 region 58:17 regionally 46:19 Registered 1:19 related 22:22,24plain 53:13 plain 53:13 plain 53:13present 7:6 24:24 47:5 51:20provided 3:7 11:24 28:8 29:15reading 12:18 14:6 realization 30:22 realing 12:18 14:6Registered 1:19 regionally 46:19plaintiff 1:7,17 2:2 34:5,20 37:5presentation 13:23 presentation 13:23provides 53:17 providing 12:23realized 28:17 realized 28:17related 22:22,24 s2:20plaintiff's 3:2 5:5,6 12:6 29:6 37:1254:14,25 61:10 64:213:6 68:4 proximate 13:740:6 43:20 53:15 realm 31:3,4relates 13:7 31:12 67:2412:6 29:6 37:12 44:9 45:5 71:6presented 14:3 70:9,2333:13 34:9 66:6 70:9,23reason 4:11,16 relationship 40:5relationship 40:5 41:2 45:12pleuritic 49:12 bleuritic 49:12 8:2167:7 presume 38:13 pretty 27:16 primary 8:15,16publications 22:8 22:12 pulmonary 8:6 pulmonologist25:3 26:7 45:19 32:15 33:25 66:22reliable 24:8 25:2,3 44:18 remainder 10:6starprimary 8:15,16 pulmonologistpulmonologist 32:15 33:25 66:2232:15 33:25 66:22 44:18 remarkable 55:7					
pieces 18:2010:25 19:4 51:8provide 11:19,2068:14 69:2region 58:17place 17:9 70:1552:15 67:633:13 54:20readily 32:13regionally 46:19plain 53:13present 7:6 24:24provided 3:7 11:24reading 12:18 14:6Registered 1:19plaintiff 1:7,17 2:247:5 51:2028:8 29:15realization 30:22relate 10:10 24:2134:5,20 37:5presentation 13:23provides 53:17realized 28:17related 22:22,24plaintiff's 3:2 5:5,654:14,25 61:1013:6 68:440:6 43:20 53:15relates 13:7 31:1212:6 29:6 37:1264:2proximate 13:7realm 31:3,467:2444:9 45:5 71:6presented 14:333:13 34:9 66:6reason 4:11,16relationship 40:5PLEAS 1:147:23,25 48:1567:2115:18 16:4 25:1641:2 45:12pleave 29:25 68:854:17 57:21 65:8Public 1:20 69:2434:24 51:17relative 37:8 70:16pleuritic 49:1267:770:9,23reasonably 24:8relevant 23:22 24:3pleuwine 49:18Presently 22:11publications 22:825:3 26:7 45:19reliable 24:8 25:2,3s:21prety 27:16pulmonary 8:6recall 5:23,24 32:14remainder 10:6s:219:11 16:352:25recived 5:2,4remarkable 55:7					1
place 17:9 70:1552:15 67:633:13 54:20readily 32:13regionally 46:19plain 53:13present 7:6 24:24provided 3:7 11:24reading 12:18 14:6regionally 46:19plaintiff 1:7,17 2:247:5 51:2028:8 29:15reading 12:18 14:6realization 30:2234:5,20 37:5presentation 13:23provides 53:17realized 28:17relate 10:10 24:21plaintiff's 3:2 5:5,654:14,25 61:1013:6 68:440:6 43:20 53:15relates 13:7 31:1212:6 29:6 37:1264:2proximate 13:7realm 31:3,467:2444:9 45:5 71:6presented 14:333:13 34:9 66:6reason 4:11,16relationship 40:5PLEAS 1:147:23,25 48:1567:2115:18 16:4 25:1641:2 45:12plaese 29:25 68:854:17 57:21 65:8Public 1:20 69:2434:24 51:17relative 37:8 70:16pleuritic 49:1267:770:9,23reason 35:4 62:10relatel 24:8 25:2,3pleurite 49:18presume 38:1322:12reason 35:4 62:1025:18,23 26:88:21pretty 27:16pulmonary 8:6recall 5:23,24 32:14remainder 10:648:20,24 49:8,139:11 16:352:25recived 5:2,4remarkable 55:7	1 ^				
plain 53:13 plain fift 1:7,17 2:2 34:5,20 37:5present 7:6 24:24 47:5 5 1:20provided 3:7 11:24 28:8 29:15reading 12:18 14:6 realization 30:22Registered 1:19 relate 10:10 24:21 relate 22:22,24plaintiffs 35:6,8 plaintiff's 3:2 5:5,647:5,16 49:2 54:14,25 61:10provides 53:17 providing 12:23realiy 14:10 18:16 40:6 43:20 53:1532:2012:6 29:6 37:12 44:9 45:5 71:664:2 prosented 14:3proximate 13:7 33:13 34:9 66:6reason 4:11,16 reason 4:11,16relates 13:7 31:12 relates 13:7 31:12PLEAS 1:1 pleurite 49:12 plexus 49:1847:23,25 48:15 67:767:21 70:9,2315:18 16:4 25:16 reason 35:4 62:1041:2 45:12 relations 22:8 25:3 26:7 45:19preumonectomy 8:21 pretty 27:16 pleuring 48:19 48:20,24 49:8,13Presently 22:11 primary 8:15,16 p:11 16:3pulmonary 8:6 pulmonologist 52:25recall 5:23,24 32:14 32:15 33:25 66:22remainder 10:6 44:18 remarkable 55:7					
plaintiff1:7,172:247:551:2028:829:15realization30:22relate10:1024:2134:5,2037:5presentation13:23provides53:17realized28:17related22:22,24plaintiff's35:6,847:5,1649:2providing12:23realized28:17related22:22,2412:629:637:1264:2providing12:23realized32:20relates13:731:1244:945:571:6feresented14:333:1334:966:6reason41:1,16relationship40:5PLEAS1:147:23,2548:1567:2115:1816:425:1641:245:12please29:2568:854:1757:2165:8Public1:2069:2434:2451:17relative37:870:16pleuritic49:1267:770:9,23reasonably24:8reliable24:2224:3pleuritic49:18presume38:1322:12reasons35:462:1025:18,2326:88:21pretty27:16pulmonary8:6recall5:23,2432:14remainder10:648:20,2449:8,139:1116:352:25received5:2,4remainder55:7					
34:5,20 37:5 plaintiffs 35:6,8 plaintiff's 3:2 5:5,6presentation 13:23 47:5,16 49:2 54:14,25 61:10provides 53:17 providing 12:23realized 28:17 really 14:10 18:16related 22:22,24 32:2012:6 29:6 37:12 44:9 45:5 71:654:14,25 61:10 64:213:6 68:4 proximate 13:740:6 43:20 53:15 realm 31:3,4relates 13:7 31:12 67:2444:9 45:5 71:6 PLEAS 1:1presented 14:3 47:23,25 48:1533:13 34:9 66:6 67:21reason 4:11,16 15:18 16:4 25:16relationship 40:5 41:2 45:12please 29:25 68:8 pleuritic 49:12 presume 38:1354:17 57:21 65:8 70:9,23Public 1:20 69:24 70:9,2334:24 51:17 reasonably 24:8 25:3 26:7 45:19relative 37:8 70:16 relative 37:8 70:16pneumonectomy 8:21 pretur 27:16 48:20,24 49:8,13Presently 22:11 primary 8:15,16 p:11 16:3pulmonary 8:6 pulmonologist 52:25recall 5:23,24 32:14 32:15 33:25 66:22remainder 10:6 44:18 remarkable 55:7		•			0
plaintiffs 35:6,8 plaintiff's 3:2 5:5,647:5,16 49:2 54:14,25 61:10providing 12:23 13:6 68:4really 14:10 18:16 40:6 43:20 53:1532:20 relates 13:7 31:1212:6 29:6 37:1264:2 presented 14:3proximate 13:7 33:13 34:9 66:6reason 4:11,16 15:18 16:4 25:16relationship 40:5 41:2 45:12PLEAS 1:1 please 29:25 68:8 pleuritic 49:12 pneumonectomy 8:2147:23,25 48:15 67:767:2115:18 16:4 25:16 15:18 16:4 25:1641:2 45:12 relative 37:8 70:16pleuritic 49:12 pneumonectomy 8:2167:7 presume 38:13 pretty 27:16Publications 22:8 pulmonary 8:6 pulmonologist 52:2525:3 26:7 45:19 recall 5:23,24 32:14 remainder 10:6remainder 10:6 44:18 remarkable 55:7					
plaintiff's 3:2 5:5,6 54:14,25 61:10 13:6 68:4 40:6 43:20 53:15 relates 13:7 31:12 12:6 29:6 37:12 64:2 proximate 13:7 realm 31:3,4 67:24 44:9 45:5 71:6 presented 14:3 33:13 34:9 66:6 reason 4:11,16 relationship 40:5 PLEAS 1:1 47:23,25 48:15 67:21 15:18 16:4 25:16 41:2 45:12 please 29:25 68:8 54:17 57:21 65:8 Public 1:20 69:24 34:24 51:17 relative 37:8 70:16 pleuritic 49:12 67:7 70:9,23 reasonably 24:8 reliable 24:8 25:2,3 pleuwa 49:18 presume 38:13 22:12 reasons 35:4 62:10 25:18,23 26:8 s:21 pretty 27:16 pulmonary 8:6 recall 5:23,24 32:14 remainder 10:6 paumonia 48:19 9:11 16:3 52:25 received 5:2,4 remarkable 55:7	· · ·	-	r		
12:6 29:6 37:1264:2proximate 13:7realm 31:3,467:2444:9 45:5 71:6presented 14:333:13 34:9 66:6reason 4:11,16relationship 40:5PLEAS 1:147:23,25 48:1567:2115:18 16:4 25:1641:2 45:12please 29:25 68:854:17 57:21 65:8Public 1:20 69:2434:24 51:17relative 37:8 70:16pleuritic 49:1267:770:9,23reasonably 24:8relevant 23:22 24:3plexus 49:18Presently 22:11publications 22:825:3 26:7 45:19reliable 24:8 25:2,3pneumonectomypresume 38:1322:12reasons 35:4 62:1025:18,23 26:88:21pretty 27:16pulmonary 8:6recall 5:23,24 32:14remainder 10:6pneumonia 48:199:11 16:352:25recived 5:2,4remarkable 55:7					
44:9 45:5 71:6presented 14:333:13 34:9 66:6reason 4:11,16relationship 40:5PLEAS 1:147:23,25 48:1567:2115:18 16:4 25:1641:2 45:12please 29:25 68:854:17 57:21 65:8Public 1:20 69:2434:24 51:17relative 37:8 70:16pleuritic 49:1267:770:9,23reasonably 24:8relevant 23:22 24:3plexus 49:18presently 22:11publications 22:825:3 26:7 45:19reliable 24:8 25:2,3s:21pretty 27:16pulmonary 8:6recall 5:23,24 32:14remainder 10:6pneumonia 48:199:11 16:352:25recived 5:2,4remarkable 55:7					
PLEAS 1:1 47:23,25 48:15 67:21 15:18 16:4 25:16 41:2 45:12 please 29:25 68:8 54:17 57:21 65:8 Public 1:20 69:24 34:24 51:17 relative 37:8 70:16 pleuritic 49:12 67:7 70:9,23 reasonably 24:8 relevant 23:22 24:3 pleumonectomy presume 38:13 22:12 reasons 35:4 62:10 25:18,23 26:8 st21 pretty 27:16 pulmonary 8:6 recall 5:23,24 32:14 remainder 10:6 pneumonia 48:19 9:11 16:3 52:25 received 5:2,4 remarkable 55:7	1				·····
please 29:25 68:8 54:17 57:21 65:8 Public 1:20 69:24 34:24 51:17 relative 37:8 70:16 pleuritic 49:12 67:7 70:9,23 reasonably 24:8 relevant 23:22 24:3 pleuritic 49:18 Presently 22:11 publications 22:8 25:3 26:7 45:19 reliable 24:8 25:2,3 pneumonectomy presume 38:13 22:12 reasons 35:4 62:10 25:18,23 26:8 8:21 pretty 27:16 pulmonary 8:6 recall 5:23,24 32:14 remainder 10:6 patemonia 48:19 9:11 16:3 52:25 received 5:2,4 44:18					, ×.
pleuritic 49:12 67:7 70:9,23 reasonably 24:8 relevant 23:22 24:3 plexus 49:18 Presently 22:11 publications 22:8 25:3 26:7 45:19 reliable 24:8 25:2,3 pneumonectomy presume 38:13 22:12 reasons 35:4 62:10 25:18,23 26:8 s:21 pretty 27:16 pulmonary 8:6 recall 5:23,24 32:14 remainder 10:6 pathenologist 32:15 33:25 66:22 44:18 48:20,24 49:8,13 9:11 16:3 52:25 received 5:2,4 remarkable 55:7	1 F				
plexus 49:18 Presently 22:11 publications 22:8 25:3 26:7 45:19 reliable 24:8 25:2,3 pneumonectomy presume 38:13 22:12 reasons 35:4 62:10 25:18,23 26:8 8:21 pretty 27:16 pulmonary 8:6 recall 5:23,24 32:14 remainder 10:6 pneumonia 48:19 primary 8:15,16 pulmonologist 32:15 33:25 66:22 44:18 48:20,24 49:8,13 9:11 16:3 52:25 received 5:2,4 remarkable 55:7	3 *				
pneumonectomy presume 38:13 22:12 reasons 35:4 62:10 25:18,23 26:8 8:21 pretty 27:16 pulmonary 8:6 recall 5:23,24 32:14 remainder 10:6 9neumonia 48:19 primary 8:15,16 pulmonologist 32:15 33:25 66:22 44:18 48:20,24 49:8,13 9:11 16:3 52:25 received 5:2,4 remarkable 55:7					
8:21 pretty 27:16 pulmonary 8:6 recall 5:23,24 32:14 remainder 10:6 pneumonia 48:19 primary 8:15,16 pulmonologist 32:15 33:25 66:22 44:18 48:20,24 49:8,13 9:11 16:3 52:25 received 5:2,4 remarkable 55:7					
pneumonia 48:19 primary 8:15,16 pulmonologist 32:15 33:25 66:22 44:18 48:20,24 49:8,13 9:11 16:3 52:25 received 5:2,4 remarkable 55:7	1 ° ' 1	· ,			
48:20,24 49:8,13 9:11 16:3 52:25 received 5:2,4 remarkable 55:7				· · · · · · · · · · · · · · · · · · ·	
51:5,14,17,19 print 5:19 pure 20:18 28:16 remember 27:18				· · · ·	
	51:5,14,17,19	print 5:19	pure 20:18	28:16	remember 27:18

			·····	Page
33:21,24 34:2	12:8 25:12 28:13	second 2:6 16:3	similar 18:18 21:1	sort 15:9,21 20:13
37:4,11 42:19,21	29:7,10,19 31:25	28:21	32:23 33:12 34:5	29:1 55:20
42:23	34:4,18 48:9	secretary 5:17	34:14 46:9	sounds 4:14
Reminger 2:12,12	reviewed 6:13,19	section 25:21	Sinai 36:14,17,24	speak 5:21
38:1,1 43:1,1,6,6	12:2 22:13 23:19	security 16:9,11	since 12:18 18:12	speaking 55:17
43:7,8,9,9,15,16	24:2 29:4 32:5,18	see 6:8 12:2 18:8,11	24:1 31:21 35:4	specific 9:18 21:19
44:2,2,7,14,15	33:11 41:3	19:12,13 40:10	35:14 37:15	23:6 35:4 41:15
remotely 67:2	reviewing 29:2,5	49:22 57:14 65:22	sitting 26:1	46:1 55:6 58:14
removed 30:6	31:24 35:6	66:1 67:15	situation 34:6	61:20
rendered 30:2	revisiting 17:20	seeing 65:8	50:16	specifically 22:24
repeat 50:19,22	re-mediastinoscope	seemed 28:9	situations 23:4	23:24 24:5 25:4
59:4	9:16	seen 22:2 27:14	six 32:3 42:10 52:7	29:17 33:25 39:9
rephrase 4:13	rid 32:9	58:2 60:15 64:17	six-month 34:6	42:23 48:11 50:3
replicate 59:25	right 4:8 11:13	64:21	six-week 51:11	specifics 62:25
report 3:25 4:19	16:10 17:9,9	sees 40:11	size 11:9,10 18:9	specified 70:15
5:8,11,12,21,25	21:24 26:2 36:8	Segal 37:6	19:11,20,25 20:4	spoken 5:15
6:1,11,14 11:17	57:12 65:10,13	sending 5:22	20:9,12,23 21:19	spread 46:18 61:20
12:9,13,21 14:7	risk 16:3-17:8	sensitive 53:16	46:9	SS 70:4
16:7 23:23,25	Road 1:23	sent 4:1 29:22	Skylight 2:5	stage 7:19,23,25 8:3
24:1 29:8 44:18	Rob 38:8	separate 28:19	slice 18:21,21,24	9:1 10:12,13,15
45:6 47:23 62:11	ROBERT 2:13	September 4:23 5:1	slicing 18:19	10:22,23,23 11:7
reporter 1:20 45:2	robimyein 30:4	sequence 30:16	slides 41:3	11:8,8 13:11,16
reporting 70:17	ROGER 1:9	serious 52:16	slipped 26:22	13:16,25 14:3,14
reports 12:3,3,4,19	roughly 10:5 21:2	serve 42:5	small 17:24 50:13	14:15,17,20,20
29:22	rounds 28:20	served 41:5 43:18	56:10,20 64:6	15:3,3 17:4,4,10
represent 3:23	routine 4:6	43:22	smaller 11:9 18:24	17:16,16,21 18:4
represented 42:6	Rozman 12:4 39:1	services 35:10	smallest 20:13,23	18:6 20:6 23:9,10
representing 42:5	39:14 41:6,16	serving 37:23 41:7	smoke 17:7,12	23:13,17,17 27:13
reputation 27:25	Rozman's 38:23	41:10 43:4	smoker 16:22 51:21	27:14 30:11,17
REQUESTED 69:5	rule 33:5 52:14	set 1:24 59:14 60:10	51:22	31:7 54:19 55:11
require 40:2	70:18	62:11 70:12,19	smoking 16:23,25	56:9,9,14 64:3,4,9
required 17:17	Rules 3:8	seven 45:4	17:2	stages 20:5
resection 8:5,15,16		shape 67:13	smooth 55:8	staging 20:20 23:21
8:19,20 9:11 14:5	S	shed 59:10 60:9	snippet 13:14 14:13	24:20 25:7
23:5	safe 15:6	shedding 59:13	snippets 14:7	stand 26:6,10
resections 8:18	same 24:2 34:5 47:3	60:16	some 3:24 4:2,11	standard 12:22
9:24	62:19,23	sheep 35:11	9:17 17:24 18:8	13:1 21:16 28:14
resective 9:7	sampling 8:11	show 37:3	35:20 39:19,19	52:20 53:2,5
resolved 35:25	saw 58:8	showed 31:11 51:11	40:10 59:21,22	66:12
51:19 52:10	saying 25:25 54:11	51:24	somebody 30:16	standards 28:10
respond 30:6	scalene 8:11 57:25	shower 59:17	somehow 4:12	standpoint 25:23
responded 51:5	61:23 67:10	shown 50:23	11:24 39:25	28:4 31:5
response 59:17,23	scan 31:10 46:7	side 12:6 34:14	someone 10:17	start 53:22
restating 66:6	52:24 53:1,11,15	sides 12:3	13:16 30:11 42:1	started 30:5 59:21
result 49:15	61:5,10	Sidney 37:6	something 5:16	starting 37:3
resulting 49:18	scans 18:17	Signature 68:18	32:13 34:12 46:5	state 1:20 3:13
results 60:4	scenario 60:8	signed 5:11 6:2	46:7,8 52:15	32:17,19,21 54:8
retained 12:5,5	scheduled 38:3,7,9	significance 55:10	sometime 4:23	70:3,9,24
retroactive 20:20	school 14:10	significant 10:20	sometimes 5:20,22	statement 17:13,14
retrospect 48:14	scientific 60:24	16:17 17:25 18:14	19:23	55:19,23
retrospectively	scratching 38:8	34:9 40:1 53:24	somewhere 23:7	statements 36:4,9
47:19 48:25 65:4	screen 53:6	58:21 59:2 60:1	27:2	station 50:14 55:13
65:7	seal 70:19	60:11,20	sorry 19:14 27:14	57:25
review 4:23 5:3,10	seated 41:21	silent 12:21	59:20	stationery 5:13
L				

				Page
stations 9:14 62:3	sure 4:7 13:21	talk 14:7 35:18	30:5 31:8,16	23:20,22 24:3,9
67:9	16:12 33:24 35:2	talked 60:16	32:21 33:20 35:3	25:3,22 27:6
status 47:21	60:22	talking 13:22 56:21	35:19 36:7 38:8	35:19
statute 1:18	surgeon 6:22 7:22	taught 14:9	39:5 42:21 43:20	topics 22:23
stay 15:16 27:3	8:7 67:4,15	taxol 30:3	44:23 45:11,16,18	total 45:4
Steele 25:13,17	surgeons 7:17 9:17	team 28:9	46:15 48:18,20	touch 22:15
41:17 66:21	24:23	tell 4:12 20:8,13	51:1,2,15,15 52:7	Tour 54:4
stenotypy 70:12	surgeries 7:1,2,16	31:24 33:22 34:1	52:20 53:5 62:3	Tower 2:5
sternomastoid	surgery 7:6,7,8,8	34:19 41:11 45:9	63:15,17,22 64:21	track 32:8
58:17	7:10,22 8:7,8 9:7	46:21 47:9 55:11	66:5 67:3	transcribed 48:12
Steve 34:4 43:23	10:6,18 16:16	56:23 57:5,7,9	thinking 65:21,24	70:13
44:6,6	17:12 30:23	58:9,25 61:18	thoracic 7:8 10:7	transcript 69:2
still 16:2 18:3 26:12	surgical 7:12,21 8:4	tendency 11:11	22:23 38:24 39:21	transcription 70:13
40:9 48:21 52:9	8:15,18,23 9:5,22	tender 55:8 58:17	thoracotomy 8:14	transcripts 29:21
53:5,19 60:3	9:24 10:7 13:19	tennis 18:19 19:1	thorough 68:2	treat 14:20
63:19	14:5,23 22:21	term 13:7 19:23	though 16:25 22:25	treated 64:9
stipulate 46:3 47:14	23:3 28:4 37:8	45:11	44:2 53:13 60:22	treating 28:3
48:11	39:2,8,19 62:10	terminal 30:20,22	thousands 17:1	treatment 13:19
stipulated 5:4 50:3	64:11,15 66:9,16	terms 4:6 8:22	three 34:17,22 35:1	22:16 24:11 27:16
stipulates 58:15	survivability 11:4	10:18 13:12 20:4	36:22 37:22 42:15	30:25 36:12 62:14
61:11	survival 11:5 15:10	23:20 24:11,21,24	45:6 64:24 68:9	62:16 66:17 67:21
stipulations 1:21	15:12,13,20 16:18	30:21 31:24 34:9	through 3:3 6:2	trial 11:20 12:24
story 50:9	17:18 45:13 67:1	34:18 43:14 45:15	14:8 28:22 29:12	26:15 38:7,14
Street 2:6	67:22	46:12 47:1 53:2	30:19 60:19 69:3	42:11 68:5
stretch 30:10	survive 30:14	53:24 54:7 57:15	71:7	trials 38:10
strong 54:13 67:8	surviving 15:8	60:8,23 67:21	throughout 15:17	true 29:16 70:13
strongly 64:1	suspect 7:5 23:11	terribly 4:3 10:1	tie 66:3	truly 20:4
studies 9:20 17:24	45:24	test 8:6	time 6:13,19 7:19	trust 45:1
21:13 22:2 24:7	suspicion 52:1 53:3	testicular 54:3	11:20 12:24 13:14	truth 70:11,11,11
60:15,21	55:2	testified 34:13	13:14,23 14:3,11	1
study 11:1 20:21	Sutherland 41:18	42:11	14:13 15:2,23	trying 53:24 TUESDAY 1:14
30:7	66:21	testify 28:12 38:14	· · · · ·	
subgroups 11:6	sworn 3:9 69:20	70:11	16:5,16 17:9,19	tumor 8:15,16,25 9:1,11 11:1,6,9,10
subject 19:2,2 33:6	70:11	testimony 12:23	19:16,20 20:7	
Subscribed 69:20	symptom 50:11,12	r	27:11,12 29:14,23	18:10 19:4,10,15
subsequent 52:8	57:21	13:6 26:15 44:13 68:4 70:12,13	30:3,10,12 31:1	19:19,25 20:9,23
subsequently 5:4	• · · · ·)	34:8 36:8 37:19	21:6,9,17,18,20
9:16 30:6	symptoms 47:25 48:4,7,13,15 49:3	thank 68:12	44:8 45:14 46:4	21:23 22:1 46:3,4
substantial 51:22	48:4,7,15,15 49:5	their 16:1 24:14,15	47:5,16,18 48:21	46:16,22 47:2
		24:18,24,25 28:15	51:11 52:18 53:10	50:13 56:24 57:3
succeed 60:10 succeeds 59:14	65:12	35:10 51:25	54:10,14,16,18	59:17,23,24
succinct 29:11	synopsis 29:8	theories 60:23	55:6 56:16,25	tumors 22:17 59:10
	System 40:16	therapy 9:13,15,21	59:5 64:2,24	turn 14:19 20:10
suggest 17:24	systemic 62:23	17:17,23 18:4	65:21 68:4,13	twice 64:18
suggestion 64:25	systemically 46:18	28:16 30:4,5 31:6	70:15	two 27:1,3 28:19
suit 32:20		51:6,18 64:11,11	timely 33:15	34:17,22 35:1,4
Suite 2:7 Sullivan 1:19 70:9	T	64:13	times 17:23 29:12	46:6 52:17 65:12
1	tabs 41:17	thereof 16:21	35:21 37:14,18	68:9
70:23	take 11:7 20:10	thing 14:9 19:23	44:11 45:14	type 7:22 8:8,19
supposition 20:18	26:6,9 29:1 31:18	31:17	tissue 64:7	9:21 10:17 25:11
20:22 47:15 48:22 51:3	59:12 62:8	things 7:4 46:24,25	today 37:21	28:16 30:11 41:1
	taken 1:18 4:5	52:18	together 39:21 49:2	50:17 56:10 62:23
supraclavicular	51:10 68:2 70:15	think 15:6 17:20	66:4	63:12 67:16
	51:10 68:2 70:15 takes 46:5 59:2 taking 18:19	think 15:6 17:20 18:3,13,16 19:7 25:4 27:16 28:21	66:4 tools 52:13 topic 12:22 22:15	63:12 67:16 types 24:12 49:8 52:13

Page 10

T	1	1	·	<u></u>
typically 53:12	visits 64:25 65:12	28:23	1	4
T1 18:7 21:7,10,15	voir 36:1,7	whole 70:11	1 3:3 4:19 5:12 6:2	4 3:3 18:11,15,23
21:17,20,23 22:5	vs 1:8	widely 54:3,6	1 C C C C C C C C C C C C C C C C C C C	
T1-N1 18:6		WILLIAM 1:4	6:11,18 69:3 71:7 10 56:21	19:24 20:1,1 21:2
T2 18:7 21:8,9,11	Ŵ	willing 5:3	E Contraction of the second se	29:1,6 44:23 45:5
21:14,18,20,22,25	waiting 4:7	wish 5:20	100 23:8 34:23	46:10 57:10 71:7
22:5	waived 68:18	witness 1:17 43:19	61:19	4.5 18:14,15 19:24
	Walters 43:23	59:4 68:14 70:19	101 2:15	21:3
U	want 11:13 13:21	won 54:4	12-9-99 13:24,25	44113 2:8
ultimately 13:12	25:19 35:9,18	woods 27:9	48:12	44115 2:16
65:15	44:19,20 66:3	worded 10:2 32:24	13 32:4	457634 1:8
under 1:18 9:12	67:19	words 4:4 45:6	14 26:20 32:4	5
46:23 70:17	Warner 2:13 4:2,20	work 27:2,4 29:1	1400 2:14	
undergoing 29:13	5:11 11:23 20:17	31:21 39:19 41:13	15 32:5 56:21	5 46:8 57:11
understand 4:7,10	31:2 38:13 41:23	42:25 45:2	150 23:8	5:15 1:24
10:2,3 11:18	42:6,9 43:3 44:5	worked 43:15	16 25:6 37:16	50 15:4,7 66:25
13:21 14:6 19:17	44:9 49:25 50:24	works 22:10	1660 2:6	500 10:4
19:22 25:25 65:10	52:3,6,19 56:2	workup 53:3	1988 31:22 37:16	
understood 4:16	57:1 58:12 61:6	worth 27:2,4	1996 34:4	6
unfair 51:1	65:17 68:9	wouldn't 66:13	1999 47:6,11,17	6 70:25
unfortunately 31:5	wasn't 21:21 35:15	wound 11:13	48:16 54:17 57:22	6th 64:22
66:7	55:4	written 24:14 60:22	66:16 67:8	60 7:6 10:9 11:5
University 27:15,19	way 12:16 15:17,21	wrong 51:17 65:13		37:17
36:16,20 40:6,16	16:1 28:11 54:24	wrote 4:20	2	660 2:7
unless 27:1 44:3	61:18 67:13	mioue 1 ,20	2 6:5 18:23	6780 1:23
unlikely 58:24	weakness 48:2 49:5	X	20 23:11 32:6	68 69:3
until 23:14 31:1	49:14	X 54:12,12	200 10:5,8	687-1311 2:17
35:14 56:13	wedge 8:20	X-ray 50:19,23	2000 19:10 53:21	
untreated 45:17	weeks 52:8 68:9	51:23,24 52:8	55:7 57:4,6,8,16	7
46:14	Weinberger 37:13	53:13	57:19 61:7,8	7:00 68:17
unusual 30:16	well 7:4 11:1 12:4,6	00110	64:22 66:7	70 7:6,9 37:17
51:12,16	16:13 17:18 20:15	Y	2002 4:1,23	0
upper 48:23	22:23 24:11,20	year 10:4 20:11	2003 23:1	8
use 15:10,19 19:24	28:2 30:6 50:15	21:2 30:9 32:1,4	2004 1:14 23:2	80 7:9 11:5 37:17
used 45:11	55:23	32:6,11,12 42:17	69:21 70:20	Λ
usually 5:18 11:11	went 23:14	54:12 61:3 63:11	2006 70:25	9
32:9	were 3:3 4:22 5:24	63:21	216 2:9,17	9 47:23 48:7,8
	14:18 17:24 20:22	years 7:5 13:3	241-2600 2:9	54:21 64:18
V	21:4 23:4,9,12,16	14:12 15:8,15	25 10:11	9th 54:14,16 55:1
value 25:24	27:22 28:19 29:2	16:5,7 25:6 26:20	250 10:5,8	70:20
varies 32:2	29:22 33:12 36:17	32:2 34:17,22	26 33:5	99 19:9 20:10 61:6
variety 51:14	36:23 37:19,23	35:1 36:22 37:16	28(D) 70:18	
vary 8:10,19 11:5	38:8 41:7 48:4,5	41:25 45:14,24	29 4:1	
venture 10:8	48:16,18 62:16	46:1,5 51:22	3	
venued 33:1	65:13,14 66:20	young 41:21,22,24		
verse 6:3	71:7	" "	3 1:14 4:24 5:5,7	
versus 34:20	West 2:6,15	\$	6:1,8 18:23 20:24	
very 9:18 25:2,3	we'll 11:15 14:7	\$10,000 26:24	21:6,8,10,14,15	
54:5 58:24 64:1	we're 14:8 29:12	\$250 26:12	21:18,19,22,23,24	
view 46:23 57:11	35:5 57:11	\$4,000 26:15,18,19	22:3,4,4 55:8,10 3.5 19:25 20:1,2	
vigorously 53:20	we've 17:21 52:21	26:22	3:12 71:4	
violated 66:12	54:2 62:10	\$5,000 26:15,17,22	3:1 2 71:4 3:2 71:7	
virulent 45:19	WHEREOF 70:19	26:23,25	30 7:7 10:11 23:12	
visit 48:8	while 17:7 18:12		48:16 64:19	
			-10.10 04.17	
	I			